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Abstract 
There is increasing evidence linking chronic pain to altered levels of central 
nervous system (CNS) inflammation and increased levels of perceived pain, anxiety, 
depression and sleep disturbance. However the inflammatory molecules responsible for 
physiologic and psychological components of chronic pain still warrant identification and 
exploration. Using central inflammation as a paramount factor in the creation and 
maintenance of chronic pain, this study aimed to investigate and describe the physical 
and psychological aspects of chronic pain associated with CNS inflammation. 
Using a cross-sectional correlational design, cerebrospinal fluid (CSF) 
inflammatory cytokine patterns present in 8 chronic pain participants were compared to 
inflammatory cytokine patterns present in 30 control CSF samples using multivariate 
analysis of variance (MANOVA), with analysis of variance (ANOVA) analysis as a 
follow-up. Levels of depression, anxiety, sleep disturbance and pain were measured in 
approximately 8 chronic pain patients and correlated to CSF levels of inflammatory 
cytokines using Pearson's r, or Spearman's Rho correlations. Demographic information 
was also explored for relationships to central inflammation and descriptive statistics were 
examined for responses. 
To our knowledge, this is the first study to describe increased CSF levels of 
Interleukin-8 (IL-8) in a population of majority Failed Back Surgery Syndrome chronic 
pain patients (F (I, 36) ~ 14.89, p < 0.001, partial 11 2 ~ 0.293). Gender (F (1,6) ~ 7.782, p 
~ 0.032, 11 2~ 0.565), socioeconomic status (r ~ -0.823, p ~ 0.012) and educational level (r 
~ 0.727, p ~ 0.041) were also correlated with central levels of inflammation, indicating 
that central physiologic changes may be related to host sex and psychosocial factors. All 
participants reported poor sleep quality and took at least one opioid medication, 
indicating that sleep and opioids may scaffold a portion of the chronic pain paradigm. 
This study richly describes the dynamic experience of chronic pain through the 
lens of Psychoneuroimmunology. Incorporating both physiologic and psychological 
aspects of the disease, this study describes an association between chronic pain, central 
inflammation, gender, socioeconomic status, opioid medications and poor sleep quality. 
Thus, the future of pain treatment must consider these aspects when treating patients and 
look to future studies for possible new treatment options which target these factors. 
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Chronic pain is a health concern of tremendous scope. An estimated 116 million 
Americans suffer from, and are disabled by this chronic illness (Tsang et al., 2008) at a 
cost of $630 billion in lost work revenue, sick time and health care costs (Gaskin & 
Richard, 2011 ). Most important, is the cost in quality of life that the patient pays. 
Patients report not only a wide spectrum of painful symptoms, but also suffer the 
negative psychological effects of constant pain. Current modalities utilized to treat these 
patients both physically and psychologically are limited, and are often ineffective for a 
large portion of the chronic pain population. Recent investigations reported in chronic 
pain literature have revealed a new direction for therapeutic advancement: central 
nervous system (CNS) inflammatory mechanisms that are believed to exacerbate and 
prolong neuropathic pain states (Kreutzberg, 1996; Reeve, Patel, Fox, Walker, & Urban, 
2000; Samad, Wang, Broom, & Woolf, 2004; Watkins & Maier, 2003; Watkins, 
Milligan, & Maier, 2001) also influence anxiety (Baker et al., 2001; Camara et al. 2015), 
depression (Bonne et al., 2011; Levine et al., 1999; Lindqvist et al., 2009) and sleep 
disturbances (Dauvilliers et al., 2014). Though preclinical data is accumulating, there 
remains a dearth of human data in this rapidly developing area of investigation which 
links central inflammation, chronic pain and the psychology of pain. 
This study investigated the emerging relationships between chronic pain 
syndromes and the role of central inflammation, through examination of cerebrospinal 
fluid (CSF) patterns of inflammatory mediator molecules. More specifically, this study 
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investigated whether human CNS levels of pro- and anti-inflammatory cytokines were 
similar to those described in chronic pain-induced animal studies (Inoue et al., 1999; 
Morioka et al., 2002; Raghavendra, Tanga, & DeLeo 2004; Song & Zhao, 2001). This 
study also explored the relationships between central inflammation and the psychological 
responses to the chronic pain experience (pain perception, anxiety, depression and sleep 
quality). This was accomplished using the Short-Form McGill Pain Questionnaire 
(Melzack, 1975; Melzack, 1987), by scoring on the Hamilton Anxiety Rating Scale 
(Hamilton, 1959), Beck Depression Inventory-II (Beck, Ward, Mendeson, Mock & 
Arbough, 1961) and the Pittsburgh Sleep Quality Index (Buysse, Reynolds, Monk, 
Berman, & Kupfer, 1989). Keeping central inflammation paramount to the chronic pain 
experience, this study examined the relationship of central inflammation to chronic pain 
and the psychology that accompanies chronic pain. 
This exploration of psychological and physiologic interaction was supported by a 
discipline that links the mind and body known as Psychoneuroimmunology. As a field 
of study, psychoneuroimmunology explores the interactions between behavioral, neural, 
endocrine and immune processes. Psychoneuroimmunology is a rapidly growing 
specialty within psychology tasked with exploring the adaptive processes of 
physiological and behavioral responses to physical and psychological environmental 
stressors (Ader, 2000). Because there is a scarcity of human evidence supporting the link 
between physical and psychological pain, and central levels of inflammatory mediator 
molecules associated with these constructs, this study provided evidence of this 
multimodal relationship utilizing psychoneuroimmunology as a foundational research 
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paradigm. 
Increased knowledge of the relationships between the psychoneuroimmune 
responses to prolonged pain states propagated by central inflammatory mechanisms, will 
lead to information pertinent to more effective analgesic and psychological treatment of 
these patients. It was the goal of this study to explore and describe the 
psychoneuroimmune relationship of central inflammation, chronic pain, anxiety, 
depression and sleep disturbance in the chronic pain population. 
Purpose and Specific Aims 
The purpose of this study was to examine and characterize the relationships 
between the physical and psychological components of chronic pain and inflammatory 
mediator molecules, more specifically cytokines called interleukins (ILs) and tumor 
necrosis factor-alpha (TNF-u). Specific aims of this study include the following: 
1) 	 Investigation of altered CSF levels of pro-inflammatory cytokines including 
interleukin-! (IL-1 ), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor 
necrosis factor-alpha (TNF-u) in patients with chronic pain as compared to 
control samples; 
2) 	 Investigation of alterations in levels of anti-inflammatory interleukin-! 0 (IL­
10) in chronic pain patients as compared to control samples ofCSF. 
This study also aimed to explore the relationship between central inflammation 
and the psychological responses to chronic pain as evidenced by results gathered from the 
following psychological tests: 
1) 	 The experience of chronic pain as measured by the Short Form McGill Pain 
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Questionnaire (SF-MPQ); 
2) Pain-related anxiety levels as measured by scores on the Hamilton Anxiety 
Rating Scale (HAM-A); 
3) The presence or absence of depression as measured by the Beck Depression 
Inventory-II (BDI-II); 
4) Sleep disturbances in chronic pain patients as measured by the Pittsburgh 
Sleep Quality Index (PSQI). 
The secondary aims of this study included assessing for relationships between the 
participant demographics, type of chronic pain diagnosis, length of diagnosis, type(s) of 
medication(s) used to treat chronic pain and length of time taking those medication(s) to 
levels of central inflammation. 
Hypotheses 
1. 	 Patients with chronic pain syndromes will have elevated CSF levels of 
pro-inflammatory cytokines IL-1, IL-6, IL-8 and TNF-u as detected with 
Multiplex assay analysis when compared to control samples of CSF. 
2. 	 Patients with chronic pain syndromes will have decreased CSF levels of anti­
inflammatory cytokine IL-10 as detected with Multiplex assay analysis when 
compared to control samples of CSF. 
3. 	 There will be a positive correlation between the severity of perceived pain as 
measured by the Short Form-McGill Pain Questionnaire (SF-MPQ), anxiety 
as measured by scores on the Hamilton Anxiety Rating Scale (HAM-A), 
extent of depression as measured by the Beck Depression Inventory-II (BDI­
4 
II), and sleep disturbance as measured by the Pittsburgh Sleep Quality Index 
(PSQI), and levels of pro-inflammatory cytokines in the CSF. 
4. 	 There will be an inverse correlation between the severity of perceived pain as 
measured by the Short Form-McGill Pain Questionnaire (SF-MPQ), anxiety 
as measured by scores on the Hamilton Anxiety Rating Scale (HAM-A), 
degrees of depression as measured by the Beck Depression Inventory-II (BDI­
II), and sleep disturbance as measured by the Pittsburgh Sleep Quality Index 
(PSQI), and levels of anti-inflammatory IL-10 in CSF. 
5. 	 Prolonged length of diagnosis, opioid medications used to treat chronic pain 
and prolonged length of time taking medication(s) will positively correlate 
with increased levels of pro-inflammatory cytokines in the CSF of chronic 
pain patients. 
6. 	 There will be an inverse relationship between central levels of anti­
inflammatory IL-10 and prolonged length of diagnosis, opioid medications 
used to treat chronic pain and prolonged length of time taking medication(s). 
Theoretical Perspective 
For the purpose of this study, the presence of chronic pain was held as the 
paramount stressor that was integrated into an amalgam of biological and behavioral 
factors influencing the overall health and disease status of the patient. Pain is defined by 
the International Association of the Study of Pain (IASP) as "an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or described in 
terms of such damage" (Merskey & Bogduk, 1994). Given thatthe definition of pain by 
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IASP incorporates sensory, emotional and biologic components, the 
Psychoneuroimmunology (PNI) theoretical framework was adopted as a basis for this 
study because of its multifaceted approach to the health outcome of a patient. More 
specifically, McCain and colleagues' generic theoretical framework of PNI was adapted 
and utilized to help guide this study (Figure 1) (McCain, Gray, Walter, & Robins, 2005). 















Figure 1. The Psychoneuroimmunology Theoretical Framework adapted from McCain, 
Gray, Walter, & Robins, 2005, p. 13. 
Their framework identifies the patterns, processes and consequences of stress and 
coping as they relate to the multidimensional psychobehavioral-neuroendocrine-immune 
system interactions that relate to health dynamics (McCain et al., 2005). The PNI 
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framework scaffolds this investigation by defining the association between the mind and 
body. As a framework, it merges psychological variables such as anxiety and depression 
with the perceived stress ofpain and relates the neuroendocrine mediators that influence 
sleep quality and pain levels as it applies to the chronic pain condition. As a framework, 
it also correlates the measurable irrununological inflammatory markers in the chronic 
pain study population. Applied to this study, pain and symptoms ofdepression, anxiety 
and sleep deprivation can thus be compared to the central biological markers of 
inflammation associated with chronic pain in a cross-sectioual study process (see Figure 
2). 
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Figure 2. The Psychoneuroimmunology Theoretical Framework applied to the study 
Psychoneuroimmunology and Chronic Pain. Adapted from McCain. Gray, Walter, & 
Robins, 2005, p. 13. 
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Within the PNI theoretical perspective, chronic pain is approached as a 
multifaceted dynamic condition with many involved factors including psychological, 
neuroendocrine and immunologic components. When considering the factors of pain, 
anxiety, depression, sleep deprivation, and altered levels of inflammatory biomarkers in 
the presence of chronic pain, causal pathways are unclear, but these factors have been 
found to contribute to, or be associated with the chronic pain process in both humans and 
animals (Baker et al., 2001; Dworkin & Gitlin, 1991; Heffner, France, Trost, Ng, & 
Pigeon, 2011; Meller, Dykstra, Grzybycki, Murphy, & Gebhart, 1994). The PNI 
theoretical framework by McCain et al. (2005) acknowledges these relationships and 
makes them explicit in an iterative, fluid continuum. Use of the PNI theoretical 
framework thus provides this study a mechanism to bring these multidisciplinary 
components together in a more inclusive view of the chronic pain process rather than 
detail the complex physiological and pathophysiological interactions as independent 
underlying processes. 
Psychoneuroimmunology as a paradigm in nursing research supports the premise 
that there is bidirectional neuroendocrine-immune system interaction (Rabin, Choen, 
Ganguli, Lysle, & Cunnick, 1989) that justifies psychobehavioral nursing interventions 
designed to address stress and coping, considering an associated physiological basis 
(McCain et al., 2005). Psychoneuroimmunology combines the Lazarus and Folkman 
(1984) cognitive-transactional model of stress with psychology, behavioral, and 
pathophysiologic processes of the patient's health status. The mind-body interaction 
(Zeller, McCain & Swanson, 1996) inferred in PNI has been shown in animal and human 
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models in a myriad of multidisciplinary studies: From the inception of the concept of 
PNI (Solomon & Moos, 1964) to the work that demonstrated behavioral conditioning's 
influence on the immune system (Ader & Cohen, 1975), PNI is still a relatively new 
theory in nursing research. However, it is one that incorporates a more holistic view of 
specific stressors and the effect on the patient's health spectrum. 
Within the PNI framework described by McCain and colleagues (2005), the 
identified cofactors are those components that have the potential to predispose an 
individual to certain stress, coping and health patterns (potential cofactors) or the health 
related features of one's life (pretreatment critical cofactors). The potential demographic 
cofactors identified in this study were: the patients' age, gender, race, education level, 
socioeconomic status (SES), level of activity as measured by metabolic equivalents 
(METS), and body mass index (BMI). The pretreatment critical cofactors identified 
included: the cause or diagnosis of chronic pain, the length of diagnosis, type(s) of 
medication(s) utilized to treat the chronic pain symptoms, and the length of time taking 
medication(s) for chronic pain relief. The psychological --"psycho"-- component of the 
psychoneuroimmunology model includes sociobehavioral components such as negative 
affect and distress (McCain et al., 2005). The perceived stress of chronic pain and the 
effectiveness of the patients coping patterns will be measured by their experience of pain 
through the Short Form-McGill Pain Questionnaire, their level of anxiety via the 
Hamilton Anxiety Rating Scale, the extent of depression related to the chronic pain 
symptoms by the Beck Depression Inventory-II, and their sleep quality via the Pittsburgh 
Sleep Quality Index. The neurological --"neuro"-- and "immunology" components of the 
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McCain PNI theoretical framework focus on the physiological responses to psychosocial 
stressors, the effect of stress on the immune system, and the interrelationship between the 
neuroendocrine and immune system (McCain et al., 2005). The physiologic responses to 
the stressor of chronic pain (which amalgamates the effect of stress on the immune 
system and the interrelationship between the neuroendocrine and immune system) will be 
measured through patterns of CNS inflammatory cytokines. 
Seminal literature demonstrates there is a central neurological component related 
to the biomarkers measured in this study with the initiation, maintenance and quality of 
sleep (Fontana, Kristensen, Dubs, Gemsa, & Weber, 1982; Ishimori, 1909; 
Pappenheimer, Miller, & Goodrich, 1967). Within the PNI framework, and because of 
the fluid, interrelated interaction of the components within this model, sleep (as measured 
by the Pittsburgh Sleep Quality Index), will also be regarded within the neuroendocrine 
function of this framework. 
The biological markers investigated by this study will be patterns of biomarkers 
called cytokines, more specifically IL-1, IL-6, IL-8, IL-10 and TNF-u. These biomarkers 
are released by both peripheral and central immune cells in response to a wide array of 
physiologic insults, however nociceptive central sensitization common in chronic pain 
models has been associated with the release of these biomarkers specific only to CNS 
cells called glia (Zhang et al., 2008). Thus, the PNI framework correctly identifies these 
CNS cytokines in the neurological --"neuro"-- categorical point of reference within the 
PNI framework for this specific study. Once glia release inflammatory biomarkers, it is 
known that these molecules contribute a wide array of immunologic functions. The PNI 
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framework also correctly maintains these biomarkers as neuroimmune mediators properly 
categorized under the "neuroimmunology" component of the theoretical framework. The 
neuroimmune mediators will be measured in this study using Multiplex assay analysis to 
assess levels of cytokines within the CSF of patients, presumably reflecting inter-related 
central neuronal and immunological functions. Through triangulation of the various 
results, this study yields novel information about relationships between chronic pain, the 
perception of pain, anxiety, depression, sleep deprivation and central biomarker 
mediators all under the architecture of the PNI framework. 
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Chapter 2: REVIEW OF THE LITERATURE 
Background 
Chronic Pain in America 
Chronic pain is the loose definition of devastating symptomatology that affects an 
estimated 116 million Americans (Tsang et al., 2008) and spans across all socioeconomic 
boundaries, educational levels, cultural, gender and age demographics (Pleis, Ward, & 
Lucas, 2010). Its causes are indiscriminate, its effects on sufferers can be incapacitating 
and intolerable. Currently there is no cure for the pain these patients suffer, no remedy or 
vaccination to restore an enjoyable quality oflife. 
A developing body of neuroimmune research demonstrates mounting evidence of 
alternative pain pathways that perpetuate the chronic pain state via physiologic self­
propagating, or positive feedback mechanisms. Much of this new evidence points to the 
inflammatory process involving the signaling molecules secreted by neuronal cells called 
glia. Investigative work on glial cells has identified a selection of various molecules 
involved in positive feedback loops responsible for chronic pain, and has established that 
the underlying mechanisms involved render our current methods of fighting pain 
ineffective. As previously discussed, some of the proposed responsible molecules 
secreted by glial cells are called pro-inflammatory mediator molecules, specifically 
interleukin- I (IL-I), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor­
alpha (TNF- a). Multiple preclinical investigations have demonstrated that ifthe effects 
of these pro-inflammatory mediator molecules are blocked using various approaches, 
symptoms of chronic pain can be reversed and the analgesic functions of opioid 
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treatments return. 
In addition to widespread and indiscriminate effects, chronic pain also holds an 
astonishingly high price tag for our health care system. The Institute of Medicine has 
reported that chronic pain is estimated to cost society an estimated $630 billion annually 
in health care related costs and loss of productivity (Gaskin & Richard, 2011). In the 
United States, chronic pain accounts for millions of sufferers; more than all diabetic, 
coronary heart disease, stroke and cancer patients combined (Tsang et al., 2008). A 
myriad of anatomical areas are affected by chronic pain (National Centers for Health 
Statistics, 2006) with a spectrum of severity and quality of pain, making this disease 
difficult to treat with current practices. The psychological impact of unrelenting pain is 
also devastatingly prohibitive to a favorable quality of life. A 2006 survey completed by 
the American Pain Foundation, described more than half of the respondents felt they had 
little or no control over their pain and reported breakthrough pain at least once a day that 
severely impacted their quality of life and overall wellbeing (David Michaelson & 
Company, LLC, 2006). This potentially can lead to the overall feeling of loss of control, 
helplessness and apprehension, which can compound the negative impact pain holds over 
the sufferer's life. The survey also disclosed that over half of those surveyed reported 
that their pain impacted on their overall enjoyment oflife, with over 75% reported feeling 
depressed because of their pain and 74% relaying their pain impacted their energy levels 
(David Michaelson & Company, LLC, 2006). Clearly chronic pain symptoms are not 
just incapacitating to the physical being, but spreads through the entire existence of the 
sufferer and impact all aspects of life. 
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Physiologic Pain Verses Chronic Pain 
Pain is an elegant mechanism developed as a protective measure to preserve 
cellular function and life. When pain pathways work as they were intended, pain signals 
transmit from the periphery through the body to the central nervous system (CNS) for 
processing. Through a complex series of cellular interactions, pain perception 
(nociception) is the body's way of removing itself from a dangerous situation. In this 
way, pain, the proper perception of pain, and thus the proper withdrawal reaction to 
painful stimuli has aided in our species' survival and propagation. However, there are 
many instances in which individuals' pain perception and reaction to painful stimuli 
have, through no fault of their own, developed into chronic states of pain that serve no 
survival or protective benefit. Many individuals with chronic pain can exhibit 
hyperalgesia, a state in which there is an increased sensitivity to painful stimuli and can, 
additionally, report allodynia, the sensation of pain in response to a stimuli not normally 
responsible for pain. 
A barrage of aberrant pathways contributes to the initiation and maintenance of 
nociception in chronic pain states and one of the mechanisms responsible for, and 
described in the literature is through glial cell activity. Immune cells known as glia are 
located in the CNS in close proximity to neurons. Until recently, glia were thought to 
exclusively contribute to the structure and nourishment of neurons (Barres, 1991; Kandel, 
1991). Current literature has shown that glia do more than just nourish and provide 
structure to neurons; glial cells are immunologic cells that are activated following tissue 
injury, illness or inflammation (Tsuda, Inoue, & Salter, 2005; Watkins & Maier, 2000), 
14 
and have been shown to be a fundamental component for enhanced pain perception 
(Watkins & Maier, 2003). Once activated, glial cells release a cascade of molecules, 
more prominently pro-inflammatory cytokines, which have been shown to excite pain 
transmission and experience (Kreutzberg, 1996; Watkins, Milligan, & Maier, 2001 ). The 
same pro-inflammatory cytokines can ramp up dorsal horn neurons in pain transmission 
(Reeve, Patel, Fox, Walker, & Urban, 2000; Samad, Wang, Broom, & Woolf, 2004), they 
increase the release of neurotransmitters from sensory afferent nerves responsible for 
pain response (Inoue et al., 1999; Morioka et al., 2002) and may enhance pain via 
upregulation of AMPA (2-amino-3-(5-methyl-3-oxo-l,2- oxazol-4-yl) propanoic acid) 
and NMDA (N-Methyl-D-aspartate) receptor expression and activity (Beattie et al., 2002; 
Samad et al., 2004, Viviani et al., 2003; Wang, et al., 2005). 
Cytokines and Chronic Pain 
Cytokines are polypeptide, nonstructural proteins that are small (5-140 kDa) and 
effective at minute concentrations (pM) (Clark, Old, & Malcangio, 2013). They span a 
spectrum of physiologic functions that are limited in function only by the types of cells 
that express their receptors (Dinarello, 2007). Because of the vast physiologic 
effectiveness of cytokines, these soluble messenger proteins have extreme duality: They 
can be immensely protective (as in the case of immune defense of a host against 
infection) or highly lethal (as in the cases of cellular apoptosis, sepsis and specific 
cancers). Cytokines are further denoted by their propensity to be pro-inflammatory, or 
anti-inflammatory, and subdivided into larger protein families (such as interferons, 
interleukins, chemokines, mesenchymal growth factors, adipokines or the tumor necrosis 
15 
factor family) (Dinarello, 2007). 
The interleukin (IL) family is perhaps one of the largest cytokine families that 
includes over 30 cytokines, both pro- and anti-inflammatory (Dinarello, 2007). 
Interleukin-I (IL-1) is a relatively small pro-inflammatory cytokine (17.5 kDa)that also 
has the ability to initiate the expression and secretion of other pro-inflammatory 
cytokines. It belongs to a larger IL-1 gene family that is responsible for a myriad of 
functions including physiologic temperature regulation, T cell immunity against infection 
and hepatic protein synthesis (Dinarello, 2007). This pro-inflammatory cytokine is 
primarily secreted by glial cells in the CNS (Felts et al., 2005; Zhang et al., 2008), 
although there is data to show neuronal expression as well (DeLeo, Colburn, & Rickman, 
1997; Sweitzer, Colburn, Rutkowski, & DeLeo, 1999). Additionally, neurons, glia and 
astrocytes all contain IL-1 receptors (Gruber-Schoffnegger et al., 2013; Zhang et al., 
2008), making these CNS cells prime locations for IL-1 synthesis, secretion and cellular 
action. In order for neurons and astrocytes to express IL-1, an additional enzyme class 
called matrix metalloproteases has to cleave the inactive precursor (pro-IL-1) to produce 
the physiologically active form of the cytokine (Kawasaki et al., 2008). Not surprisingly, 
preclinical trials have demonstrated that rodents that genetically lack IL-113, IL-la, the 
IL-1 receptor, or overexpress IL-1 receptor antagonist, all fail to develop either 
mechanical hypersensitivity, or mechanical and thermal pain behaviors when exposed to 
an experimentally induced nerve injury (Honore et al., 2006; Wolf, Gabay, Tai, Yirmiya, 
& Shavit, 2006). Thus, IL-1 plays an unequivocal role in central processes of the pain 
expenence. 
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Tumor necrosis factor-alpha (TNF-a) is a pro-inflammatory cytokine that is part 
of a group of over 20 proteins called the tumor necrosis factor superfamily (Dinarello, 
2007). It is a relatively small cytokine (17 kDa) and is produced peripherally by 
macrophages (Aggarwal, Gupta, & Kim, 2012), and centrally by neurons and glial cells 
(Ohtori, Takahashi, Moriya, & Myers, 2004; Xu, Xin, Zang, Wu, & Liu, 2006). Tumor 
necrosis factor-alpha also has extreme duality in it's function under normal physiology: 
It aids host immunity, but also has been implicated in sepsis (Eichacker et al., 2002), 
cancers, cardiovascular, neurologic, pulmonary, autoimmune and metabolic disorders 
(Aggarwal et al., 2012). Under normative conditions, CNS expression ofTNF-a is 
minimal, however in response to nerve injury, TNF-a induces dorsal horn glia to release 
additional pro-inflammatory cytokines and increase neuronal sensitivity (Andrade et al., 
2011; Clark et al., 2013; Inoue, 2006). 
In contrast to the other cytokines discussed above, Interleukin-I 0 (IL-I 0) is an 
anti-inflammatory cytokine. Originally classified as a T-helper-2 (Th2) cytokine, it is 
now known that the functions of IL-10 encompass more than T cells. The actions of this 
cytokine are principally derived from the type of cell that produces it, the type of cell that 
responds to it and the inflammatory cytokine milieu in which it is released (Mosser & 
Zhang, 2008). This anti-inflammatory cytokine is expressed by mast cells, macrophages, 
natural killer (NK) cells, eosinophils, neutrophils and glial cells (Saraiva & O'Garra, 
2010). It is a potent regulator of immune responses; IL-10 attends to conditions ranging 
from parasites to allergens (Saraiva & O'Garra, 2010), and is in many ways the 
physiologic antidote to pro-inflammatory cytokines and overactive immune responses, as 
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it suppresses Interferon Gamma (IFN-g), IL-1, TNF-a and IL-6 (Dinarello, 2007). 
Dysregulation ofIL-10 thus leads to autoimmune and inflammatory conditions and 
diseases (Clark et al., 2013; Mosser & Zhang, 2008; Saraiva & O'Garra, 2010). In 
response to CNS pathology and certain chronic pain states, levels ofIL-10 are increased 
via activation of glial cells (Ledeboer et al., 2003)most likely to combat the transient rise 
in pro-inflammatory cytokines. However in other chronic pain conditions, IL-10 
concentrations have been noted to be lower when compared to healthy controls 
(Alexander, Perreault, Reichenberger, & Schwartzman, 2007; Backonja, Coe, Muller, & 
Schell, 2008). Thus, the literature illustrates that the intrinsic anti-inflammatory 
regulatory mechanism of IL-10 is corrupted or altered in some processes of chronic pain. 
Chronic Pain Treatment & Glial Cells 
Interestingly, preclinical studies have also shown that glial cells contribute not 
only to nociception upon insult (Meller, Dykstra, Grzybycki, Murphy, & Gebhart, 1994), 
but also perpetuate the maintenance of pain when it is treated with opioids. Multiple 
studies have shown that upon administration of chronic opioids to pain-induced rodents, 
there was an increase in glial cell activity in the CNS (Raghavendra, Rutkowski, & 
DeLeo, 2002; Song & Zhao, 2001; Tai et al., 2006). Glia have also been shown to 
upregulate pro-inflammatory cytokines production and release in the CNS when the 
organism is treated with longstanding systemic or intrathecal opioids; this increase of 
cytokine production and release in the CNS has been shown to contribute to opioid 
tolerance and withdrawal induced pain enhancement (Johnston et al., 2004; Raghavendra, 
Tanga, & De Leo 2004; Song & Zhao, 2001 ). These investigations suggest that not only 
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are glia partially responsible for the maintenance of chronic pain symptoms, but they are 
also responsible for decreasing the efficacy of one of the most prominent treatments of 
pain-opioid drugs. Thus, when a chronic pain-induced rodent is treated for pain, over 
time the very treatment that relieves the pain will be part of a self propagating cascade of 
events that will be responsible for perpetuating the pain, increasing the level of pain, 
decreasing the effectiveness of treatment (through opioid tolerance) and creating painful 
responses to stressors that normally should have no painful reaction (allodynia). 
Glial Cell Inhibition in Treatment of Chronic Pain 
Inhibiting glia cells is not an option in the treatment of chronic pain because the 
full physiologic function of these cells is not well understood. Animal model studies 
show that arresting glial cell function in vivo using fluorocitrate, a glial metabolic 
inhibitor, suppresses glial cells from amino acid uptake and can result in host seizures. 
Minocycline, a microglia inhibitor and antibiotic, may prevent glial hyperactivation but it 
cannot be utilized in cases where there is established neuropathic pain (Milligan et al., 
2006). Consequently, a body of research has shifted its approach from directly inhibiting 
glial cells to investigating what effects could be rendered by targeting the pro­
inflammatory mediators released by glia. The results of animal model studies show 
phenomenal promise for future treatment of chronic pain: Several studies have proposed 
that morphine tolerance can be slowed or reversed by knocking out the signaling of the 
glia-produced pro-inflammatory cytokine IL-1, or by blocking IL-1 with a receptor 
antagonist (IL-lra) (Hutchinson et al., 2008; Shavit, Wolf, Goshen, Livshits, & Yirmiya, 
2005). Thus, animal model studies illustrate a cellular relationship that could be explored 
19 
for future treatment of chronic pain, but human research is still lacking. 
Preclinical Verses Human Chronic Pain Studies 
Unlike the animal model of pain research, where a chronic pain state can be 
surgically created in a precise manner, such as a chronic constriction injury of the sciatic 
nerve performed commonly in rodents, human studies have to account for the wide 
spectrum of pain states and symptoms, the cause( s) of pain and the location( s) of pain. 
Likewise, rodent studies are also able to meticulously treat a cohort of rodents with the 
same treatment, medication and dose in a measurable protocol; human studies have to 
adjust for the individual treatment regimens that utilize many types of medications, at 
varying doses or holistic treatments that manipulate varying physiologic processes. 
Additionally, rodent studies are performed in a homogenous population of genetically 
similar organisms; human studies incorporate varying physiologic and psychological 
factors associated with pain. Unlike the rodent models in chronic pain research, humans 
cannot be sacrificed for direct measurement of pro-inflammatory cytokines, and thus the 
two methods available for cytokine data collection in human models is limited to serum 
and cerebrospinal fluid (CSF) analysis. The wide variance in types of pain states, 
medications used for treating pain, co-existing physiologic and psychological variables 
and the indirect methods of gathering data limit human studies. Preclinical studies, 
however, offer limited value to understanding the relationship of chronic pain and levels 
of cytokines in humans. Rodent studies offer no insight into the relationship between the 
psychology of pain and the neuroimmune responses of chronic pain. Anxiety, depression 
and sleep disturbances are ascertained in rodent models with a certain degree of 
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interpretation. Rodent models also do not clearly describe what will occur in human 
physiology. While animal studies may provide a basic understanding of a phenomenon, 
human studies are nevertheless paramount in progressing towards translation into 
treatment modalities. 
Human Chronic Pain Studies & Inflammation 
The human research on pro-inflammatory cytokines is very limited and 
developing now. Prior human studies focused on measuring pro-inflammatory cytokines 
through serum analysis secondary to the decreased invasiveness and ease of collection. 
However, several of these studies discovered confounding levels of cytokines that were 
measured in the serum verses CSF of the study participants: levels of cytokines found to 
be high in the CSF were found to be low or undetectable in the serum and vice versa 
(Backonja et al., 2008; Brisby, Olmarker, Larsson, Nutu, & Rydevik, 2002; Kadetoff, 
Lampa, Westman, Andersson, & Kosek, 2012; Ludwig, Binder, Steinmann, Wasner, & 
Baron, 2008; Lundborg, Hahn-Zoric, Biber, & Hansson, 2010; Rozen & Swidan, 2007; 
Zin, Nissen, Moore, & Smith, 2010). Possible reasons include cytokine production via 
peripheral physiologic processes, which may or may not be related to nociception, verses 
cytokine production via glia in the CNS in response to pain signaling. This study will 
focus on CSF analysis because of the role of CNS processing in chronic pain, and the 
accompanying central location of glia, cytokines, and neurons. This approach proves 
more logical than examining serum levels of mediator molecules-subject to multiple 
competing physiological stimulin of peripheral immune cells-as a means of supportive 
analysis for developing pain literature. 
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Currently CSF has been examined in patients with complex regional pain 
syndrome (Alexander et al., 2007; Alexander, van Rijn, van Hilten, Perreault, & 
Schwartzman, 2005; Backonja et al., 2008; Munts et al., 2008), fibromyalgia (Bjersing, 
Dehlin, Erlandsson, Bokarewa, & Mannerkorpi, 2012; Kadetoff et al., 2012), those 
receiving intrathecal opioid infusions for pain management (Zin et al., 2010), persistent 
headache (Rozen & Swidan, 2007), neuropathic pain related to previous spinal surgery 
(McCarthy, Connor, & McCrory, 2013; Capelle, Weigel, Schmelz, & Krauss, 2009), 
sciatica (Brisby et al., 2002), lumbar radiculopathy (Nagashima, Morio, Yamane, Nanjo, 
& Teshima, 2009; Ohtori et al., 2011), polyneuropathy (Ludwig et al., 2008), post 
herpetic neuralgia (Kikuchi, Kotani, Sato, Takamura, Sakai, & Matsuki, 1999; Kotani et 
al., 2000; Rijsdijk et al., 2013) and chronic osteoarthritis pain (Buvanendran et al., 2006; 
Lundborg et al., 2010; Yeager et al., 1999). Additional studies analyzing human CSF can 
be found summarized by Bjurstrom et al. (2014). Grouping of study participants based 
on diagnosis may control for some error by standardizing the type of pain, quality, 
location, causes and triggers as well as the treatment for the specific pain. This study 
included all forms of chronic pain patients with the intention of grouping the types and 
causes of pain before determining the most meaningful analysis methodology. In 
general, the preceding studies demonstrated that IL-1, IL-6, IL-8 and TNF-a were found 
to be elevated in the CSF of human study participants, but more evidence is still needed 
to corroborate the behavior of these molecules in pain syndromes. Other research has 
demonstrated a decrease in CSF levels of anti-inflammatory IL-10 (Alexander et al., 
2007). This current study targeted IL-1, IL-6, IL-8, TNF-u and IL-10 for analysis and 
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focused on providing supportive human data for the chronic pain population. By 
measuring CSF rather than serum, grouping patients based on their diagnosis of pain and 
basing the cytokine analysis on previous investigations, this study provides a greater 
understanding of the developing role cytokines play in chronic pain. 
Evidence Supporting Inflammatory Contributions to Anxiety and Depression 
As previously mentioned, preclinical studies provide little insight into how 
psychological states (i.e., anxiety and depression) relate to the neuroimmune response of 
chronic pain in humans. All types of anxiety and depression cannot be directly 
ascertained in any rodent model, and is an integral component in the pain process and 
definitive treatment plan of chronic pain. Part of the psychoneuroimmunologic 
component to pain is the interaction between inflammation, cytokines and the behavioral 
complex known as sickness behavior or sickness response. Feelings of sickness can be 
characterized by fatigue, decrease appetite, fever, lack of mobility, sleep disturbances, 
depression and an inability to concentrate (Dantzer, 2001; Hart, 1988; Watkins & Maier, 
2000). Though the neuroimmune-mediated sickness behavior/response may promote 
unsavory feelings, this natural response to illness is ultimately protective as it aids in 
healing and is usually short-lived with resolution of the offending illness. However, like 
chronic pain, when the protective mechanism of the sickness behavior/response goes 
awry, feelings of depression and anxiety can be perpetuated longer than the illness or 
stress. If the psychological effects of anxiety and depression are related to the illness or 
stress of pain, the mechanism is still unclear. Inflammatory cytokines offer one possible 
explanatory link between all of the psychoneuroimmune responses and pain, but central 
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levels of cytokines in humans have not been extensively studied thus far. In addition to 
the relationship of chronic pain to altered levels of centrally-produced cytokines, anxiety 
and depression must be examined in humans to determine their relationship to chronic 
pain and central inflammation. 
Inflammation & Anxiety 
While a majority of research and attention has focused on the relationship 
between chronic pain and depression (Dersh, Polatin, & Gatchel, 2002), there is literature 
that supports associations with chronic pain and anxiety disorders. In a large, 
retrospective analysis of over five thousand participants, Mc Williams and colleagues 
found there was a stronger association of chronic pain and panic disorder (PD) and post­
traumatic stress disorder (PTSD) than depression (Mc Williams, Cox, & Enns, 2003). 
Thus, this study and other literature suggest the possibility that efforts to treat chronic 
pain should be combined with anxiolytic treatment. 
Peripheral levels of inflammatory cytokines have been examined with conflicting 
results in human studies related to anxiety disorders. While some investigations 
examining relationships between anxiety and systemic cytokines levels have shown 
increases in serum levels ofIL-1~ and IL-6 (Maes et al., 1999; Spivak et al., 1997), 
results of other studies are contrary to those findings (Koh & Lee, 2004; van Duinen et 
al., 2008). Possible explanations for the discrepancies between these studies include the 
type of anxiety (acutely experiment-produced or a chronic underlying diagnosis), whether 
the cytokines measured were from induced lymphocyte production or systemically 
circulating levels, and the sensitivity of the assay used to detect the cytokines. Using 
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Multiplex assay analysis with the Luminex® system (Austin, TX), Hoge and colleagues 
were able to demonstrate elevations in serum levels of eighteen cytokines including pro­
inflammatory IL-1~, IL-6, IL-8 and TNF-u as well as anti-inflammatory IL-10 in PD and 
PTSD study participants (Hoge et al., 2009). However, these peripheral results do not 
clarify ifthere is a central mechanism that links anxiety, inflammation and pain. 
The data on central inflammation and anxiety is very limited. Similar to chronic 
pain studies that examine peripheral and central cytokine patterns, anxiety research 
exemplifies the same theme: Peripheral and central levels of cytokines do not appear to 
agree in magnitude or direction in most investigations. According to Baker et al. (2001), 
levels of IL-6 were found to be increased in the CSF but not increased in the serum of 
PTSD participants. Clearly, there is opportunity to examine the relationship between 
anxiety, commonly found with pain-related conditions, and the centrally mediated 
response of inflammation. 
Inflammation & Depression 
The direct correlative relationship between depression and pain has been 
thoroughly documented in the literature showing that both depressed patients exhibit at 
least one painful symptom (Vaccarino, Sills, Evans, & Kalai, 2009) and chronic pain 
patients frequently exhibit depression (Dworkin & Gitlin, 1991 ). In a study by the 
American Pain Foundation, over half of the chronic pain sufferers surveyed reported that 
pain impacted their overall enjoyment of life and over 75% reported feeling depressed 
because of their pain (David Michaelson & Company, LLC, 2006). Thus pain and 
depression warrant mutual inspection. 
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Similar to the anxiety literature, the relationship between levels of pro- and anti­
inflammatory cytokines and their neuroimmune relationship in the pathophysiology of 
depression are not fully understood. Through a meta-analysis of 136 studies on serum 
levels of cytokines in depressive patients, Dowlati and colleagues found both supportive 
and contradictory results supporting the role of peripherally measured inflammatory 
cytokines and depression. They were only able to report a significant increase in IL-6 
and TNF-u in depressed subjects when compared to control subjects (Dowlati et al., 
2010), and it is unclear to what degree peripheral levels of cytokines relate to depression 
itself verses the chronic generalized stress depression causes. 
Because some antidepressants work centrally and have been shown to reduce 
levels of inflammatory cytokines (Basterzi et al., 2005; Janssen, Caniato, Verster, & 
Baune, 2010), the patterns of CNS inflammatory cytokines in the depressed patient begs 
for more extensive investigation. The evidence of central levels of pro- and anti­
inflammatory cytokines and depression in humans is very limited but presently 
underway. Cerebrospinal fluid levels of cytokines have been measured in unmedicated 
depressed patients (Levine et al., 1999), suicidal populations (Lindqvist et al., 2009), and 
chronic PTSD sufferers (Bonne et al., 2011) all with conflicting results. Clearly chronic 
pain and depressive symptoms are usually experienced together, but there is no data 
currently available exploring the role of central inflammation and the pathophysiology of 
these co-existing symptoms. More data must be collected to ascertain the relationship of 
central inflammation and depression, especially in the chronic pain population. This 
study adds valuable data in its examination of the relationship of central inflammation 
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and the depressive psychological component of chronic pain. 
Evidence Snpporting Inflammatory Contributions to Sleep Deprivation 
The complex relationship between pain and poor sleep quality is one that has been 
extensively documented in the literature, but its causality not fully understood. Both 
processes of pain causing poor sleep, and poor sleep causing pain are primary paradigms 
in the bidirectional relationship between pain and sleep. From the protective sickness 
behavior/sickness response theory, as previously described, sleep has been suggested as a 
critical component in the restorative process of healing (Dantzer, 2001; Hart, 1988; 
Watkins & Maier, 2000). Counterproductively, in the presence of chronic pain 
pathophysiology, the restorative process is impaired by a lack of sleep: In a complex, 
detrimental dynamic, pain itself causes sleep deprivation and sleep deprivation has been 
shown to increase pain perception (Chiu et al., 2005; Lautenbacher, Kundermann, & 
Krieg, 2006; Moldofsky, 2001; Smith & Haythornthwaite, 2004). Up to 53% of chronic 
back pain patients and 88% of neuropathic pain patients report sleep disturbances 
(Meyer-Rosberg et al., 2001; Tang, Wright, & Salkovskis, 2007). Furthermore, patients 
with chronic lower back pain are 18 times more likely than normal control subjects to 
experience clinical insomnia (Tang et al., 2007). Thus, literature supports that sleep and 
pain do interact with one another, the abnormalities of sleep are frequently reported by 
the chronic pain population, and the effects are not benign: The effects of sleep 
disturbances have been linked with poor physical and psychological outcomes, absence 
from work, decreased performance, difficulty with personal relationships, accidents and 
cognitive decline (Fulda & Schulz, 2001 ). Even in healthy individuals, sleep deprivation 
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has been noted to cause spontaneous pain (Smith, Edwards, McCann, & 
Haythornthwaite, 2007). Clearly a holistic approach to treating these patients must 
involve attention of both the sleep and pain symptomatologies. The causes or common 
mechanisms between poor sleep and pain are just starting to develop and warrant 
investigation for treatment of these patients. Interestingly, one of the foremost emerging 
theories on the link between pain and sleep deprivation include circulating inflammatory 
cytokines. 
Inflammation & Sleep 
Historic, seminal studies on sleep have demonstrated repeatedly that there is a 
centrally produced mechanism or substrate for sleep. At the turn of the century, Ishimori 
demonstrated that upon injecting rested animals with the CSF of sleep deprived animals, 
the rested animals fell into a deep sleep (Ishimori, 1909). Pappenheimer and colleagues 
reported similar findings, demonstrating that when the CSF of sleep-deprived animals 
was injected into rested rodents, a decrease in activity and an increase in sleep was 
observed (Pappenheimer, Miller, & Goodrich, 1967). Later when it was found that 
muramyl peptide induced synthesis and secretion ofIL-1 by astrocytes, a biological basis 
for sleep alteration by a centrally mediated mechanism was confirmed (Fontana, 
Kristensen, Dubs, Gemsa, & Weber, 1982). Repeated animal studies have shown that 
upon central administration of IL-1 to both rabbits and rats, the result is an increase in 
various aspects of sleep (Krueger, Walter, Dinarello, Wolff, & Chedid, 1984; Tobler, 
Borbely, Schwyzer, & Fontana, 1984) independent of, but similar to the somnogenic 
effects ofTNF-u (Shoham, Davenne, Cady, Dinarello, & Krueger, 1987; Kapas et al., 
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1992). The concentrations of inflammatory cytokine required to influence sleep, either 
positively or negatively, is variable in the literature. In one study, Opp and colleagues 
found that low doses of intracerebroventricular doses of a pro-inflammatory cytokine did 
not affect rapid eye movement sleep (REMS) while higher doses did impair both non­
rapid eye movement sleep (NREMS) and REMS (Opp, Oba!, & Krueger, 1991). Thus, 
there is not only evidence that central inflammatory cytokines influence sleep, but the 
amount of the inflammatory cytokine circulating influences the quality and type of sleep 
as well. 
Unfortunately, monitoring of central inflammatory cytokines in human sleep 
studies has been very lacking thus far, and those studies that have monitored peripheral 
concentrations of inflammation have yielded conflicting results. Peripherally monitored 
cytokines have been measured in humans, but on a limited basis and have focused on IL­
1, IL-6 and TNF-u. Prior human studies have found that peripherally circulating levels of 
IL-6 have been correlated with decreases in slow wave sleep (Hong, Mills, Loredo, 
Adler, & Dimsdale, 2005) and increased REMS (Irwin et al., 2004) (both of which are 
associated with poor sleep quality). However, V gontzas and colleagues found that levels 
ofIL-6 were associated with decreased REMS (Vgontzas et al., 2003) (a result that points 
to more restful sleep). Patients with excessive daytime sleepiness disorder have been 
found to express increased plasma IL-6 levels (Motivala, Sarfatti, Olmos, & Irwin, 2005) 
and TNF- a levels (V gontzas et al., 1997). Thus it seems that an increase in peripherally 
circulating inflammatory cytokines is present when there is poor sleep or in conditions of 
chronic sleep deprivation, but there is conflicting experimental data. Further studies must 
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describe the means to scaffold concrete treatment options for these patients. 
Similar to animal studies that illustrate the pertinent role of inflammatory 
cytokine concentration on either sleep promotion or sleep disturbance, human plasma 
studies have also yielded similar results: Peripheral pro-inflammatory cytokine 
concentrations seem to peek after sleep onset and have higher circulating levels at night 
(Bauer et al., 1994; Redwine, Hauger, Gillin, & Irwin, 2000). However, when there is 
poor sleep quality and/or sleep deprivation, higher peripheral levels of pro-inflammatory 
cytokines are common (Haack, Sanchez, & Mullington, 2007; Moldofsky, Lue, 
Davidson, & Gorczynski, 1989). These studies beg the question that at what 
concentration do inflammatory cytokines stop being sleep promoting and begin to be part 
of the cycle of sleep deprivation? Perhaps the measured peripheral levels of cytokines 
are not sensitive enough to detect the intricacies of the inflammatory cytokine sleep 
cycle. Perhaps the central cytokine levels are predominantly the cause of sleep 
deprivation. Unfortunately none of these studies examined central levels of 
inflammatory cytokines related to sleep quality, regardless of the seminal sleep literature 
that suggests central levels of cytokines are sonmogenic. 
Pain, Inflammation & Sleep 
In human pain populations there exists almost a complete deficiency of data 
comparing inflammatory markers, sleep and pain. A study by Heffner and colleagues, 
substantiates that patients with chronic lower back pain were found to have higher levels 
of plasma IL-6 than healthy control subjects. In the chronic pain population studied, poor 
sleep quality was found to be associated with greater pain on the following morning 
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(Heffner, France, Trost, Ng, & Pigeon, 2011). Thus there is scant data to support the 
theory that inflammatory cytokines may contribute to the poor sleep quality endured by 
the chronic pain population, and central levels have not been examined even with the 
knowledge that there is a CNS component to sleep. Human data is requisite and 
developing presently. With a better understanding of central inflammatory cytokines 
associated with chronic pain and poor sleep quality, further discussion can be instigated 
to encompass a more holistic approach to treating the entire experience of the pain 
patient. This study offers a novel and exciting exploration of previously unexamined 
interactions between three critical physiological phenomena: pain, sleep, and the central 
inflammatory cytokine responses. 
Implications for Future Knowledge Development 
Because there is a scarcity of human evidence supporting the link between 
chronic pain, anxiety, depression and sleep deprivation and central inflammation, this 
study hopes to provide supportive evidence of this relationship. If this study, and future 
human studies illustrate the same association that preclinical models show, the 
implications for chronic pain treatment in our patient population are tremendous. 
Hutchinson and colleagues' preclinical study demonstrated that by blocking the pro­
inflammatory cytokine IL-1, the length of time of intrathecal opioid analgesia was 
doubled and the time of systemic opioid analgesia increased by over one-and-a-half 
times. The study also demonstrated an approximate seven-and-a-half -fold increase in 
analgesic efficacy with morphine was possible by co-administrating the opioid with a 
receptor blocker ofIL-1. These results were not just limited to morphine, Hutchinson's 
31 
study also produced similar results with methadone as well (Hutchinson et al., 2008). In 
another preclinical study, Johnston and colleagues indicated that by blocking IL-1 in the 
CNS, the analgesia of an intrathecally administered opioid was enhanced, opioid 
tolerance was blunted and both newly developed and established allodynia and 
hyperalgesia were reduced (Johnston et al., 2004). Because newly marketed 
antidepressants have elicited central responses through changes in inflammatory cytokine 
levels (Basterzi et al., 2005; Janssen et al., 2010), the central patterns of these cytokines 
must be examined in the depressed pain patient. 
With supportive evidence that there is a relationship between chronic pain, 
anxiety, depression and sleep deprivation and central inflammation in humans, the 
responsible cytokines can be isolated and targeted. With further human evidence that 
inflammatory cytokines are part of the physiologic and psychological chronic pain cycle, 
there is a potential to treat chronic pain patients with opioids that would have a longer 
duration of action and increased efficacy. With further human evidence there is a 
potential to blunt opioid tolerance that develops over time, and reduce the allodynia and 
hyperalgesia chronic pain populations experience. With more advanced neurologies that 
pharmacologically target central inflammation, perhaps anxious and depressive 
symptoms can be better mitigated. Finally, with further human understanding of the 
psychoneuroimmunologic aspect of chronic pain, the complete patient will find relief in 
therapy that addresses all facets of the disease. 
Conclusion 
Animal models show in repeated studies that chronic pain states, opioid tolerance, 
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hyperalgesia, allodynia, anxiety, depression and sleep deprivation can be linked to 
aberrant levels of inflammation. By blocking pro-inflammatory cytokines, animal studies 
have shown that analgesia time and efficacy can be dramatically increased, opioid 
tolerance can be decreased and hyperalgesia and allodynia can be resolved. Similar 
advancements in inhibition of inflammation in the treatment of anxiety and depression 
are just now showing similar results. Because our current treatment techniques for 
chronic pain are restrictive and ineffective for certain sufferers, corroborative human 
evidence needs to be accumulated to illustrate the link between inflammation and chronic 
pain. If the same relationship that exists in rodent models can be shown in humans, new 
and innovative treatment modalities can be developed to treat intractable chronic pain and 
the psychological attributes that accompany this disease. One cannot continue to treat 
patients with medications and procedures that provide minimal relief for a short duration 
of time. With new avenues and pathways to target chronic pain, anxiety, depression and 
sleep deprivation, inflammatory cytokines certainly provide an exciting possibility in the 
future of chronic pain therapy. 
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This was a cross-sectional, correlational study with a convenience sample of 
approximately eight chronic pain patients recruited from the Pain Management Center at 
the University of California, Los Angeles (UCLA). One-time collections of 
cerebrospinal fluid (CSF) samples were analyzed and compared to 30 control CSF 
samples to allow for testing of the first and second hypothesis. Psychological tool 
analysis of study participants allowed for testing of the third and fourth hypothesis. 
Demographic analysis allowed for testing of the fifth and sixth hypothesis. 
Sample and Sample Size Calculation 
Study Participants 
Approximately eight patients with the diagnosis and symptomatology of chronic 
pain who were eligible for, and medically recommended treatment with an intrathecal 
opioid infusion pain pump (the Medtronic SynchroMed® II Pain Pump) were enrolled in 
this study after informed consent (Appendix A) was obtained. Potential participants 
were recruited from the Pain Management Center at UCLA. Inclusion criteria for this 
study melded both surgical and experimental criteria; examples of such criteria include 
the participant's age (the surgical eligibility for an implant of an intrathecal opioid 
infusion pain pump is 18 years of age) and duration of diagnosis (this study required 
subjects have a chronic pain diagnosis greater than 6 months duration to be considered 
"chronic"). Diagnosis of chronic pain was made on standard clinical criteria, as 
suggested by the International Association for the Study of Pain (IASP). Exclusion 
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criteria also incorporated a combination of surgical and experimental criteria; surgical 
criteria that would exclude a patient from obtaining an implanted intrathecal opioid 
infusion pain pump included meningitis, active upper respiratory infection/flu or febrile 
nature, acute medical or psychiatric disorders, acute psychological or physiologic 
danger/instability, altered mental status, pregnancy and the inability to communicate in 
English. Experimental exclusion criteria included a diagnosis of cancer, human 
immunodeficiency virus (HIV), recent epidural injections for treatment of chronic pain 
(within six months), drug abuse, meningitis or history of meningitis, history of blood 
transfusion(s) and palliative pain treatment. The inclusion and exclusion criteria were 
confirmed using standard clinical and laboratory methods of analysis, not above or 
beyond the standard of care, or at any additional burden to study participants. All study 
participants were instructed to continue all of their medications and therapies without 
making any changes prior to, or during study involvement. 
Control Samples 
Control samples ofCSF were obtained from the California NeuroAIDS Tissue 
Network. Thirty random, individual control samples of 1-2 milliliters (mL) ofCSF, 
collected through the HIV Neurobehavioral Research Center between the years 2005­
2012, were utilized from this tissue bank as a means to compare levels of central 
inflammatory cytokines. The CSF samples obtained from this tissue bank were 
supported by the HIV Neurobehavioral Research Center (HNRC) P30 MH62512 
(Principle Investigator: Robert K. Heaton, PhD) and supplied by Scott Letendre, MD 
through a collaboration with the University of California, San Diego (UCSD). The 
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control samples of CSF were selected randomly to include seronegative HIV and 
hepatitis C virus (HCV) donors, with no history of recreational drug use, no diagnosis of 
cancer and an approximate equal distribution of men and women donors. No other 
information pertinent to the control sample donors was provided to the research team 
except the date of collection. 
Sample Size Calculation 
In order to estimate the sample size needed to yield statistically significant results 
in the testing of the difference between two means (the CSF cytokine levels between 
healthy and chronic pain participants), the effect size was estimated using Cohen's d. 
Using this power analysis to estimate the sample size and reduce the risk of a Type II 
statistical error, aided in estimating the sample size when the population effect size was 
not known. Human chronic pain CSF studies are just beginning to be explored and as 
such, this novel new research is not advanced enough to lend proven effect sizes. This 
could be because the average chronic pain CSF study incorporates small sample sizes 
(usually 10-40 participants) (Bjurstrom, Giron, & Griffis, 2014) due in part to the 
invasiveness of collecting CSF, participant burden and risk, and the expense of analyzing 
cytokines. There are approximately 19 studies to date that have been published on the 
analysis of CSF cytokines in chronic pain populations. Only two of these studies utilize 
Multiplex assay analysis (McCarthy et al., 2013; Rijsdijk et al, 2013). Thus, a sample 
size calculation for this study was necessary. 
Given the significance level was set at 0.05 (to reduced the risk of a Type I 
statistical error) and the power was set at 0.80 for this study, the effect size was estimated 
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using results from similar studies that explored CSF levels of cytokines in chronic pain 
and healthy controls. Rather than estimate the effect size based on the expectations of a 
small, medium or large effect, Cohen's d was calculated for each cytokine analyzed by 
several prior studies that analyzed chronic pain patients' levels of cytokines (see Table 1). 
Table 1 


















0.84 NIM 2.37 NIM NIM 
Lundborg et 
al., 2010 
0.69 0.27 0.85 NID 0.52 
Backonja et 
al., 2008 
1.06 0.68 0.33 0.97 NID 
Ohtori et al., 
2011 
NIM 1.35 NIM NIM NIM 
Alexander et 
al., 2007 
NIM 0.67 0.47 0.02 NIM 
Nagashima 
et al., 2009 




NIM NIM NIM NIM 0.36 
Ludwig et 
al., 2008 
NIM 0.52 NIM NIM 0.55 
Alexander et 
al., 2005 
0.73 1.08 NIM NIM 0.18 
Aver~e 1.00 0.82 1.01 0.50 0.40 
Note. NIM denotes that the study did not measure this variable. NID denotes that the 
variable was not detectable. 
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Referring to Polit and Beck's sample size estimates (Polit & Beck, 2012, p. 424), 
given the a of0.05 and a power of0.8, the approximate sample sizes were obtained from 
the average Cohen's d (see Table 2). 
Table 2 







Average Cohen's d 















Note.· Values taken from Table 17.6 in Polit & Beck, 2012, p.424. 
The planned number of study participants was set at approximately 30, given the 
amount of time and the budget for the study, based on this power analysis. The amount 
of healthy CSF samples obtained from the California NeuroAIDS Tissue Network was 
30, allowing for a total n~60. According to the Cohen's d calculation, this sample size 
would be large enough to detect significance in the majority of inflammatory cytokines 
tested. Approximately 36 study recruits would be solicited to account for up to 20% 
attrition. 
The actual number of study participants recruited from April 2013 to December 
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2014 was eight. Potential factors that contributed to the lower than anticipated study 
participant recruitment included changes in the personnel of the UCLA Pain Management 
Office, a decrease in the number of physicians performing the intrathecal opioid infusion 
pain pump procedures, an increase in the number of intrathecal neurostimulator 
placement procedures and hence, lower than anticipated intrathecal opioid infusion pain 
pump placement procedures. Only one patient who was solicited to participate in this 
study refused, making the actual attrition rate approximately 11%. 
Setting 
The UCLA Pain Management Center was the primary location of subject 
recruitment, consent and psychological testing. Subjects recruited from the UCLA Pain 
Management Center had CSF collected in an operative procedure performed at UCLA 
Santa Monica Orthopedic Hospital Outpatient Surgery Center. The UCLA Cousins 
Center for Psychoneuroimmunology Inflammatory Biology Laboratory served as the 
specimen processing, storage and analysis site of this study. 
Instrumentation 
Multiplexing Assays 
To analyze the patterns of inflammatory markers in both chronic pain and control 
samples of CSF, Luminex Performance Human High Sensitivity Cytokine Panel (R&D 
Systems, Minneapolis, MN) and the Bio-Plex 200 instrument (Luminex®) with Bio-Plex 
Manager software version 5.0 were utilized for the precise and highly sensitive 
measurement of inflammatory cytokines. Multiplex assays were chosen over high­
sensitivity enzyme-linked immunosorbant assays (ELISAs) to analyze the CSF samples 
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because of the minimal amount of sample needed to perform the analysis, the decreased 
time to analyze the samples for inflammatory cytokines ( analytes ), the decreased cost of 
analyzing multiple analytes, and because of its novel new laboratory analysis technique. 
Multiplex assays utilize fluorescence and spectral analysis as a reporter system instead of 
the enzyme amplification of antibody-antigen "sandwiches" utilized by ELIS As. 
Specifically, the Luminex® multi-analyte profiling system uses digital processing to 
analyze polystyrene beads for up to 500 different analytes at one time (Andreasson, 
Protelius, Pannee, Zetterberg & Blennow, 2012). It implements a two-laser instrument 
that detects three-color fluorescence; two colors are used for analyte classification and the 
third color is used to detect the intensity or amount of analyte. Because of the spherical 
medium and the use of spectral identification with fluoroscene, multiple analytes can be 
analyzed simultaneously (Elshal & McCoy, 2006). 
Precision, accuracy and error. When assessing measurement tools of biophysical 
samples, such as a new laboratory technique like Multiplex assays, the precision and 
accuracy of the tool must be reviewed, and the potential error surrounding the tool 
identified. According to Ryan-Wenger, precision is similar to the concept of reliability; it 
is not a characteristic of the tool but rather how the tool is utilized by the researcher. 
Precision reflects the tool's sensitivity, or tool's ability to reflect a change in value if 
there is a corresponding change in the value being measured (Ryan-Wenger, 2010, p. 
373). Accuracy is similar to the concept of validity; it is the extent to which the 
measured values are in agreement with true scores elicited from a gold standard (Ryan­
Wenger, 2010, p. 374). Thus, for the purpose of critiquing Multiplex assays, the 
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precision of the tool reflects the consistency across the measurements, and the accuracy 
reflects the agreement with the gold standard. 
Precision. To assess the consistency across measurements, or precision of Multiplexing 
in measuring human biological samples, studies were examined that reported on greater 
than two Multiplex assay analysis on the same biologic sample or control sample. To 
measure the repeatability or precision of the Luminex® Multiplex tool, the coefficient of 
variation (%CV) was inspected in several studies. The %CV was examined for 
Multiplexing as a statistic to relay the error in precision given that tools that have high 
%CVs are considered to have a high error in their precision, and therefore are not 
consistent in their measurement. 
In a 2013 study examining the validation of three Mulitplex kits utilizing the 
Luminex® platform, Belabani et al. reports that the intra-assay %CV between three 
Multiplex kits inspected was less than 25% with the exception of one cytokine in one of 
the Multiplex kits. For the lower limit of quantification, the %CV was less than 30% for 
all cytokines in all kits with the exception of two cytokines in two kits (Belabani, 
Rajasekharan, Poupon, Johnson, & Bar-Oh, 2013). DuPont's study shows the inter-assay 
%CV for two Luminex® Multiplex kits as less than 25%, except for one cytokine in one 
of the kits. The intra-assay %CV for both kits was less than 25%, except for one 
cytokine in the aforementioned kit (duPont, Wang, Wadhwa, Culhane, & Nelson, 2005). 
These studies illustrate the specific nature of this testing modality: Not all kits are 
appropriate for testing all biomarkers. Manufacturer recommendations should be 
followed explicitly when selecting a kit for the specific biomarkers to be measured. 
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Chowdhury's 2009 piece illustrates that the Luminex® Multiplex intra-assay 
%CV was less than 25%. The mean inter-assay %CV when measuring high 
concentrations of cytokines was 25%; for low concentrations of cytokines %CV was 30% 
(Chowdhury, Williams & Johnson, 2009). This exemplifies again the importance of 
proper kit selection given the expected concentration of analyte. Not all Multiplex kits 
can measure all ranges ofbiomarker values. 
Kang and colleagues demonstrated intra-laboratory precision values (reported as 
%CV) for Luminex® Multiplexing between 5.3%-10.8% for the three cytokines 
analyzed. The inter-laboratory %CV for Multiplexing ranged from 13.1 %- 17.9%, 
demonstrating the importance of developing protocol standards in laboratory techniques 
for maximizing precision in Multiplexing (Kang, Vanderstichele, Trojanowski & Shaw, 
2012). 
If precision of a measurement is not a characteristic of the tool, but how the tool is 
utilized by the researcher, the aforementioned studies illustrate this definition of precision 
for Multiplexing: Proper kit selection, strict adherence to manufacturer recommendations 
and standardization of protocols all influence the %CV or precision of this specific tool. 
Given that the %CV is consistently less than 30% across all studies, precision for the 
Luminex® Multiplexing assay seems adequate for the analysis of human biologic 
samples. It is stressed however, that continued validation of the tool must be ongoing 
and collaborative between laboratories is essential to develop standards for this new 
assay. 
Accuracy. To assess the accuracy of Multiplexing in measuring human biologics, 
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studies were examined that reported the values of the Luminex® Multiplex tool 
compared to the gold standard of ELISA analysis. This was done by analyzing the 
correlations of Multiplexing to ELISA either reported as r or r' (correlation or regression 
coefficients of various statistical analysis). Table 3 (adapted from Elshal & McCoy, 
2006) summarizes the correlations of various Multiplex assays to the gold standard 
ELISA from a variety of studies. 
Table 3 
Correlations Between Multiplexing and ELISAs 






Chen et al., 
1999 
Prabhakar 






IL-1~ 0.964 0.96-0.98 0.838 
IL-6 0.847 0.98 0.903 
IL-8 0.999 0.946 0.92-0.96 0.9816­
0.9859 
IL-10 0.926 1.0 0.820 
TNF-a 0.998 0.911 0.97 0.96 0.938 
Correlation 
Calculation 
r r2 r r2 r2 r 
Note. Table 3 is adapted from Elshal & McCoy, 2006, p.321 with data from Richens, 
Urbanowicz, Metcalf, Corne, O'Shea, & Fairclough, 2010. 
Unfortunately, limitations of these correlations across the different studies include 
different methodological approaches, poorly described statistical analysis, utilization of 
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different Multiplex kits and variation in kit manufacturers. However, from the high 
degree of correlation detailed in the literature it can be deduced that Multiplexing is 
appropriate in the analysis of biologic analytes measured by ELISAs. However, 
throughout the literature, it is stressed that the values elicited from ELIS As and 
Multiplexing are not interchangeable. Trends or patterns in biomarkers correlate well 
between ELIS As and Multiplexing, but future comparisons of specific values should note 
that ELISAs and Multiplex assays do not yield the same values. 
Error or bias. Using classic test theory for the evaluation of Multiplexing as a tool to 
measure cytokines in biologics, it is postulated that the observed value ofbiomarkers (0) 
is equal to the true value ofbiomarkers (T) plus error. 
0 ~ T +error 
Error diminishes the extent to which the measured biomarker values serve as 
adequate representations of the values trying to be measured. Because error in precision 
and accuracy is cumulative, the extent of the error or bias must be identified and 
prevented a priori, controlled for, and accounted for the in the research design (Ryan­
Wenger, 2010, p.371). 
Multiplexing was also assessed for its capacity to analyze biological samples for 
the presence and amount of biomarkers. However, the error or bias that can occur and 
convolute the final values involves all parts of the experimental process: from the 
collection of the sample, through the storage, to the handling of the specimens, through 
the Multiplex assay process and analysis, and documentation of the results, error can 
occur. Some of the potential errors with analyzing biological specimens (specifically 
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CSF) using Multiplexing has been identified by Kang and colleagues. When the error 
can temporally occur in the experiment, the source of the error and suggestions for 
correcting the error is presented in Table 4 (Kang et al., 2012). These sources of error 
cited by Kang and colleagues helped scaffold the methodological approach of this study, 
as all precautions were taken to avoid these potential sources of error. 
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Table 4 
Potential Error in Multiplexing 
Phase of Experiment Source of Error iu 
Procedure 
Means to Correct Error 
Preanalytical Phase Lumbar Puncture Training and Standardization 
Use of Polypropylene 
Collection Tubes 
Avoid Blood Contamination 
ofCSF 
CSF Collection in Morning 
Fasting 
CSF Handling and Storage Immediate Freezing ofCSF 
Samples 
Use of Polypropylene 
Storage Tubes 
Limited Dead Volume in 
Tubes 
Limit Freeze-Thaw Cycles 
Reagent Handling Standardized Procedures 
Follow Manufacturers 
Instructions 
Analytical Phase Quality Control Procedures Predefined Run-Acceptance 
Criteria 
Use of Aqueous QC Samples 
and CSF Pools to Assess 
Within-Run and Between-
Run Analytical Performance 
Use of Samples for Lot-to-
Lot Consistency 
SOP for Calibration Curve 








Shaking of Reagents 








Proficiency Panel to Qualify 
Performance of Analysts 
Standardization of Sample 
Thawing Procedure (Temp 
and Time) Before Testing 
Follow Manufacturer's 
Instructions 
Standardization of Vacuum 
Pressure and Equipment 
Use Orbital-Type Shaker 
Standardization of 




Use of Polypropylene Tips 
Avoid Up and Down 
Pipetting 
Standardized Regular 
Validation and Maintenance 
SOP for Testing 
Use of Nonlinear Logistic 
Curve-Fit 
Predefined Run Acceptance 
Criteria 
Efforts to Minimize the 
Variation by Kit 
Manufacturer 
Lab Establishes Criteria for 
Acceptable Variability 
Limits 
Commit to Collaborative 




Detailed Standard Operating 
Procedure 
Identify Possible Sources of 
Error and Provide 
Troubleshooting Guidelines 
Note. QC denotes quality control. SOP denotes standard operating procedures. Table 4 
is adapted from Kang, Vanderstichele, Trojanowski, & Shaw, 2012, p.487. 
With a review of validation studies of Multiplex assays, the precision and 
accuracy of this measurement tool was explored. From the literature, the precision and 
reproducibility of Multiplex values were found to be good both intra- and inter-assay. 
The correlations of various biomarkers were assessed between Multiplexing and the gold 
standard ELISA, and found to be relevant and acceptable. Multiplexing therefore was 
chosen to measure biomarkers in this study's biological specimens with the 
understanding that further validation reports should be reported with this research. The 
individual analytes, or cytokines, that the Multiplex analysis can detect are summarized 
in Table 5 along with the sensitivity of each assay. 
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Table 5 














IFN-g (Interferon Gamma) 
TNF-alpha 
VEGF (Vascular 




























Note. Adapted from manufacturer's website, 
http://www.rndsystems.com/Products/FCST09, R & D Systems, Inc .. 
Psychological Instruments 
To measure the psychological variables within chronic pain, several tools were 
selected for this study and are discussed in detail. These psychological tools were 
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selected for their internal consistency and reliability (reflected in Table 6 as the 
Cronbach's us ), their ease of completion and their use in previous chronic pain 
inflammatory studies. They were used to measure the study participants' level of pain 
perception, anxiety, depression, and sleep quality. 
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Table 6 
Summary ofPsychological Tools Utilized 





Pain The Short Form- Scores for the questionnaire can 
b0.96 
Questionnaire 
range from 0 to 45 on the Pain 
Rating Index, from 0 to 5 on the 
(SF-MPQ) Present Pain Intensity, and from 
0 to 10 centimeters on the 
Visual Analog Scale. No 




The Hamilton A total anxiety score of<17 
indicates mild anxiety levels; 18 
Scale to 24 mild-moderate anxiety 
(HAM-A) levels; and 25 to 30 indicates 
moderate-severe anxie!Y_levels 
Depression The Beck 0-13: minimal depression; 14­ °0.91 
Depression 19: mild depression; 20-28: 
Inventory-II moderate depression; and 29­
(BDI-II) 
'0.83 
63: severe depression 
Sleep 
Quality 
The Pittsburgh Nineteen components that yield 
Sleep Quality a global score of0-21, with a 
Index total of< 5 associated with 
(PSQI) good sleep quality and < 5 
associated with poor sleep 
_g_uali!Y_ 
a bNote. Taken from Burckhardt & Jones, 2003. Reported as an Intraclass Correlation 
Coefficient for total pain score by Grafton, Foster, & Wright, 2005. c Taken from 
Kummer, Cardoso, & Teixeira, 2010.d Reported as a Coefficient Alpha by Beck, Steer, 
Ball, & Ranieri, 1996. 'Reported by Buysse, Reynolds, Monk, Berman, & Kupfer, 1989. 
Measure of pain perception. The Short Form McGill Pain Questionnaire (SF-MPQ) is 
a self-reported survey that consists of fifteen descriptors known as the Pain Rating Index 
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(PRI); eleven sensory descriptors and four that are affective in nature. Each descriptor is 
rated on a scale of 0-3: 0 (none) to 3 (severe). It also includes a Present Pain Intensity 
(PPI) index and a Visual Analogue Scale (VAS). Scores for the questionnaire can range 
from 0 to 45 on the PRI, from 0 to 5 on the PPI, and from 0 to 10 centimeters on the 
VAS. (Melzack, 1975; Melzack, 1987). This tool can be found in Appendix B. 
Measure of anxiety. The Hamilton Anxiety Rating Scale (HAM-A) is a survey 
completed by the researcher and measures the severity of a patient's anxiety. Based on 
14 parameters, each survey item is given a 5-point score - 0 (not present) to 4 (severe) 
and includes anxious mood, tension, fears, insomnia, intellectual impairment, depression, 
somatic complaints, autonomic symptoms, physiologic symptoms and behavior at the 
interview. A total anxiety score of <17 indicates mild anxiety levels; 18 to 24 mild­
moderate anxiety levels; and 25 to 30 indicates moderate-severe anxiety levels 
(Hamilton, 1959). This tool can be found in Appendix C. 
Measure of depression. The Beck Depression Inventory-II (BDI-II) is a self-reported 
survey that assesses and score levels of depression. The BDI-II contains 21 questions, 
each answer being scored on a scale value ofO to 3. The cutoffs values used will be: 0­
13: minimal depression; 14-19: mild depression; 20-28: moderate depression; and 29­
63: severe depression. Higher total scores indicate more severe depressive symptoms 
(Beck, Ward, Mendeson, Mock, & Arbough, 1961). This tool can be found in Appendix 
D. 
Measure of sleep quality. The Pittsburgh Sleep Quality Index (PSQI) is a self-reported 
survey that is composed of nineteen components that yield scores on subjective sleep 
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quality, sleep latency, sleep duration, habitual sleep efficacy, sleep disturbance, use of 
sleeping medication and daytime dysfunction. These seven components are scored from 
0-3 and yield a total score of0-21. Higher scores indicate worse sleep quality, with a 
total of :S 5 associated with good sleep quality and > 5 associated with poor sleep quality 
(Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). This tool can be found in 
Appendix E. 
Data Collection Protocol 
Approximately eight patients with the diagnosis and symptomatology of chronic 
pain who were eligible for, and medically recommended treatment with an intrathecal 
opioid infusion pain pump (the Medtronic SynchroMed® II Pain Pump) were enrolled in 
this study. Potential participants were recruited from the Pain Management Center at 
UCLA. After informed consent was obtained using Institutional Review Board (IRB)­
approved forms (Appendix A), subjects completed the psychological instruments to 
measure their pain perception, depression and sleep deprivation (Appendices B, D, E). 
The anxiety tool (Appendix C) was completed by the practitioner collecting the 
demographic clinical data (Appendix G) and consent for study involvement. Participants 
underwent a structured interview to compile their demographic information (Appendix F) 
and results were number coded to ensure participant anonymity. All psychological study 
results and demographic information were number coded for anonymous participant 
identification and entered into a password-protected spreadsheet for analysis. Upon 
completion of the questionnaires, study participants were given a $25 Visa gift certificate 
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for their participation in the study. Participants were also reimbursed for their parking 
fees upon enrollment of the study for the date for the trial operation. 
Approximately one month after the preclinical office visit, the study participant 
underwent a surgical outpatient operation called an intrathecal opioid infusion pain pump 
trial. This operative surgical procedure and study procedure of collecting intraoperative 
CSF samples was performed in the operating suite at UCLA Santa Monica Orthopedic 
Hospital Outpatient Surgery Center. Three mL of CSF were collected from the eight 
study participants undergoing intrathecal opioid infusion pain pump trials for the 
treatment of their pain. Standard preoperative preparation and evaluation took place in 
the preoperative suite of UCLA Santa Monica Orthopedic Hospital Outpatient Surgery 
Center. A qualified member of the preoperative evaluation team started peripheral 
intravenous fluids in the preoperative suite and preoperative vital signs were recorded. 
The patient participant was then brought to the operating room and positioned per 
surgeon preference, and standard monitors (electrocardiogram, noninvasive blood 
pressure cuff, pulse oximeter) were applied. Patient participants were given 2-4 L/min 
nasal cannula oxygen and a combination of intravenous versed and fentanyl was titrated 
for comfort by a qualified operating room nurse at the surgeon's direction. Strict, 
standard sterile surgical protocol was followed per the regulations and policies of UCLA 
Santa Monica Orthopedic Hospital guidelines. Intrathecal access was performed with or 
without the use offluoroscopy per the surgeon's discretion. All samples of CSF were 
collected intraoperatively before 1300 in appropriate polypropylene specimen collection 
tubes, properly labeled with a number code for anonymous participant identification and 
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placed on ice in UCLA approved specimen transportation boxes. A member of the 
research team then transported the specimens from UCLA Santa Monica Orthopedic 
Hospital to the UCLA Cousins Center for Psychoneuroimmunology Inflammatory 
Biology Laboratory in the 300 Medical Plaza building of the UCLA Westwood campus 
via car, with an estimated transportation time of30 minutes. Upon receipt of the 
specimens, the UCLA Cousins Center for Psychoneuroimmunology Inflammatory 
Biology Laboratory centrifuged the samples at 2000G for 10 minutes at 4°C, and 
partitioned the 3 mL samples into 0.25 mL aliquots with appropriately labeled 
anonymous participant identification. The aliquots were then stored at -80°C until batch 
analysis was performed. 
After collection of 3 mL of CSF in a specimen collection tube, the surgeon 
administered a dose of opioid through an intrathecal trial catheter. The catheter was 
secured and dressed in a sterile fashion and the patient participant was taken to the 
postoperative suite for recovery. The patient participant was then monitored for side 
effects and complications arising from the administration of the intrathecal opioid. 
During the postoperative stay, the participants' hemodynamic stability and vital signs 
were continually assessed by a member of the pain management team and/or 
postoperative nursing staff. Once a member of the pain management team determined 
that the patient participant had not incurred any serious side effects from the 
administration of an intrathecal opioid, the participant was then eligible to have a 
permanent opioid infusion pain pump. The catheter was removed, a sterile dressing 
placed over the operative site and the participant was discharged home with instructions 
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and emergency contact information. 
Control samples ofCSF were analyzed from the California NeuroAIDS Tissue 
Network obtained from Dr. Scott Letendre at the University of California, San Diego 
(UCSD). Thirty samples of 1-2 mL ofCSF were utilized from this tissue bank as a 
means to compare levels of central inflammatory cytokines. Samples of 1-2 mL were 
obtained in specimen collection tubes and placed on ice in the appropriate biological 
hazard transport container. The specimens were shipped from UCSD to the UCLA 
Cousins Center for Psychoneuroimmunology Inflammatory Biology Laboratory in Los 
Angeles. Upon receipt of the specimens, the UCLA Cousins Center for 
Psychoneuroimmunology Inflammatory Biology Laboratory centrifuged at 2000G for 10 
minutes at 4°C, and partitioned the 1-2 mL individual samples into 0.25 mL aliquots with 
appropriately labeled identification. The aliquots were then be stored at -80°C until batch 
analysis could be performed. Figure 3 depicts the complete cross-sectional study process 
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Figure 3. Data collection for cross-sectional study ofPsychoneuroimmunology and 
Chronic Pain. 
Cerebrospinal fluid levels of IL-1, IL-6, IL-8, TNF - a and IL-10 were determined 
using the Luminex® Performance Human High Sensitivity Cytokine Panel (R&D 
Systems, Minneapolis, MN). All assays were performed in duplicate per manufacturers 
recommendations. Cerebrospinal fluid samples were diluted 1 :2, following the protocol 
recommended for serum and plasma. All analyses were run in duplicate per the 
manufacturer's recommendation. Samples with o/<£V > 20 % between duplicates were 
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evaluated on a case-by-case basis for repeat assays and/or modified data analysis. The 
cytokine levels for all of the samples obtained, both from UCLA and UCSD are reported 
as picograms'milliliter (pg/ml). The data analysis plan and potential dissemiuation of 
study findings are outlined in Figure 4. 
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Figure 4. Data analysis plan for cross-sectional study ofPsychoneuroimmunology and 
Chronic Pain. 
Statistical Analysis 
Descriptive statistics were calculated for all variables in the study and examined 
for responses. Multiple approaches were used to analyze the data and the level of 
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significance was set at p < 0.05 for all statistical testing. To test the first and second 
hypothesis, CSF levels of inflammatory cytokines in study participants were compared to 
controls using parametric statistics for normally distributed variables to include 
multivariate analysis of variance (MANOVA) followed up with analysis of variance 
(ANOV A) (non-parametric testing using Mann-Whitney U analysis would be 
implemented for non-normally-distributed variables). To test the third through the sixth 
hypothesis, correlations were calculated to explore relationships between psychological 
instrument measures, potential cofactors (demographics), pretreatment critical cofactors 
and biomarkers using Pearson's r, Spearman's Rho or non-parametric correlations for 
non-normally distributed data. Multivariate analysis of variance and ANOV A was used 
to examine differences between gender, diagnosis and types of medications. Calculations 
were accomplished with SPSS software version 22 (SPSS, IBM Inc., Armonk, NY). 
The planned analysis was primarily exploratory given the small study population 
size, and designed to answer the question: Are there significant relationships between 
such psychological variables as pain perception, anxiety, depression or sleep deprivation 
and levels of inflammatory mediators in the CSF of the chronic pain patient? 
Compliance Plans 
Data and Safety Monitoring Plan 
Data and safety monitoring for this study proceeded in an exacting manner and 
met all UCLA and University of San Diego (USD) IRB requirements. The data collected 
from paperwork, including but not limited to, the psychological tests administered, were 
entered into a spreadsheet database that was password-protected, and all paper copies 
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stored in a locked cabinet at the UCLA Pain Management Center. No electronic data was 
anticipated to be stored on servers, but in the event that electronic data storage was 
necessary, UCLA protected servers that are in compliance with Good Clinical Practice 
(GCP) and Health Insurance Portability and Accountability Act (HIPP A) regulations 
would have been utilized. 
Throughout the study there was a review of data to carefully ensure that there 
were no adverse effects to study participants. The study was reviewed and all adverse 
effects would have been reported to the UCLA and USD IRBs by the Principal 
Investigator (PI) of the study. The Co-Investigators provided a second level of review as 
the study proceeded. Data was entered on an ongoing basis and weekly reports detailing 
health events, study progress, data accuracy and completeness was generated for review 
by the PI and Co-Investigators. Quality assurance activities were supervised by the PI. 
Statement ofAssumptions and Protection of Human Subjects 
Informed Consent 
This study protocol was reviewed and approved by the IRBs (Human Subjects 
Protection Committee) of UCLA and USD. All participants received a California 
Experimental Subject's Bill of Rights and voluntarily signed an informed consent, 
specific to the study protocol, prior to study participation in a private setting. All study 
participants were asked to read and ask questions, and complete consent forms prior to 
study participation. Risks of study participation were carefully detailed in the consent 
form. Participants had the option to withdraw consent at any time without prejudice to 
their future medical care at UCLA Medical Center. 
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Risks of Study Participation 
This study analyzed CSF collected during the surgical procedure necessary for 
determining chronic pain patients' eligibility to receive a surgically implanted, Food and 
Drug Administration-approved device for the treatment of their chronic pain symptoms. 
Patients received this device regardless of their participation in this study, this device did 
not sponsor this study, the device was not paid for by the study and in no way was being 
tested by this study. The surgical risks of performing the trial catheter insertion were 
known risks to the surgical procedure and were consented for by the patient, but did not 
represent additional patient burden for those participating in this study. Participants were 
assured via the consent process that they could discontinue their study participation at 
any time if they decided not to undergo the intrathecal opioid infusion pain pump trial. 
Minimal adverse effects have been reported with intrathecal opioid infusion pain pump 
trials. The UCLA Pain Management Center medical doctors that performed the 
intrathecal opioid infusion pain pump trials in this study have done so in hundreds of past 
patients with no adverse events related to surgical placement of the intrathecal catheter or 
pain pump. Additional risks posed to the patient study group above and beyond the 
surgical risks are listed here. 
Cerebrospinal fluid sampling. Study participants were scheduled for a surgical 
procedure called an intrathecal opioid infusion pain pump trial and CSF drainage is a 
known and accepted component of performing this surgical technique. Cerebrospinal 
fluid was available for collection with the same risks and benefits as the surgical 
procedure for which the participants were consented for with no expected increase in 
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participant burden. Potential additional risks to the study participants (above the surgical 
risks) were minimal; a spinal headache is the most common side effect of CSF volume 
depletion. Because the majority of CSF volume collected was minimized and not 
anticipated to be greater than what would normally be lost intraoperatively, the risk of the 
study participant developing a spinal headache was no greater than the surgical risk of 
developing a spinal headache. The CSF sample represents a minimal amount of CSF 
present in the adult central nervous system (CNS): Approximately 150 mL of CSF is 
present in the CNS of the average adult. Cerebrospinal fluid is manufactured and 
replaced every eight hours, hence the adult body produces around 500 mL of CSF per day 
(Marieb, 2001). Given the amount ofCSF in the CNS and the rapid production of this 
fluid, the 3 mL sample of CSF necessary for study analysis represented a small but 
noteworthy participant burden. The risk of developing a spinal headache from 3 mL of 
CSF sampled was a small, but serious risk to the study participant. The literature 
supports that spinal headaches occur after approximately 20 mL of CSF is drained from 
the CNS (Wolff, 1948). While the risk is low, a spinal headache is a serious side effect to 
monitor for. Throughout the intrathecal opioid pain pump trial, and for approximately 8­
10 hours postoperatively, vital signs were continuously monitored and staff was available 
to talk to participants about any discomforts or side effects they experienced. In 
accordance with UCLA IRB requirements, and operating room protocols, an Advanced 
Cardiovascular Life Support (ACLS)-certified study physician was immediately available 
during all procedures. This was fully explained in the consent form. 
Infection. During the surgical procedure where study samples of CSF were 
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collected, there was a risk of infection to the participant. This risk of infection was the 
same as the surgical risk of infection and did not represent any additional subject burden 
above and beyond the surgical risk. An infection after a surgical intrathecal needle stick 
is rare, but represented a potential risk to the participant. Should an infection occur, 
treatment including antibiotics or additional surgery may have been necessary. 
Bleeding. It is possible, though unusual, to experience an excessive bleeding 
episode through an intrathecal needle stick. The risk of developing a bleeding episode 
where an intervention would be necessary was no greater than the surgical risk to study 
participants. Should bleeding occur, it may require emergency treatment to drain 
accumulated blood called a hematoma. This was fully disclosed to study participants 
upon enrollment in the study and fully explained within the consent. 
Scarring. In rare cases, scarring from an intrathecal needle stick may result. This 
represented a small risk to study participants, but not above and beyond the surgical risk 
of scarring. This was fully disclosed to study participants upon enrollment in the study 
and fully explained within the consent. 
Confidentiality 
All records will be kept strictly confidential. No person except the research team 
will know the subjects were in a research study. Data forms for the collection of health 
and study data was coded with an anonymous identification number. No data form 
identified the participants by name. Data forms were kept in a locked cabinet at the 
UCLA Pain Management Center. No presentation or publication of the results of this 




The potential benefits for both the participants and broader segments of society 
include improved understanding of the psychoneuroimmunologic consequences of pain, 
anxiety, depression and sleep disturbances leading to more effective therapies and 
prevention. However, participants were informed that no change in their chronic pain 
treatment or direct benefit was expected to accrue to them from participation in the study. 
Subject Reimbursement 
Study participants were reimbursed for the parking visit needed for the trial 
operative day visit. Upon completion of the psychometric tools and after study 
enrollment, patients were given a $25 Visa gift certificate. 
Inclusion ofWomen 
The chronic pain population of the UCLA Pain Management Center is 
approximately evenly divided with respect to gender, and women were recruited as part 
of the study sample. Pregnant women were excluded from this study as it is surgically 
contraindicated in the intrathecal pain pump trial and permanent pump insertion. 
Inclusion of Minorities 
The chronic pain population of the UCLA Pain Management Center is extremely 
ethnically diverse. Recruitment efforts were equally directed toward members of all 
racial and ethnic groups. 
Inclusion of Children 
Subjects who are 18-20 years of age (defined as "children" by the National 
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Institutes of Health) were eligible for recruitment from the UCLA Pain Management 
Center. Children below the age of 18 would have been excluded as the experience of 
pain in the pediatric population differs from that of adults (McGrath & Brigham, 1992). 
Further, the imposition of surgical intrathecal pain pump trials and permanent pump 
insertions on children below the age of 18 is usually surgically contraindicated. 
Safety Precautions and Emergency Protocols 
Trained medical and nursing personnel were in attendance during all surgical 
procedures. Any adverse event related to CSF sampling was immediately evaluated by 
the study physician. If injury occurred and deemed minor, treatment would have been 
administered on-site and the participant followed on an outpatient basis. In the extremely 
unlikely event of a significant injury, the subject would have been referred to the 
appropriate UCLA service for treatment and follow-up care. The UCLA and USD IRB 
would have been informed by telephone within 24 hours by the investigators of any 
serious adverse event, and a written report would follow within three days. 
Description of the System for Maintenance of Records 
Upon consent and enrollment in the study, the subject's name, address, email, 
phone number(s), medical record number, enrollment date, intrathecal catheter trail date 
and demographic data (including the patient's age) was all recorded on a single 
spreadsheet representing that specific study subject. All identifying information was 
removed from all subsequent research paperwork, psychological tools and CSF samples, 
and alphanumerically coded to maintain anonymity. The study anticipated approximately 
thirty study subjects to participate in this study and alphanumerically coded each study 
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participant in random assignment of study enrollment. Study subjects enrolled were 
alphanumerically assigned a code from SGPOO 1 to SGP030. Additional numbers could 
have been added ifthere were additional study recruits. The paper copies of the 
aforementioned information and copies of psychological surveys completed by the study 
subjects (identifiable only by the subjects alphanumeric code) were stored in a locked 
cabinet at the UCLA Pain Management Center. A key or legend linking the study 
subject's information to their alphanumeric identifier was kept in a locked file cabinet at 
the UCLA Pain Management Center. The key or legend included the assigned 
alphanumeric code (i.e. SGPOOl) and the patient's last name and first initial. The laptop 
computer used to create the study subjects spreadsheet and code list was password 
protected, utilized only secure Internet connections and was maintained only for study 
purposes. Sarah Giron was the sole user of this laptop computer. 
Cerebrospinal fluid samples from patients were stored in deep freeze storage at 
the UCLA Cousins Center for Psychoneuroimmunology Inflammatory Biology 
Laboratory with only the alphanumeric code identifier. Samples were stored with 
anonymous identification in deep freeze storage until batch analysis was performed per 
manufacturers recommendations. Throughout the laboratory analysis of the samples, 
only the alphanumeric code was available to lab personnel for identification of samples. 
Limitations 
Because of the cross-sectional, correlational nature of this study's design, 
causality of chronic pain and the causal relationships between levels of pro- or anti-
inflammatory cytokines, chronic pain, anxiety, depression and sleep deprivation were not 
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determined. The study design itselflimits the findings of this study to simply providing 
support for prior studies and serving as a basis for developing future studies. Given the 
specific criteria and study population of this cross-sectional study, this study design also 
limited the ability to generalize the results. 
The small sample size also limited study findings: Even though a power analysis 
was performed and determined that the sample size was adequately powerful enough to 
determine significant changes between three of the five cytokines analyzed, the sample 
size would have been possibly too small to detect changes with IL-10 and TNF-u. The 
sample size necessary to detect changes in IL-10 and TNF-u would have been 64-99 
participants, but given the budget and time available for this study, this sample size was 
unrealistic. Nevertheless, because IL-10 and TNF-u are cytokines analyzed on the same 
Multiplex assay as the other three cytokines, they were still explored with minimal 
increase in cost or time. 
Obtaining the control samples from an outside source was also a limitation of this 
study. While obtaining these samples confirmed that 30 healthy CSF samples could be 
obtained and it decreased the time to acquire the CSF samples, lessened the participant 
burden and cost of recruiting participants to obtain these samples, these control CSF 
samples only came with a limited description and external assurance. The control 
samples may not adequately represent the CSF of healthy participants in the general 
public. 
The unequal number of participants between the chronic pain and control CSF 
samples, as well as the small sample size, may limit the reliability of statistical analysis 
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of this study. Likewise, because psychological testing was not performed on the control 
subjects from whom the control CSF came, statistical analysis between inflammatory 
cytokines and psychological instrument data will only be possible in chronic pain 
participants. 
Three of the four psychometric tests utilized by this study were from direct 
participant report, while the Hamilton Anxiety Scale was completed by the practitioner 
consenting and obtaining demographic information from study participants. While this 
study tried to limit the number of practitioners completing the scales on the participants, 
to limit inter-reporter variability, a total of four practitioners ultimately completed the 
Hamilton Anxiety Scale for this study. This number of practitioners may have skewed 
the results for this psychological variable. 
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Abstract 
Chronic pain is a devastating amalgam of symptoms that affects millions of 
Americans at a tremendous cost to our healthcare system and, more importantly, to 
patients' quality oflife. Literature and research demonstrate that neuroimmune cells 
called glia are not only responsible for initiating and maintaining part of the chronic pain 
disease process, but also release inflammatory molecules responsible for decreasing the 
efficacy of one of the most prominent treatments for pain, opioid analgesia. This article 
describes chronic pain as a disease process that has ineffective treatment modalities; 
explores the mechanisms of glial cell activation and inflammatory responses that lead to 
chronic pain and decreased opioid treatment efficacy; and hypothesizes novel chronic 
pain treatment modalities based on the glial cell inactivation and anti-inflammatory 
pathways. 
Keywords: Inflammation, Chronic Pain, Cytokines, Opioids, Glia 
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Chronic pain is a serious health concern of tremendous scope that spans 
socioeconomic boundaries, educational levels, and cultural, gender, and age 
demographics (Pleis, Ward & Lucas, 2009). An estimated 116 million Americans suffer 
and are disabled by this chronic condition (Tsang et al., 2008), with a cost of $630 billion 
in lost work revenue, sick time, health care costs (Gaskin & Richard, 2011 ), and, most 
importantly, at the cost of patients' quality of life. Patients report not only a wide 
spectrum of painful symptoms and psychological effects, but also suffer from different 
types of pain in various anatomical locations. Current modalities utilized to treat these 
patients are limited in scope, and often ineffective for a large portion of the chronic pain 
population with a host of dangerous or self-limiting side effects. This raises the question 
of what more can be done for a patient population larger than all diabetic, coronary heart 
disease, stroke and cancer patients combined (Tsang et al., 2008)? 
For decades, pain research focused on neuronal opioid receptors as the mainstays 
of pain physiology and management. Isolated from opium in the 1800's, morphine has 
become a mainstay of pain therapy (Ahlbeck, 2011; Mehendale, Goldman, Mehendale, & 
Rana, 2013), and clinicians eventually developed an array of powerful synthetic opioids 
for pain relief. Yet, despite the useful addition of variably efficacious anti-depressive and 
anti-convulsant drugs, which decrease neuropathic pain symptomatology (Vranken, 
2009), consistently effective treatment of chronic pain eludes the medical community. 
Fortunately, recent scientific discoveries have started to unmask various chronic pain 
neuroimmune pathways, which could lead to more effective treatment of this epidemic. 
One of the new directions for inquiry highlights central nervous system (CNS) 
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inflammatory mechanisms that are believed to exacerbate and prolong neuropathic pain 
states via positive feedback mechanisms (Griffis, 2011 ). Recent pain literature suggests 
that the inflammatory mechanisms responsible for the initiation and prolongation of 
chronic pain are perpetuated by opioid therapy (Raghavendra, Rutkowski, & DeLeo, 
2002; Tai et al., 2006). Given the widespread use of opioids in the anesthetic or pain 
management of patients with chronic pain, it is imperative for nursing and medical 
practitioners to understand the underlying mechanism of neuroimmune-mediated CNS 
inflammation, its hypothesized role in chronic pain, and the possibilities for novel pain 
management modalities if these inflammatory mechanisms are targeted. 
Acute Pain Verses Chronic Pain 
Pain is an elegant physiologic mechanism that functions as a protective measure 
to preserve cellular function and life. The International Association for the Study of Pain 
(IASP) defines pain as "an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage" (Merskey & 
Bogduk, 1994, p. 213). However there are instances when pain ceases to be protective 
and begins to be destructive. The neuroimmune-mediated CNS inflammatory 
mechanisms described here offer one possible way to differentiate between these two 
very different pain states. 
Acute Pain 
When pain pathways work as intended to detect tissue damage or trauma, pain-
sensing receptors known as nociceptors detect chemical, mechanical, or thermal stimuli. 
Nociceptive detection is then converted and transduced as neural electrical impulses. Ao 
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and C primary afferent nerve fibers transmit these nociceptive signals to synapse at 
Rexed' s Laminae II (located in the substantial gelatinosa) of the dorsal horn of the spinal 
cord (Todd, 2012). Via ascending spinothalamic tracts in the spinal cord, these 
nociceptive neural signals are transmitted to the thalamus where the pain sensation is 
relayed to higher cortical regions for processing. The basal ganglia, anterior cingulate 
cortex, amygdala, periaqueductal grey region, hypothalamus, prefrontal cortex and rostral 
ventromedial medulla are all areas of the higher cortex that process ascending 
nociception. As nociception proceeds, descending pain modulatory systems may be 
activated, resulting in increases and decreases in pain perception by the host. All of the 
higher cortical regions except the basal ganglia participate in descending pain 
modulation. Figure 1 depicts the acute pain process as described (Garland, 2012). 
Through a complex series of peripherally and centrally mediated neuro-cellular 
interactions, and reflex and cognitive actions, sensing and responding to acute 
nociceptive pain helps the host remove itself from danger. Thus, pain, the proper 
perception of pain, and the proper withdrawal reaction to painful stimuli has aided in our 
species' survival. 
Chronic Pain 
Unfortunately, there are many conditions in which individuals' nociception and 
reaction to painful stimuli have developed into chronic pain states that provide no 
survival or protective benefit. Chronic pain, a term loosely and inconsistently defined in 
the literature, can be classified as any pain that endures beyond the expected healing 
phase following an injury or in the absence of injury, or pain that lasts longer than three 
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months (Ruetsch et al., 2013). Common attributes of chronic pain, include hyperalgesia, 
an increased sensitivity to painful stimuli, and allodynia, a sensation of pain in response 
to stimuli not normally responsible for pain. A barrage of sustained pain signaling via 
afferent pathways contributes to the maintenance of the chronic pain state and has been 
described in the literature as central sensitization (Millin & Kerr, 2013; Woolf, 2011), 
however this paper will focus on the contributions of neuroinflammation to chronic pain 
syndromes as well as resistance to opioid analgesic therapy. 
Glial activation. Glia are neuroimmune cells located in the brain and spinal cord 
and comprise approximately 70% of all cells in the CNS. Though there are multiple glial 
cells responsible for the proposed inflammation-driven chronic pain pathways; in 
accordance with most of the experimental investigations of the phenomenon, this 
discussion will focus on two innate immune cell types known as microglia and astrocytes. 
Historically, glia were thought to contribute exclusively to the structure and 
nourishment of neurons, until research using a rodent model of sciatic nerve injury 
identified a positive correlation between astrocyte activity and the level of hyperalgesia 
observed after an experimentally-induced nerve injury (Garrison, Doughterty, Kajander, 
& Carlton, 1991). Over a decade later, multiple pre-clinical investigations consistently 
support what Garrison et al. 's study initially suggested: glial functions comprise much 
more than nourishment, protection, and structural support of neurons. Glial cells are 
involved in the development and formation of the blood brain barrier and myelin sheath 
(Watkins, Hutchinson, Johnston, & Maier, 2005; Watkins et al., 2007) and are activated 
following tissue injury, illness, or inflammation (Tsuda, Inoue, & Salter, 2005; Watkins 
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& Maier, 2000). Once activated by peripheral or central stimuli, glial cells in the brain 
and spinal cord have been shown to release a cascade of molecules, including pro­
inflammatory cytokines, contributing to CNS plasticity in pain responses (Mika, 
Rojewska, Makuch, & Przewlocka, 2010; Wei, Guo, Zou, Ren, & Dubner, 2008). Studies 
have also suggested that glial cells may represent some of the fundamental components 
for nociception, and neural detection of pain (Watkins & Maier, 2003; Wieseler-Frank, 
Maier, & Watkins, 2004). Figure 2 depicts a possible mechanism by which activated glia 
contribute to increased pain perception through increased neuronal firing via the 
ascending spinothalamic tract. 
Subsequent research among glia cells has delineated a specific order of cellular 
activation that is fundamental to the genesis of chronic pain states. These data suggest 
that microglia may initiate the chronic pain cycle, as they are the first glial cells activated 
by excessive sensory afferent neural signaling, and may play a role in astrocyte 
activation. Astrocytes may be implicated in the persistence of chronic pain, remaining 
activated long after microglial activation has ceased (Fleming et al., 2006; Ledeboer, 
Hutchinson, Watkins, & Johnson, 2007; Romero-Sandoval, Chai, Nutile-McMenemy, & 
DeLeo, 2008). Published reports propose that in chronic pain scenarios microglia cells 
undergo a transformation from a resting, homeostatic state, to an activated state in the 
dorsal horn minutes to hours after nerve damage or injury, followed by astrocyte cellular 
activation 24 hours to several days later. The activated microglia remain activated for 
several months, and astrocyte activation persists after microglial activation has subsided, 
sometimes for months to years (Fleming et al., 2006; Ledeboer et al., 2005; Romero­
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Sandoval et al., 2008). Figure 3 illustrates the temporal nature of glial cell activation in 
chronic pain. The exact characteristics of neural signaling stimuli that initially cause 
microglia to activate and begin the chronic pain cascade, as well as the molecular signals 
that transmit the message from activated microglia to initiate astrocyte activation remain 
unclear, though fractalkine (a neuron-bound chemoattractant molecule) may play a role in 
neuron-to-glia signaling (Chapman et al., 2000; Milligan et al., 2004; Milligan, Sloane, & 
Watkins, 2008). What is more certain from research is that there may be a specific order 
of cellular activation among these glial cells that is necessary for chronic pain to be 
initiated and then maintained (Fleming et al., 2006; Ledeboer at al., 2007; Ledeboer et al., 
2005; Romero-Sandoval et al., 2008). 
Acute pain models demonstrate, and may be associated with a lack of microglial 
cellular activation. With stimuli that results in acute pain, microglia are not activated, 
astrocyte activation occurs immediately (rather than the delayed response in chronic 
pathways) and then subsides after several days (rather than months to years in the chronic 
pain process) (Romero-Sandoval et al., 2008). Figure 4 illustrates the temporal nature of 
acute pain glial activation. Thus, without the activation of microglia to initiate the 
chronic pain process, acute pain models currently demonstrate that microglia and 
astrocyte activation is a specific and necessary component to chronic pain physiology. 
However, because there is evidence indicating glial activation can occur within one week 
of injury (Winkelstein, Rutkowski, Sweitzer, Pahl, & DeLeo, 2001 ), the possibility that 
microglial activation contributes to acute pain responses cannot be ruled out. 
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Inflammatory response from glia. Once activated in the chronic pain model, 
glial cells release inflammatory mediator molecules including cytokines; more 
specifically these cells release pro-inflammatory interleukins (ILs) and tumor necrosis 
factor-alpha (TNF-u). Research suggests that pro-inflammatory cytokines can increase 
pain transmission in dorsal horn neurons (Reeve, Patel, Fox, Walker, & Urban, 2000), 
and increase the release of neurotransmitters from peripheral nociceptive sensory afferent 
nerves (Inoue et al., 1999; Morioka et al., 2002). These pro-inflammatory cytokines may 
also enhance pain via upregulation of AMPA (2-amino-3-(5-methyl-3-oxo-l,2- oxazol-4­
yl) propanoic acid) and NMDA (N-Methyl-D-aspartate) receptor expression and activity 
(Beattie et al., 2002; Viviani et al., 2003; Wang et al., 2005). The pain-enhancing effects 
of pro-inflammatory ILs and TNF- a have been implicated in both pre-clinical (Dubovy, 
Jancalek, Klusakova, Svizenska, & Pejchalova, 2006; Sacerdote et al., 2008; Sung et al., 
2004; Zelenka, Schafers, & Sommer, 2005) and human studies (Backonja, Coe, Muller, 
& Schell, 2008; Kadetoff, Lampa, Westman, Andersson, & Kosek, 2012; Zin, Nissen, 
O'Callaghan, Moore, & Smith, 2010) of chronic pain syndromes. All of these 
investigations indicate that where there is chronic pain, there are excessive levels of CNS 
pro-inflammatory cytokines. Thus, the literature supports the theory that through the 
intricate activation sequence of neuroglial cells, followed by the production and release 
of inflammatory molecules, chronic pain is initiated and maintained. 
Chronic Pain Treatment 
To date, the most common form of treatment for the chronic pain patient is opioid 
analgesics. Approximately 3% of adults in the U.S. receive long-term opioid therapy for 
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treatment in chronic non-cancer pain, with close to six million hospital visits per year 
directed at obtaining opioid prescriptions (Boudreau et al., 2009; Caudill-Slosberg, 
Schwartz, & Woloshin, 2004). A study of over 70,000 chronic pain patients' healthcare 
utilization patterns found that prescriptive costs to treat the pain increase dramatically 
after a second year of treatment. Remarkably all of the chronic pain patients in this study 
realized a rise in their prescriptive costs, often exceeding $5,100 per year (Ruetsch et al., 
2013). The rising costs indicate what many practitioners treating chronic pain already 
know: As the pain continues, so does the use of increasing doses of medications to 
control the pain. As these drugs are used over time, tolerance (the need for increasing 
dosages to control pain) develops. Interestingly-glial activation and pro-inflammatory 
cytokines, known to be present in and contribute to chronic pain syndromes, may offer an 
explanation for the decrease in opioid efficacy. 
Opioid-Gila Interactions 
As previously described, studies have repeatedly shown that glial cell activation 
contributes to increased nociception following injury, and in the initiation and 
maintenance of chronic pain states. Recently, multiple preclinical studies have shown 
that the administration of long-term opioids also results in an increase in CNS glial 
activity (Eidson & Murphy, 2013; Hutchinson et al., 2011). This phenomenon could be 
mediated in part, by microglial kappa- and mu-opioid receptors (Chao et al., 1996), as 
well as toll-like receptors on glial cells (TLRs) that bind opioid molecules (Chao, Hu, 
Sheng, Gekker, & Peterson, 1997). Opioid molecules binding to both types of receptors 
initiate microglial activation with subsequent production and release of pro-inflammatory 
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cytokines (Woller & Hook, 2013). Astrocytes have also been found to have mu-, delta­
and kappa-opioid receptors, and respond similarly to opioid agonist effects (Dobrenis, 
Makman, & Stefano, 1995; Eriksson, Hansson, & Riinnbiich, 1990). Figure 5 depicts how 
opioid administration increases nociception via activated glia and the pro-inflammatory 
response. 
Thus, based upon this, theories hypothesizing glia as neuroimmune cells that 
contribute solely to structure and function of neuronal cells are incorrect. Pre-clinical 
studies of chronic opioid administration in the absence of chronic pain syndromes 
demonstrate that this glial-induced increase in CNS cytokine activity contributes to both 
opioid tolerance and pain enhancement in opioid withdrawal (Eidson & Murphy, 2013; 
Johnston et al., 2004; Raghavendra, Tanga, & DeLeo, 2004). These investigations suggest 
that not only are glia partially responsible for the maintenance of chronic pain, but they 
are also responsible for decreasing the efficacy of opioid drugs, and thus, one of the most 
common treatments of pain. It is hypothesized that tolerance results when opioid­
activated immune cell pro-inflammatory cytokine production leads to up-regulation of 
CNS nociceptive neurons, increasing pain perception and severity (Raghavendra et al., 
2002; Raghavendra et al., 2004; Song & Zhao, 2001). Thus, when treating chronic pain 
with opioids, over time the very treatment prescribed to relieve the pain will become part 
of a self propagating cascade of events responsible for perpetuating the pain, increasing 
the level of pain, decreasing the effectiveness of treatment (through opioid tolerance), and 
contributing to allodynia. 
Glial Inhibition in Chronic Pain Treatment 
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Inhibiting glial cells is not currently an option in treatment of chronic pain 
patients because the health implications to the host are still being explored. Multiple 
investigations using pre-clinical neuropathic pain models have shown that arresting glial 
cell function in vivo using fluorocitrate, a glial metabolic inhibitor, attenuates neuropathic 
pain in these animals (Lan et al., 2007; Nakagawa et al., 2007). Fluorocitrate has also 
been shown to enhance morphine analgesia (Song & Zhao, 2001). Minocycline, a 
microglia inhibitor and tetracycline derivative, may prevent glial hyperactivation, but it 
cannot be used in cases of established neuropathic pain unless it is given prior to the 
injury and is continued after the injury (Mika et al., 2010). This may be due, in part, to 
the fact that minocycline suppresses microglia but not astrocytes (Yoon, Patel, & 
Dougherty, 2012) which are believed responsible for perpetuating chronic pain once 
established. Intrathecal or peripheral administration of minocycline has, however, 
demonstrated the ability to reduce the symptoms of allodynia and hyperalgesia (Ledeboer 
et al., 2005; Mika, Osikowicz, Makuch, & Przewlocka, 2007), and has also demonstrated 
neuroprotective properties in neurodegenerative disease associated with glial activation 
(Tikka, Fiebich, Goldsteins, Keinanen, & Koistinaho, 2001 ). Not surprisingly 
minocycline has also been shown to reduce tolerance to morphine in a dose-dependent 
manner when administered intrathecally (Cui et al., 2008). 
Inflammatory Mediator Inhibition in Chronic Pain Treatment 
A new direction for research in chronic pain treatment involves targeting the pro-
inflammatory mediators released by glia. Two methods to alter the activity of pro­
inflammatory cytokines are commonly cited in pain studies: inhibiting the production of 
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the cytokine (Genevay, Stingelin, & Gabay, 2004; Iwatsuki et al., 2013; Ohtori et al., 
2012b) or blocking the cytokine's receptor binding site (Hutchinson et al., 2008; Shavit, 
Wolf, Goshen, Livshits, & Yirmiya, 2005; Wolf, Gabay, Tai, Yirmiya, & Shavit, 2006). 
The results of animal model studies targeting cytokines are compelling: Several studies 
have suggested that morphine tolerance can be slowed or reversed by genetically 
inactivating the pro-inflammatory cytokine interleukin-I (IL-1) or by blocking IL-1 with 
a receptor antagonist (Hutchinson et al., 2008; Shavit et al., 2005). As predicted from the 
theoretical discussion above, the analgesic time and efficacy of both morphine and 
methadone were found to increase when IL-1 was blocked with a receptor antagonist 
(Hutchinson et al., 2008). Hence, receptor antagonists may offer one approach to improve 
opioid pharmacology in the chronic pain population where opioid tolerance and analgesic 
efficacy must be ameliorated. 
Ibudilast, a phosphodiesterase inhibitor, selectively targets the synthesis of pro­
inflammatory cytokines by microglia and has been globally used as a treatment for 
asthma, a disease often associated with inflammation of the respiratory system (Rolan, 
Hutchinson, & Johnson, 2009). Given that pro-inflammatory cytokines have also been 
implicated in the initiation and maintenance of chronic pain, it is encouraging to see this 
drug has been effective in blocking neuropathic pain symptoms in animal models 
(Ledeboer et al., 2007). In addition, ibudilast has also been shown to enhance morphine 
and oxycodone analgesia, further supporting the possibility that opioid management of 
chronic pain patients could benefit by using this type of pharmacotherapy (Hutchinson et 
al., 2009). 
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The possible effects of using these approaches to treat chronic pain, delay opioid 
tolerance in humans, and their potential side effects remain unknown. It should be 
emphasized, however, that inhibition of pro-inflammatory cytokines does not appear to 
interfere with the neural basis of the acute pain process (Milligan et al., 2001; Sweitzer, 
Martin, & De Leo, 2001 ). This treatment could potentially offer a possible treatment for 
chronic pain without interfering with acute, protective pain physiology. Thus, the 
literature suggests that there are several modalities that could be explored for future 
treatment of chronic pain involving direct manipulation of glial cells or the inflammatory 
markers they release, but additional studies are needed. Figure 6 provides a synopsis of 
glial-mediated inflammation inhibition and the agents used to block the neuroimmune 
effects (Thomas & Hutchinson, 2012). 
Implications for Future Treatment of Chronic Pain 
If future human-based studies can illustrate the same link that preclinical studies 
show between glial activation, inflammatory mediator release, chronic pain persistence 
and decreased opioid efficacy, the implications for treatment in the chronic pain patient 
population are far-reaching. Research demonstrates that by blocking a pro-inflammatory 
cytokine in rodents, the effective analgesic duration of an intrathecally-administered 
opioid can be doubled, and the analgesic duration of systemically administered opioids 
can be increased more than one-and-a-halftimes. The same study also demonstrated an 
approximately seven-and-a-half-fold increase in analgesic efficacy with morphine by 
administrating the opioid in combination with a receptor blocker of IL-1. These results 
were found with both morphine and methadone (Hutchinson et al., 2008). 
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Similar investigations demonstrate that drugs which block a pro-inflammatory 
cytokine in the CNS enhance intrathecally-administered opioid analgesia, blunt opioid 
tolerance, and reduce both newly developed and established allodynia and hyperalgesia 
(Johnston et al., 2004). Ibudilast has been shown to increase the analgesic potency of 
morphine and oxycodone by three to five times the average potency when administered 
concurrently with the opioid (Hutchinson et al., 2009). The same class of drugs targeting 
TNF-a has been used successfully in autoimmune disease therapy for rheumatoid 
arthritis, psoriasis, and enteritis (all of which have inflammatory etiologies) (Sfikakis, 
2010), and has also been shown to decrease neuropathic pain when administered 
intrathecally in a pre-clinical trial (Marchand et al., 2009). In addition, drugs in this class 
are being investigated for use in the treatment of sciatica (a painful nerve compression 
condition) (Genevay et al., 2004). 
Similarly, anti-interleukin receptor monoclonal antibody therapy has been shown 
to reduce pain in patients with lumbar spinal stenosis (Ohtori et al., 2012a) and in 
rheumatoid arthritis (a painful inflammatory disorder of the joints) (Burmester et al., 
2011 ). In many of these studies, therapy targeting interleukins improved symptoms for 
weeks with little to no side effects noted except serious infection in one study (Burmester 
et al., 2011). Pre-clinical investigators noted that anti-interleukin treatment was only 
effective against mechanical allodynia if given at the time of injury; delayed 
administration of the TNF-a blocker demonstrated no clinical improvement in 
mechanical allodynia (Marchand et al., 2009). 
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Thus, further progress and understanding of safe interruption of glial cell and 
cytokine participation is necessary for future chronic pain treatment. Research suggests 
that chronic pain could be treated with opioids that would have a longer duration of 
action and increased efficacy. With additional understanding, opioid tolerance could be 
curbed, and the allodynia and hyperalgesia chronic pain patients experience may be 
reduced. 
Conclusion 
Animal models show that chronic pain states, opioid tolerance, hyperalgesia, and 
allodynia can be linked to glial activation and increased levels of pro-inflammatory 
cytokines. By blocking the pro-inflammatory cytokines or the glial cells which produce 
them, studies have shown that analgesia time and efficacy can be dramatically increased, 
opioid tolerance can be improved, and hyperalgesia and allodynia can be diminished. 
Advancements in inflammatory inhibition of other diseases are showing similar results. 
Because our current treatment techniques for chronic pain are restrictive and ineffective 
for many chronic pain patients, additional human evidence needs to be accumulated to 
illustrate the link between glia, cytokines, and chronic pain. An in depth understanding 
of these complex relationships will hopefully lead to innovative therapies that can safely 
interrupt the devastating consequences of the self-perpetuated cycle of 
neuroinflammation underlying chronic pain syndromes and scaffold highly effective 
opioid therapy. 
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Figure 1. Acute pain process. In the acute. pain physiology, nociception is regulated by 
an ascending and descending modulating system Microglia and Astrocytes in the central 







Dorsal Horn of 
Rexe""s 















Activate6 _ · - - ­
A S!t'OC'jte , ' - ~ -;,:~~ 
~- ~ \ 
u 




Figure 2. G Iial mediated increased nociception. Glial cells increase nocicepti11e relay of 
action potentials through release ofpro-inflarrunatory cytokines in the central nervous 
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I. Title 
Psychoneuroimmunology and Chronic Pain 
II. Specific Aims 
Chronic pain is a serious health concern of tremendous scope. An estimated 116 
million Americans suffer and are disabled by this diagnosis (Tsang et al., 2008) at a cost 
of $630 billion in lost work revenue, sick time, health care costs (Gaskin & Richard, 
201 l) and most importantly, at the cost of the patient's quality of life. Patients report not 
only a wide spectrum of painful symptoms, but also suffer from the psychological 
devastation pain can accompany. Current modalities utilized to treat these patients both 
physically and psychologically are limited, and often ineffective for a large portion of the 
chronic pain population. Recent investigations of the underlying causes of chronic pain 
have revealed a new direction for advancement: Central inflammatory mechanisms that 
are believed to exacerbate and prolong neuropathic pain states (Kreutzberg, 1996; Reeve, 
Patel, Fox, Walker, & Urban, 2000; Samad, Wang, Broom, & Woolf, 2004; Watkins & 
Maier, 2003; Watkins, Milligan, & Maier, 2001) as well as sleep deprivation (Dauvilliers 
et al., 2014), anxiety (Baker et al., 2001) and depression (Bonne et al., 201 l; Levine et 
al., 1999; Lindqvist et al., 2009). Though preclinical data is accumulating, there remains 
a dearth of human data in this rapidly developing correlation between central 
inflammation, chronic pain and the psychology of pain. 
This study will investigate the emerging relationships between chronic pain 
syndromes and the role of central inflammation, as measured by cerebrospinal fluid 
(CSF) patterns of inflammatory mediator molecules. More specifically, this study will 
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investigate ifthe same central pro- and anti-inflammatory cytokines found in chronic 
pain-induced animal models (Inoue et al., 1999; Morioka et al., 2002; Raghavendra, 
Tanga, & DeLeo 2004; Song & Zhao, 2001) are found in human chronic pain patients. 
This study will also explore the psychological responses to chronic pain as evidenced by 
scores on the Pittsburgh Sleep Quality Index, Beck Depression Inventory and the 
Hamilton Anxiety Scale, as well as chronic pain patients' perception and experience of 
pain as measured by the McGill Pain Questionnaire. Relationships between the 
psychological responses to pain and the pain experience will be made and then correlated 
to CSF levels of inflammatory markers. Because there is a scarcity of human evidence 
supporting the link between physical and psychological pain and central levels of 
inflammatory mediator molecules associated with these constructs, this study hopes to 
provide supportive evidence of this multimodal relationship. 
Specific Aim #1: This study will examine and characterize the relationships between 
chronic pain and pro- and anti-inflammatory mediator molecules. 
Hypothesis: Patients with chronic pain syndromes will have elevated CSF levels 
ofproinflammatory cytokines IL-1, IL-6, IL-8 and TNF-u and decreased levels ofanti­
inflammatory IL-10 as detected on high sensitivity enzyme-linked immunosorbent assay 
(ELISA) when compared to control samples ofCSF. 
Specific Aim #2: To explore the relationship between the psychological responses to 
chronic pain and the concentration of pro- and anti-inflammatory cytokines in the CSF. 
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Hypothesis: There will be a positive correlation between the severity of chronic 
pain as measured by the Short Form McGill Pain Questionnaire (SF-MPQ), degrees of 
depression as measured by the Beck Depression Index (BD I-II), sleep disturbance as 
measured by the Pittsburgh Sleep Quality Index, and anxiety as measured by scores on 
the Hamilton Anxiety Scale (HAM-A), and the levels ofproinflammatory cytokines in 
the CSF. There will be an inverse correlation between the severity of symptoms and the 
anti-inflammatory IL-10. 
By gaining knowledge of the relationship between the psychoneuroimmune 
responses to prolonged pain states propagated by central inflammatory mechanisms, we 
can acquire the information pertinent to more effective analgesic and psychological 
treatment of these patients. It is the goal of this study to explore the psychoneuroimmune 
relationship of central inflammation, chronic pain, sleep deprivation, anxiety and 
depression in the chronic pain population. 
III. Research Strategy 
A. Significance 
Evidence Supporting Central Inflammatory Contributions to Chronic Pain 
A myriad ofmechanisms have been hypothesized to contribute to the 
maintenance of chronic pain states, but one of the most promising new constructs 
described in the literature is via glial cell activity. Recent literature has shown that glia 
are neuroimmune cells that are activated following tissue injury, illness or inflammation 
(Tsuda, Inoue, & Salter, 2005; Watkins & Maier, 2000). Once activated, they release a 
cascade ofmolecules, predominantly inflammatory cytokines, which have been shown to 
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upregulate pain transmission and experience centrally (Kreutzberg, 1996; Watkins, 
Milligan, & Maier, 2001 ), thus they are a fundamental component for enhanced pain 
perception (Watkins & Maier, 2003 ). These pro inflammatory cytokines sensitize dorsal 
horn neurons in pain transmission (Reeve, Patel, Fox, Walker, & Urban, 2000; Samad, 
Wang, Broom, & Woolf, 2004), stimulate the release of neurotransmitters from sensory 
afferent nerves responsible for pain perception (Inoue et al., 1999; Morioka et al., 2002) 
and may enhance pain via upregulation of excitatory amino acids systems (i.e., AMP A 
(2-amino-3-(5-methyl-3-oxo-l,2- oxazol-4-yl)propanoic acid) and NMDA (N-Methyl-D­
aspartate) receptor expression and activity) (Beattie et al., 2002; Samad, Wang, Broom, 
& Woolf, 2004; Viviani et al., 2003; Wang, et al., 2005). 
Clinical research on central inflammatory cytokines in humans with chronic pain 
is very limited and developing now. Prior human studies have focused on measuring 
inflammatory cytokines through serum analysis secondary to the decreased invasiveness 
and ease of collection. However, there is evidence that these peripheral markers of 
inflammation may not reflect levels in the central nervous system (CNS), which are those 
most relevant to the proposed work. Levels of cytokines found to be high in CSF were 
found to be low or undetectable in the serum (Backonja, Coe, Muller, & Schell, 2008; 
Lundborg, Hahn-Zoric, Biber, & Hansson, 2010; Zin, Nissen, Moore, & Smith, 2010). 
While glia are uniformly distributed throughout the CNS, it has been reflected in the 
literature that only glia in the spinal cord are activated following nerve injury (Zhang et 
al., 2008). Therefore to assess the inflammatory markers related to neuropathic pain, 
specimens drawn closest to the glia that release the markers would be most accurate in 
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assessing the types and amounts of markers responsible for this type of inflammatory 
nociception. This study will focus on CSF analysis because of the central location of glia 
and cytokines, rather than serum, as a means of supportive analysis for developing 
literature on the role of central neuroimmune responses and chronic pain. 
Prior evidence supporting the use of CSF in the examination of cytokine patterns 
in chronic pain subjects has focused on patients with Complex Regional Pain Syndrome 
(Alexander, Perreault, Reichenberger, & Schwartzman, 2005; Alexander et al., 2007; 
Backonja et al., 2008; Munts et al., 2008); lumbar radiculopathy (Ohtori et al., 2011 ); 
chronic pain patients receiving intrathecal opioid infusions for pain management (Zin et 
al., 2010); persistent headache (Rozen & Swidan, 2007); chronic migraine (Peres et al., 
2004); neuropathic pain related to previous spinal surgery (Capelle et al., 2009) and 
chronic osteoarthritis pain (Lundborg et al., 2010). Various inflammatory cytokines have 
been found to be elevated in the CSF of human pain study participants including 
interleukin-I (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8) and soluble TNFa receptor 
(TNFa). Other studies have shown a decrease in anti-inflammatory cytokine interleukin­
10 (IL-10). 




Part of the psychoneuroimmunologic component to pain is the interaction 
between cytokines and the behavioral complex known as sickness behavior. Feelings of 
sickness can be characterized by fatigue, decrease appetite, fever, lack of mobility, sleep 
disturbances, depression and inability to concentrate (Dantzer, 2001; Hart, 1988; Watkins 
138 
& Maier, 2000). Though the neuroimmune-mediated sickness behavior may promote 
unsavory feelings, this natural response to illness is paramount in healing and is usually 
short-lived with resolution of the offending illness. However, like chronic pain, when the 
mechanism of the sickness behavior goes awry, feelings of depression and anxiety, and 
sleep disturbances can be perpetuated longer than the illness or stress. If the effects of 
anxiety, depression and sleep deprivation are related to the illness or stress of pain, the 
mechanism is still unclear. Inflammatory cytokines offer one possible explanatory link 
between all of the psychoneuroimmune responses and pain, but central levels of 
cytokines in humans have been relatively unstudied thus far. 
Peripheral levels of inflammatory cytokines have been examined with conflicting 
results in human studies related to anxiety disorders (Hoge et al., 2009; Koh & Lee, 2004; 
van Duinen et al., 2008). However, these peripheral results do not clarify ifthere is a 
central mechanism that links anxiety, inflammation and pain. The data on central 
inflammation and anxiety is very limited. Similar to chronic pain studies that examine 
peripheral and central cytokine patterns, anxiety research exemplifies the same theme: 
Peripheral levels of cytokines do not always exemplify what is found centrally. Baker 
and colleagues discovered increased IL-6 levels in CSF but not in serum when they 
analyzed PTSD patients (Baker et al., 2001 ). Clearly, more studies are necessary to 
examine the relationship between anxiety, commonly found with pain-related conditions, 
and the centrally mediated response of inflammation. 
The direct correlative relationship between depression and pain has been 
thoroughly documented in the literature showing that both depressed patients exhibit at 
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least one painful symptom (Vaccarino, Sills, Evans, & Kalai, 2009) and chronic pain 
patients frequently exhibit depression (Dworkin & Gitlin, 1991 ). Similar to the anxiety 
literature, the relationship between levels of pro- and anti-inflammatory cytokines and 
their contribution to the pathophysiology of depression are not fully understood. Because 
antidepressants work centrally and have been shown to reduce levels of inflammatory 
cytokines (Basterzi et al., 2005; Janssen, Caniato, Verster, & Baune, 2010), the central 
pro- and anti-inflammatory patterns of these cytokines must be examined in the depressed 
patient. Cerebrospinal fluid levels of cytokines have been measured in unmedicated 
depressed patients (Levine et al., 1999), attempted suicide patients (Lindqvist et al., 
2009), and chronic PTSD sufferers (Bonne et al., 2011) all with conflicting results. 
Clearly chronic pain and depressive symptoms are usually experienced together, but there 
is no data currently available exploring the role of central inflammation and the 
pathophysiology of these co-existing symptoms. More data is necessary to ascertain the 
relationship of central inflammation and depression, especially in the chronic pain 
population. 
The complex relationship between pain and poor sleep quality is one that has been 
extensively documented in the literature, but its causality not fully understood. Up to 
53% of chronic back pain patients (Tang, Wright, & Salkovskis, 2007) and 88% of 
neuropathic pain patients (Meyer-Rosberg et al., 2001) report sleep disturbances. Thus 
the literature supports that sleep and pain do interact with one another, sleep 
abnormalities are frequently reported by the chronic pain population, and the effects are 
not benign (Fulda & Schulz, 2001). Unfortunately, monitoring of central inflammatory 
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cytokines in human sleep studies has been very lacking thus far, and those studies that 
have monitored peripheral concentrations of inflammation have yielded conflicting 
results. Peripherally monitored cytokines have been measured in humans, but on a 
limited basis and have focused on IL-I, IL-6 and TNFa with conflicting results (Heffner 
et al., 2011; Hong, Mills, Loredo, Adler, & Dimsdale, 2005; Irwin et al., 2004; Vgontzas 
et al., 2003 ). There is scant data to support that pro inflammatory cytokines may 
contribute to the poor sleep quality endured by chronic pain patients, but central levels 
have not been examined even with the knowledge from prior animal models that central 
levels of cytokines do scaffold involvement with sleep (Kapas et al., 1992; Oba!, & 
Krueger, 1991; Shoham, Davenne, Cady, Dinarello, & Krueger, 1987; Tobler, Borbely, 
Schwyzer, & Fontana, 1984). More data is crucial to discovering the role of central 
inflammation on sleep deprivation in the chronic pain patient. 
B. Innovation 
Review of the current literature on central inflammatory cytokine patterns reveals 
new relationships among chronic pain, sleep deprivation, anxiety and depression. 
Though the evidence indicates chronic pain, sleep deprivation, anxiety and depression are 
associated with central inflammatory changes, the mechanisms responsible require 
further description. Confirmatory studies are needed to clarify the pathways that have 
been tentatively identified as new relationships emerge. Thus, the proposed study is 
justified, in that it will further describe the pathophysiology of pain pathways, as well as 
explore novel relationships between the psychological responses to chronic pain and 
inflammatory mediator release. 
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If this study and future human-based studies can replicate prior findings, the 
implications for physical and psychological chronic pain treatment in our patient 
population are highly significant: Prior animal studies have demonstrated that by 
blocking the release of the proinflammatory IL-1, the length of analgesic effect of an 
opioid can double, there is an approximate seven and a half-fold increase in analgesic 
efficacy, opioid tolerance is blunted and both newly developed and established allodynia 
and hyperalgesia, both of which are common in chronic pain states, can be reduced 
(Hutchinson et al., 2008; Johnston et al., 2004). Through antagonism of the 
proinflammatory molecule TNFa, the same agent that was shown to decrease both pain 
and hyperalgesia in animals has also preliminarily been shown to decrease depression, 
pain and inflammation in human subjects (Alldred, 2001; Sommer, Schiifers, Marziniak, 
& Toyka, 2001; Tyring et al., 2006). Clearly human studies are paramount in progressing 
towards integrating comprehension of chronic pain pathways with treatment of the entire 
patient pain experience. 
The proposed project will investigate the role of inflammation in the CNS and the 
psychological impact of chronic pain. This study utilizes a rare opportunity to collect 
CSF from patients prior to and while undergoing a trial of an intrathecal opiate drug 
delivery system for treatment of chronic pain. An interdisciplinary team of nurse 
anesthetist researchers, pain management clinicians and psychoneuroimmunology (PNI) 
researchers will collaborate to measure CSF levels of inflammatory mediator molecules 
and evaluate the psychological status as each patient prepares for and then undergoes an 
intrathecal opioid catheter trial. 
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This study is a novel and unique approach to bridge chronic pain and PNI 
research. Additionally, collaboration among nurse anesthetist researchers, the physicians 
at the University of California, Los Angeles (UCLA) Pain Management Clinic and PNI 
researchers in the area of chronic pain would be instrumental in developing future clinical 
studies in the field of chronic pain. This study clearly has translational potential, as it 
may lead to targeted neuroimmunologic therapies for chronic pain, identification of 
treatment disparities within this patient population, and scaffold a better understanding of 
the psychological components of chronic pain. Given the impact chronic pain has on 
society, the healthcare system and the economy, any discoveries that would allow for 





This will be a cross-sectional, descriptive study with a convenience sample of 
approximately 30 chronic pain patients recruited from the Pain Management Clinic at 
UCLA. One time CSF draws will be analyzed and compared to control samples of CSF 
to allow for testing of the first hypothesis. Psychometric analysis of study participants 
will allow for testing of the second hypothesis. 
Sample 
Approximately thirty patients with the diagnosis and symptomatology of chronic 
pain who are eligible for and medically recommended treatment with a Food and Drug 
Administration (FDA)-approved intrathecal opioid infusion pain pump (the Medtronic 
SynchroMed® II Pain Pump) will be enrolled in this study after informed consent is 
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obtained. Potential participants will be recruited from the Pain Management Clinic at 
UCLA. Inclusion criteria include the patient being older than 18 years of age and have a 
chronic pain diagnosis greater than 6 months duration. Diagnosis will be made on 
standard clinical criteria, as suggested by the International Association for the Study of 
Pain (IASP). Exclusion criteria will include acute medical or psychiatric disorders, 
cancer, HIV, prior epidural injections for treatment of chronic pain, drug abuse, non­
English speaking, meningitis or history of meningitis, active upper respiratory 
infection/flu or febrile nature, history of blood transfusion, acute psychological or 
physiologic danger/instability, altered mental status, palliative treatment, and pregnancy. 
The inclusion and exclusion criteria will be confirmed using standard clinical and 
laboratory methods of analysis and all patients will be instructed to continue all of their 
medications and therapies without making any changes prior to study involvement. 
Measures 
Beck Depression Inventory II. The Beck Depression Inventory II (BDI-II) will 
be obtained from each patient before collection of CSF to assess and score levels of 
depression. The BDI-II contains 21 questions, each answer being scored on a scale value 
ofO to 3. The cutoffs used will be: 0-13: minimal depression; 14-19: mild depression; 
20-28: moderate depression; and 29-63: severe depression. Higher total scores indicate 
more severe depressive symptoms (Beck, Ward, Mendeson, Mock & Arbough, 1961). 
Hamilton Anxiety Scale. The Hamilton Anxiety Scale (HAM-A) measures the 
severity of a patient's anxiety, based on 14 parameters, each item given a 5-point score - 0 
(not present) to 4 (severe) and includes anxious mood, tension, fears, insomnia, 
144 
intellectual impairment, depression, somatic complaints, autonomic symptoms, 
physiologic symptoms and behavior at the interview. A total anxiety score of <17 
indicates mild anxiety levels; 18 to 24 moderate anxiety levels; and 25 to 30 indicates 
severe anxiety levels (Hamilton, 1959). 
Short Form McGill Pain Questionnaire. The Short Form McGill Pain 
Questionnaire (SF-MPQ) consists of fifteen descriptors, eleven sensory descriptors and 
four that are affective in nature. Each descriptor is rated on a scale of 0-3: 0 (none) to 3 
(severe). It also includes a Present Pain Intensity (PPI) index and a Visual Analogue 
Scale (VAS) (Melzack, 1975; Melzack, 1987). 
The Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index is 
composed of nineteen components that yield scores on subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficacy, sleep disturbance, use of sleeping 
medication and daytime dysfunction. These seven components are scored from 0-3 and 
yield a total score of0-21. Higher scores indicate worse sleep quality (Buysse et 
al., 1989). 
Procedures 
Approximately thirty patients with the diagnosis and symptomatology of chronic 
pain who are eligible for and medically recommended treatment with an FDA-approved 
intrathecal opioid infusion pain pump (the Medtronic SynchroMed® II Pain Pump) will 
be enrolled in this study. Potential participants will be recruited from the Pain 
Management Clinic at UCLA. After informed consent is obtained using Institutional 
Review Board (IRB)-approved forms, subjects will complete the psychometric 
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instruments to measure sleep deprivation, depression, anxiety and pain experience. 
Patients will undergo a structured interview to compile their demographic information 
and results will be number coded to ensure anonymity. Upon completion of the 
psychological questionnaires, study participants will be given a twenty-five dollar Visa 
gift certificate for their participation in the study. Participants will also be reimbursed for 
their parking fees upon enrollment of the study for the preclinical office visit date and the 
date forthe trial operation (a total of two parking fees per study participant). 
Approximately one month after the preclinical office visit, the study participant will be 
scheduled to undergo a surgical outpatient operation called an intrathecal opioid infusion 
pain pump trial. This operative surgical procedure and study procedure of collecting 
intraoperative CSF samples will be performed in the operating suite at UCLA Santa 
Monica Orthopedic Hospital. Three milliliters (mL) of CSF will be collected from the 
approximate 30 patient study participants undergoing intrathecal opioid infusion pain 
pump trials for the treatment of their pain. Standard preoperative preparation and 
evaluation will take place in the preoperative suite of UCLA Santa Monica Orthopedic 
Hospital. A qualified member of the preoperative evaluation team will start peripheral 
intravenous fluids in the preoperative suite and preoperative vital signs will be recorded. 
The patient will be brought to the operating room and positioned per surgeon preference, 
and standard monitors (electrocardiogram, noninvasive blood pressure cuff, pulse 
oximeter) will be applied. Patients will be given 2-4 liters/minute nasal cannula oxygen 
and a combination of intravenous versed and fentanyl will be titrated for patient comfort 
by a qualified operating room nurse at the surgeon's direction. Strict, standard sterile 
146 
surgical protocol will be followed per the regulations and policies of UCLA Santa 
Monica Orthopedic Hospital guidelines. Intrathecal access will be accessed with or 
without the use offluoroscopy per the surgeon's discretion. All samples of CSF will be 
collected intraoperatively during daylight hours in appropriate polypropylene specimen 
collection tubes, properly labeled with a number code for anonymous identification and 
placed on ice in UCLA approved specimen transportation boxes. A member of the 
research team will then transport specimens from UCLA Santa Monica Orthopedic 
Hospital to the UCLA Cousin's Institute Inflammatory Biology Laboratory in the 300 
Medical Plaza building of the UCLA Westwood campus via car, with an estimated 
transportation time of thirty minutes. Upon receipt of the specimens, the UCLA Cousin's 
Institute Inflammatory Biology Laboratory will centrifuge and partition the 3 mL samples 
into 0.5-1 mL aliquots with appropriately labeled anonymous identification. The aliquots 
will then be stored at -80°C until batch analysis can be performed. 
After collection of 3 mL of CSF in a specimen collection tube, the surgeon will 
place an intrathecal opioid infusion pain catheter and administer of a dose of intrathecal 
opioid. The catheter will be secured and dressed in a sterile fashion and the patient will 
be taken to the postoperative suite for recovery. The patient is then monitored for eight 
to ten hours for side effects and complications arising from the administration of an 
intrathecal opioid. The patients' hemodynamic stability and vital signs are also 
continually assessed during this eight to ten hour postoperative stay by a member of the 
pain management team and/or postoperative nursing staff. Once a member of the pain 
management team has determined that the patient has not incurred any serious side 
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effects from the administration of an intrathecal opioid, the patient is then eligible to have 
a permanent opioid infusion pain pump. The catheter is removed, a sterile dressing is 
placed over the operative site and the patient is discharged home with instructions and 
emergency contact information. 
Control samples ofCSF will be analyzed from the California NeuroAIDS Tissue 
Network obtained from Dr. Scott Letendre at the University of California, San Diego 
(UCSD). Thirty random, individual samples of 1-2 mL ofCSF, collected from 2005­
2012, will be utilized from this tissue bank as a means to compare levels of central 
inflammatory cytokines. Samples of 1-2 mL will be obtained in specimen collection 
tubes and placed on ice in the appropriate biological hazard container. The specimens 
will be shipped from UCSD to the UCLA Cousin's Institute Inflammatory Biology 
Laboratory in Los Angeles with an estimated travel time of two and half hours. Upon 
receipt of the specimens, the UCLA Cousin's Institute Inflammatory Biology Laboratory 
will centrifuge and partition the 1-2 mL individual samples into 0.5-1 mL aliquots with 
appropriately labeled identification. The aliquots will then be stored at -80°C until batch 
analysis can be performed. 
Control and study participant CSF levels ofIL-1, IL-6, IL-8, TNFa and IL-10 
will be determined using high sensitivity enzyme linked immunosorbant assay (ELISA) 
(R&D Systems, Minneapolis, MN) or similar. All assays will be performed in duplicate 
per manufacturers recommendations. The cytokine levels for all of the samples 
obtained, both from UCLA and UCSD will be reported as picograrns/milliliter (pg/ml). 
Variables 
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Independent Variable: Diagnosis of Chronic Pain (as defined by the International 
Association for the Study of Pain) greater than 6 months in duration. 
Dependent Variables: Proinflammatory Cytokines (IL-1, IL-6, IL-8, TNFa); 
Anti-inflammatory Cytokine (IL-1 O); Depression (as measured by Beck Depression 
Inventory II (BDI-II)); Anxiety (as measured by the Hamilton Anxiety Scale (HAM-A)); 
Pain (as measured by the McGill Pain Questionnaire). 
Categorical Covariate Variables: Age; Gender; Cause of Chronic Pain; Length of time 
from initial diagnosis; Type of medication used to treat chronic pain; Length of time 
taking medication; Race; Education Level; Income/Socioeconomic Status; Level of 
Activity; Body Mass Index. 
Possible Exclusion Criteria: Cancer; HIV; Prior epidural injections for treatment of 
chronic pain; Drug Abuse; Non-English Speaking; Meningitis or history of meningitis; 
Active URI/flu or febrile nature; History of blood transfusion; Acute psychological or 
physiologic danger/instability; Altered mental status; Palliative treatment; Pregnancy. 
Analysis Plan 
Descriptive statistics will be utilized to evaluate study CSF cytokine patterns and 
participant demographics. Statistically significant differences between patient and 
control group cytokine levels will be evaluated using multivariate statistical analysis; t-
tests and chi-square tests for parametric data. To determine the relationship of cytokine 
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patterns on sleep deprivation, anxiety, depression and self-reported pain in the study 
participants, analysis of variance (ANOV A) at one/two-tailed p < 0.05 for parametric 
data will be performed. For non-parametric data Mann-Whitney U statistical analysis 
may be selected as the appropriate statistical tool to test the second hypothesis. 
Calculations will be accomplished with the aid of the statistical software SPSS version 
v.19 or newer (SPSS, IBM Inc., Armonk, NY). 
The planned analysis at this time is primarily exploratory, and designed to answer 
the questions: Are there significant relationships between such psychological variables 
as sleep deprivation, depression, anxiety, or pain intensity and levels of inflammatory 
mediators in the CSF of the chronic pain patient? Is there a significant difference in the 
central levels of inflammatory cytokines of chronic pain patients and control samples of 
CSF? Following literature review, other analyses may be devised using a triangulation 
approach with the qualitative data obtained during the demographic interview. 
D. Investigators 
The principal investigator, Sarah E. Giron, CRNA, MS, is currently a Doctoral 
Student at University of San Diego (USD) Hahn School of Nursing and Health Science's 
PhD Program. Her prior research experience includes work at the San Diego Veterans 
Affairs Hospital for which she received the UCSD Undergraduate Excellence in Research 
Award. Ms. Giron has participated in data collection at UCLA's Department of 
Integrative Biology and Physiology, as well as a private gastroenterology office, La Jolla 
Gastroenterology. She has participated in Phase Three clinical trials of Sugammadex at 
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UCLA's Jules Stein Eye Institute and was awarded the 2012 American Association of 
Nurse Anesthetists (AANA) Baxter Research Doctoral Fellowship. Ms. Giron will be 
responsible for managing study operations, coordinating communication amongst team 
members and patients, and facilitating data collection logistical arrangements. 
Co-Investigator Charles Griffis CRNA, PhD, Associate Professor, UCLA 
Department of Anesthesiology and School of Nursing, is a well-accomplished nurse 
anesthesia expert in inflammation/chronic pain research. As a highly respected member 
of the nurse anesthesia academic and UCLA research community, Dr. Griffis was 
awarded the AANA Researcher of the Year Award in 2010. His numerous publications 
in a wide array of multi-disciplinary peer-reviewed journals also affirm his expertise in 
academic research writing. Dr. Griffis will provide faculty support at UCLA, project 
oversight pertaining to the protocol development and project details at UCLA and 
provide mentorship to Ms. Giron in academic writing and manuscript publication. 
Co-Investigator Joseph Burkard, CRNA, DNSc, Associate Professor, USD Hahn 
School of Nursing and Health Science, is also a well-accomplished nurse anesthesia 
educator and researcher. Dr. Burkard has been awarded Instructor of the Year by both 
the Navy and Kaiser Permanente Programs of Nurse Anesthesia and has been funded by 
USD and Military Grants for his ongoing research in Simulation and Emergence 
Delirium. Dr. Burkard will be providing faculty support at USD, oversight for 
procedures at USD, grant subcontract coordination between UCLA and USD, guidance 
with statistical analysis and manuscript writing. 
E. Environment 
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The UCLA Santa Monica Orthopedic Hospital and UCLA Cousin's Inflammatory 
Biology Laboratory will serve as the data collection and analysis site of this study, which 
will be primarily based at the USD Hahn School of Nursing and Health Science, PhD 
Program. The study will serve as the dissertation project for USD Doctoral Student, 
Sarah Giron CRNA, MS. Charles Griffis, CRNA, PhD and Joseph Burkard, CRNA, 
DNSc will provide academic oversight of the dissertation process. Ms. Giron will be the 
principal investigator for the project, responsible for developing, managing and 
collaborating with team members to ensure an ethical and comprehensive research 
strategy. 
The UCLA Department of Anesthesiology, Pain Management Clinic would seem 
to be an ideal setting for the participant recruitment necessary for this study. Andrea 
Nicol, MD, Assistant Clinical Professor and Director of Research for UCLA Pain 
Management Center and Michael Ferrante, MD, Director of UCLA Pain Management 
Center and Team, UCLA Department of Anesthesiology, have confirmed that once IRB 
approval is obtained, the patients could be recruited into the study in the clinic setting. 
The psychological instruments can be administered in the preoperative timeframe. The 
CSF sample collection can be accomplished at the time of an intrathecal catheter trial, 
and would not seem to require any escalation in care, nor present any increased risk to the 
patient. The UCLA Norman Cousins PNI Institute will provide support for the PNI 
theory aspects of the study through collaboration with Michael Irwin, MD, Professor and 
Director, an internationally recognized expert in this area. Additionally, Elizabeth Breen, 
PhD, a research immunologist with extensive experience in cytokine and inflammatory 
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molecule analysis will provide oversight of the immune analyses. Dr. Breen is the 
Director of the Inflammatory Biology Laboratory, which is a fully equipped research 
laboratory, located within the Cousins Center, and will be used for study sample analysis. 
IV. Biographical Sketch of Key Researchers 
Sarah Giron, CRNA, MS-USD Doctoral Student, Study Principal Investigator, AANA 
Baxter Research Doctoral Fellowship Grant Recipient 
J. Burkard, CRNA, DNSc-Associate Professor, USD Faculty Support and Oversight 
C. Griffis CRNA, PhD-Associate Professor, UCLA Faculty Support and Oversight 
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IV. Biographical Sketch of Key Researchers 
Sarah Giron, CRNA, PhD(c), is a Clinical Instructor of Anesthesiology at the 
University of Southern California (USC) where she is a full-time Faculty Nurse 
Anesthetist at the Keck Hospital of USC. She is currently enrolled as a PhD Doctoral 
Candidate at the University of San Diego's Hahn School of Nursing and Health Science, 
and is an active Committee Chair and Editor for her state nurse anesthetist association, 
the California Association of Nurse Anesthetists. She has authored several chapters in 
nurse anesthesia textbooks and will be featured as the guest speaker for the 2013 
graduating USC Program of Nurse Anesthesia Commencement Ceremony. Her most 
recent funded research endeavors focus on the role of inflammation in the psychology 
and physiology of chronic pain. 
Joseph Burkard, CRNA, DNSc, Associate Professor, USD Hahn School of Nursing and 
Health Science, is a well-accomplished nurse anesthesia educator and researcher. Dr. 
Burkard has been awarded Instructor of the Year by both the Navy and Kaiser 
Permanente Programs of Nurse Anesthesia and has been funded by USD and Military 
Grants for his ongoing research in Simulation and Emergence Delirium. 
Charles Griffis CRNA, PhD, Associate Professor, UCLA Department of 
Anesthesiology and School of Nursing, is a well-accomplished nurse anesthesia expert in 
inflammation/chronic pain research. As a highly respected member of the nurse 
anesthesia academic and UCLA research community, Dr. Griffis was awarded the AANA 
Researcher of the Year Award in 2010. His numerous publications in a wide array of 
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implanted pump for pain management. Pain Medicine, 11, 550-561. 
172 
VI. Timeline 
Psychoneurolmmunology and Chronic Pain Cross-Sectional StudyTlmellne 
P-1'ti&nt iiP!l t ient Fil •.1 Al 
Tr11tmu 11: Phru: R•t.rred t a UCLA 
Sillnti Mana 
P11n .5enriH 
Resen:h P resented :11 
AANAAnnu:i I Pa.ster 
Submitted Oc:tober 2012 forAANA General Resea 1thGrant by .S. Giron 
-----Ill" 
lnt nthan l P-1in 
Pump Prm:n t.d 
farTrBiltment af 
"'" 
lntAthK-il P-1 1n Pump 








Psvcho met n-c Too Is 
Partic1pa nt C.SF, 
ControI C.SF trom UC.SO 
Compued ta .Studv 
173 
VII. Budget 
Appendix A-AANA Foundation Grants Budget Template 
Proposal Title: Psychoneuroimmunology and Chronic Pain 
DETAILED BUDGET 
Date: September 26, 2012 
PERSONNEL 
PRO<.ECT ROLE % 
EFFOliT .S'·'IL!.lHY f;·E•j l_I ESTEC• 
Elizabeth Breen, PhD 
Co-






ELISAs 19 2467 
Subtotal: 13049 
CONSUL TANT COSTS 
Ilam~ i;· a t~ Am•:ount 
Subtotal: 
EQUIPMENT 
ltg.m Vend0r •.1\Jote•J Casi 





Item Amount Item Amount 
Lab Supplies, Processing, 
CSF High Sensitivity ELISA x 2 
2012-13 
1095 
Lab Supplies, Processing, 





Name Relation to Project Destination Amount 
Subtotal: 
OTHER EXPENSES 







Budget Justification for Psychoneuroimmunology and Chronic Pain Cross-Sectional 
Study 
Dr. Elizabeth Breen, PhD is an active Co-Investigator in this study and Director for the 
UCLA Cousins Inflammatory Biology Laboratory where all CSF samples will be 
analyzed. Her expertise in cytokine analysis and methodological experience with these 
studies is critical for successful development and completion of this study. Because of 
her academic appointment and position at the UCLA Cousins Institute of 
Psychoneuroimmunology Dr. Breen will need 5% salary and benefits to justify her 
participation in this study. One of her lab assistants, C. Perez, is skilled in handling and 
performing ELISAs on CSF samples and will be utilized from the Cousins Inflammatory 
Biology Laboratory as part of this study. This budget reflects the salary and benefits of 
both Dr. Breen and C. Perez. 
All CSF samples will be analyzed with a high-sensitivity ELISA assay to assess for 
cytokines IL-1, IL-6, IL-8, IL-10 and TNFu. From previous literature, CSF levels of 
these cytokines are not detectable using a regular ELISA, thus a high-sensitivity is 
necessary to detect levels. The rates quoted in this budget represent consumables, assay 
plates, storage test tubes, pipettes, and other lab equipment necessary for analysis. 
Upon receiving the CSF samples, the Cousins laboratory will be centrifuging the 
specimens to separate any precipitate, and making 0.5-lmL aliquots for deep freeze 
storage. This budget covers the labor of centrifugation and aliquots, and the test tube 
labeling for correct identification of study samples. 
Once centrifuged and the aliquots of CSF samples are made, the specimens need to be 
preserved at -80°C until all specimens are available for duplicate analysis. This form of 
batch analysis decreases the rate of discrepancies if assays were performed as CSF 
samples arrived. Freezer space and handling are included in this budget. 
CSF will need to be collected from the patients and transported to the lab in an 
appropriate container. Per previous studies, polypropylene specimen tubes are 
appropriate and will not alter the specimens for analysis. Because 2-3 mL of CSF will be 
collected, 4 mL polypropylene specimens tubes were selected from Fisher Scientific 




Please see the following attachments: 
Sarah Giron's CV 
Picture of Sarah Giron 
Biographical Sketch of Sarah Giron 
Dr. Charles Griffis' CV 
Dr. Joseph Burkard's CV 
Letter to Foundation Addressing IRB Application and Study Progress 
High Sensitivity ELISA Instructions 
http ://www.rndsystems.com/product_ detail_ objectname _ elisa _assay _product.aspx 
Psychological Instruments 
Found in Appendices of Dissertation 
Letters of Support 
• Dr. Andrea Nicol 
• Dr. Elizabeth Breen 
• Dr. Charles Griffis 
• Dr. Joseph Burkard 
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Sarah Elizabeth Giron, CRNA, MS 
Education: 
High School Whitney M. Young, Chicago, Illinois, Illinois State Scholar, Honor 
Roll, 1997 
University University of California San Diego, La Jolla, California, BS 
(Biochemistry and Cellular Biology), 2001 
University Columbia University, New York, New York, BS (Nursing), Dean's 
List, 2002 
Graduate School Columbia University, New York, New York, MS (Nurse 
Anesthesia), Dean's List, 2005 
University of San Diego, San Diego, California, PhD (Nursing), 
Anticipated Commencement 2014 
Honors and Awards •The AANA Doctoral Research Baxter Fellowship Award, San 
Francisco, 2012 
•Eight and Forty Scholarship, The American Legion, New York, 
2005, 
2011, 2012 
•Award for Excellence, Sigma Theta Tau, Graduate 
Commencement, New 
York, 2005 
•Excellence in Research, UCSD Faculty Mentorship Program, 
Undergraduate Symposium, La Jolla, 2000 
Board Certification Registered Nurse, 2002-present 
Other Certified Registered Nurse Anesthetist, 2005-present 
BLS and ACLS 2005-present 
Professional Background: 
Clinical Administrative Appointments 
•Clinical Instructor of Anesthesiology, University of Southern California, Los Angeles, 
California, 2009-present 
•Faculty Nurse Anesthetist, University of Southern California, Los Angeles, California, 
2009­
present 
•Senior Certified Registered Nurse Anesthetist, University of California Los Angeles, 
Los 
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Angeles, California, 2006-2009 
•Certified Registered Nurse Anesthetist, University of California Los Angeles, Los 
Angeles, 
California, 2005-2006 
•Burn Intensive Care Unit Registered Nurse, New York-Presbyterian Cornell Weill 
Medical 
Center, New York, New York, 2002-2004 
Specific Teaching Responsibilities 
•Clinical Preceptor and Didactic Faculty Member, Keck School of Medicine Program of 
Nurse 
Anesthesia, 2009-present 
•Clinical Preceptor, Kaiser Permanente and USC Student Nurse Anesthetist out-patient 
clinical 
rotations at UCLA, 2006-2009 
•Undergraduate Clinical Coordinator, Fresno State University student Registered Nurse 
clinical 
observation and volunteer rotation at UCLA, 2007-2008 
Other 
Editor in Chief, California Association of Nurse Anesthetists E-Journal, 2010-present 
Editor, California Association of Nurse Anesthetists Newsletter, 2009-present 
Society Memberships: 
Distinguished 
Sigma Theta Tau International, 2002-present 
Professional 
American Association of Nurse Anesthetists, 2003-present 
California Association of Nurse Anesthetists, 2005-present 
Service: 
Professional Organizations 
Editorial Committee Member, California Association of Nurse Anesthetists, 2011-present 
Membership Engagement/Information Technology Committee Chairperson, California 
Association of Nurse Anesthetists, 2009-present 
Committee Member, Information Technology Committee, California Association of 
Nurse Anesthetists, 2008-2009 
University/Other Committees 
University of Southern California/Keck School of Medicine Program of Nurse 
Anesthesia Webmaster, University of Southern California, Los Angeles, California, 
2010- present 
Faculty Development Chairperson, University of Southern California, Los Angeles, 
California, 2009-present 
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LEAP Scholarship Foundation Vice President, Keck School of Medicine Program of 
Nurse Anesthesia, Los Angeles, California, 2011-present 
LEAP Scholarship Foundation Secretary, Keck School of Medicine Program of Nurse 
Anesthesia, Los Angeles, California, 2010-2011 
Quality Assurance Committee, University of California Los Angeles, Los Angeles, 
California, 2007-2009 
Research Activities: 
Major Areas ofResearch Interest 
Psychoneuroimmunology, Chronic Pain, Pharmacology 
Past Clinical Research 
Sugammadex phase 3 clinical trials, University of California, Los Angeles, 2008-2009 
Invited Lectures: 
Distinguished 
"Pain, Opioids and Inflammation: Update on Physiology." CANA Spring 2009 





"Sugammadex and a Return to the Land of Neuromuscular Blockade." Winter 2008 

Educational Conference, Kaiser Permanente Nurse Anesthetist Association, Anaheim, 

California, January 2008. 

Other 
"Sugammadex (Organon 25969) Update." Faculty Development Meeting, University of 

Southern California, Los Angeles, California, February 2011. 

"Ethical Decision Making in Anesthesia." Co-Lecturer, USC School of Nurse 

Anesthesia, Los Angeles, California, November 2010, 2011. 

"Anesthesia for Out-Patient Surgery." Lecturer, USC School of Nurse Anesthesia, Los 

Angeles, California, September 2010, 2011. 

"Opioid Physiology and Pharmacology." Guest Lecturer, Samuel Merritt University, 

Oakland, California, August 2009, July 2012. 

"Opioid and Neuroglial Interactions--What Happens When Opioids Aren't Enough?" 

Guest Lecturer, Samuel Merritt University, Oakland, California, August 2009, July 2012. 

"Opioid Physiology and Pharmacology." Lecturer, USC School of Nurse Anesthesia, Los 

Angeles, California, June 2009, 2010, 2011, 2012. 

"Opioid and Neuroglial Interactions--What Happens When Opioids Aren't Enough?" 





"Opioids and Benzodiazepines: A Physiology and Pharmacology Review." Continuing 





"Sugammadex (Organon 25969) Update." Journal Club Continuing Education, UCLA 





Non Peer Reviewed 
I. Sarah Giron: The Next Big Adventure. CANA Newsletter 65 (2) 11-12, 2011 
2. Ann Keyes, Sarah Rozycki: Sugammadex (Org 25969) Update. CANA 
Newsletter 62 (2) 20-21, 2008. 
Chapters in Press 
I. Sarah Giron: Retina Surgery. In: Case Studies in Nurse Anesthesia !st Ed; Sass 
Elisha, CRNA, Ed.D. Jones and Bartlett, Sudbury, Massachusetts, 2011. 
2. Sarah Giron, Sass Elisha, Mark Gabot: Steroids. In: Pharmacology for Nurse 
Anesthesiology !st Ed; Richard G. Ouellette, M.Ed., CRNA and Joseph Anthony Joyce, 




Provide the following 1nformat1on for the Senior/key personnel and other s1gnif1cant contnbutors 1n the order listed on Form Page 2 

Follow this format for each person DO NOT EXCEED FOUR PAGES. 

NAME POSITION TITLE 
Giron, Sarah Elizabeth Clinical Instructor of Anesthesiology 
eRA COMMONS USER NAME (credential, e g, agency login) 
EDUCATION/TRAIN ING with baccalaureate or other 1mt1al professional education, such as nursmg, mclude postdoctoral trammg and 
residency trammg 1f app/1cab1:.J... 
INSTITUTION AND LOCATION DEGREE (1f appl!Cable) MMNY FIELD OF STUDY 
University of California, San Diego (La Jolla, CA) 
Columbia University (New York, New York) 
Columbia University (New York, New York) 














NOTE: The Biographical Sketch may not exceed four pages. Follow the formats and instructions 
below. 
A. Personal Statement 
Within the medical and nursing community it is imperative that advanced practice nurses take a more 
prominent role in research. Attaining a previous bachelor's degree in Biochemistry & Cellular Biology and 
experience with several undergraduate and postgraduate research projects, science has been a staple of my 
past and will continue to be a necessity for my future. I look forward to continuing research in the field of 
psychoneuimmunology with accurate, clinically significant studies that focus on the central inflammatory 
process and psychological implications of chronic pain. Such studies should help define pain pathways and 
clarify more effective pain modality treatments both analgesically and psychologically. 
B. Positions and Honors 
Positions and Employment 
1999 Undergraduate Research Assistant, Neurology Dept., University of California, Los Angeles, 
Los Angeles, CA 
2000 Hepatitis C Lookback Coordinator/Undergraduate Research Assistant, Veterans Affairs, La 
Jolla, CA 
1998-2001 Lab Technician, La Jolla Gastroenterology, La Jolla, CA 
2002-2004 Burn Intensive Care Unit staff Nurse, New York-Presbyterian Cornell Weill Medical Center, 
New York, New York 
2005-2006 Certified Registered Nurse Anesthetist, University of California, Los Angeles, Los Angeles, CA 
2006-2009 Senior Certified Registered Nurse Anesthetist, University of California, Los Angeles, Los 
Angeles, CA 
2009-present Faculty Nurse Anesthetist, University of Southern California, Los Angeles, CA 
Clinical Instructor of Anesthesiology, University of Southern California, Los Angeles, CA 
Other Experience and Professional Memberships 
2002-Present Sigma I heta I au International IVlember 
2003-Present American Association of Nurse Anesthetists Member 
2005-Present California Association of Nurse Anesthetists Member 
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CURRICULUM VITAE (04/2011) 
CHARLES ALAN GRIFFIS, CRNA, Ph.D. 
Date of Birth 
Education 
Fall 1985 - 1987 




9/11 - present 
7 /10 - present 
August 25, 1951 
Fall 2005 Doctor of Philosophy 
School of Nursing, Graduate Division 

University of California at Los Angeles 

Los Angeles, California 

Ed.Psych, Doctoral Student (36 hrs course work) 
College of Education 
Learning and Instruction 
University of California at Los Angeles 
Los Angeles, California 
Master of Science in Nurse Anesthesia 

Program of Nurse Anesthesia 





Los Angeles, CA 

Bachelor of Science in Nursing (Magna cum 
Laude) 
College of Nursing 
University of South Florida 
Tampa, Florida 
Associate of Science in Nursing 

(Magna cum Laude) 







Research and Didactic Instruction 

UCLA School of Nursing 

Associate Clinical Professor 
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8/89 - 7/2010 








5/87 - 2006 
3/92 - 12/98 
Department of Anesthesiology 
UCLA School of Medicine 
Los Angeles, CA 
Assistant Clinical Professor 
Department of Anesthesiology 
UCLA School of Medicine 
UCLA School of Nursing (secondary) 
Los Angeles, CA 
Adjunct Assistant Professor 
Department of Anesthesiology 
UCLA School of Medicine 
Los Angeles, CA 
Visiting Faculty 
University of Southern California Program of Nurse 
Kaiser Permanente Program of Nurse Anesthesia 
Per Diem Staff Nurse Anesthetist and Clinical Instructor 
Greater Los Angeles VA Healthcare System 
Department of Anesthesia 
Los Angeles, CA 
Professional Lecturer, Institute for Post-Graduate 
Principal Nurse Anesthetist 
Assistant Administrative Director, Nurse Anesthesia 
Clinical Educator, Educational Director 
UCLA Department of Anesthesiology 
Staff Senior Nurse Anesthetist and Instructor 
UCLA Department of Anesthesiology 
Los Angeles, CA 
Staff Nurse Anesthetist 
Clinical Instructor 
West Los Angeles Veteran's Administration 
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6/89 - 8/89 
1/85 - 5/87 
6/81 - 1/85 
6/81 - 1/85 
1974 - 1979 
Medical Center 
Department of Anesthesia 
Los Angeles, CA 
Staff Nurse Anesthetist (Part-time) 
Sepulveda Veterans Admin Medical Center 
Sepulveda, CA 
Director 
UCLA Program of Nurse Anesthesia 
UCLA Department of Anesthesiology 
School of Medicine 
Los Angeles, CA 
Staff Nurse Anesthetist 
Clinical Instructor 
UCLA Department of Anesthesiology 
Los Angeles, CA 
Private Anesthesia Practice (Part-time) 
Plastic Surgery Offices 
Los Angeles, CA 




St. Joseph Hospital 
Intensive Care Unit 
Staff and Charge Nurse 
Tampa General Hospital 
Coronary Care Unit 
Staff and Charge Nurse 
St. Joseph Hospital 
Cardiac Surgery Intensive Care Unit 
Staff and Charge Nurse 
Tampa, Florida 
Surgical Intensive Care unit 




California Association of Nurse Anesthetists 
American Association of Nurse Anesthetists 
International Association for the Study of Pain 
International Anesthesia Research Society 
CPR Certification 
American Heart Association 
Basic Life Support, biannual recertification 
1974 - present 
Advanced Cardiac Life Support, bi.an.recert 
1978 - present 




Approved Continuing Education Provider #CEP 14381 
California Board of Registered Nursing 
Conference Presentations 
UCLA Department of Anesthesiology Clinical Case Conference 
"Syncope During Local Anesthesia", Feb 1983 
"Cardiac Depression Following V ancomycin", Oct 1983 
"Anaphylaxis Following Ancef', May 1984 
"Tension Pneumothorax in the Recovery Room", June 1984 
"The Effects ofNaloxone on the Exercise Hyperpnea", August 1984 
"HIV Chemoprophylaxis", May 2001 
West Los Angeles VA Medical Center, Department of Anesthesia 
Grand Rounds 
"Propofol and Alfentanil for Sedation", August 1993 
"HIV Disease and Anesthesia", April 1996 
"Update on HIV and Anesthesia", November 1997 
"HIV/AIDS Drugs: Anesthetic Implications", July 1997 
Federation of American Societies for Experimental Biology, Annual Meeting April 1984. 
"The Influence of the Endogenous Opiate System on the Control of the Exercise 
Hyperpnea in Man" 
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Harbor-UCLA Medical Center, Division of Respiratory Physiology and Medicine 
Research Conference, June 1984. "The Effects ofNaloxone on the Exercise Hyperpnea" 
American Association of Nurse Anesthetists Annual Meeting, August 1984. "The Effect 
ofNaloxone on the Exercise Hyperpnea" 
Malignant Hyperthermia Association of the United States Annual Meeting, September, 
1984. "Monitoring Techniques in the Operating Room" 
American Association of Nurse Anesthetists Annual Meeting, August 1985. "End-Tidal 
C02 Monitoring" 
California Association of Nurse Anesthetists, May, 1986. "Cardiovascular Implications 
of PAR Nursing Care" 
American Society of Plastic and Reconstructive Nurses, October, 1986. "Malignant 
H yperthermia" 
California Association of Nurse Anesthetists, February, 1987. "The Future of Nurse 
Anesthesia Education" 
California Association of Nurse Anesthetists, October, 1988. "Clinical Implications of 
the Harvard Standards for Monitoring" 
California Association of Nurse Anesthetists, October, 1989. "The Use of Alfentanil for 
Sedation in Ophthalmologic Outpatient Surgery" 
California Association of Nurse Anesthetists, February, 1992. "Propofol and Alfentanil 
in Outpatient Anesthesia" 
American Association of Nurse Anesthetists Annual Meeting, August, 1993. "Use of 
Propofol/ Alfentanil Bolus and Infusion for Monitored Anesthesia" 
California Association of Nurse Anesthetists, May 1996 Annual Meeting. "HIV and 
AIDS - An Update for the Anesthesia Provider" 
American Association of Nurse Anesthetists Annual Meeting, August, 1997. 
"Perioperative Management: Anesthesia for the Ambulatory Patient" and "Risk 
Management in the Ambulatory Setting" 
California Association of Nurse Anesthetists, Fall Meeting, October, 1997 - "Update on 
the AIDS Epidemic and Chemoprophylaxis for Occupational Exposure to HIV" 
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American Association of Nurse Anesthetists Annual Meeting, August, 1998. 
"HIV/AIDS Drugs: Anesthesia Implications" 
California Association of Nurse Anesthetists, May 1999 Annual Meeting, "Anesthetic 
Implications of HIVIAIDS Drugs" 
24th Annual Gastrointestinal Nurses Seminar, March, 2000 - "Conscious Sedation: Do's 
and Don'ts" 
California Association of Nurse Anesthetists, May 2000 Annual Meeting, "Risk 
Management in Anesthesia Practice" 
American Association of Nurse Anesthetists, August 2006 Annual Meeting, Research 
Forum, "The Effect of Pain on Proinflammatory Cytokines and Leukocyte Cellular 
Adhesion Molecules" 
UCLA Department of Anesthesiology, Mortality and Morbidity Conference, September 
2006, "Anesthesia, Pain, Stress, and Immune System Responses" 
UCLA Cousin's Center for Psychoneuroimmunology, Psychoneuroimmunology Seminar, 
November, 2006, "Review of Stephen Maier and Linda Watkins Papers: Pain and 
Cytokine Responses" 
West Los Angeles Veteran's Administration Medical Center, Dept. of Anesthesia 
Morbidity and Mortality Conference, March, 07, 2007, "Implications of Perioperative 
Stress to Immune Function" 
California Association of Nurse Anesthetists, April 2007, Annual Meeting, "Implications 
of Anesthesia and Surgical Stress to Perioperative Immune Function" 
Kaiser Permanente Nurse Anesthetists Association, January, 2008, "Outpatient 
Anesthesia: Issues and Update" 
UCLA Ronald Reagan Medical Center, Emergency Department Pediatric Conference, 
Los Angeles Country Emergency Department Approved for Pediatrics (EDAP) 
requirement, November 2008, "Pediatric Sedation in the Emergency Room; Acute 
Pediatric Pain Management" 
California Association of Nurse Anesthetists, February 2009, Spring Meeting, "Pain, 
Opioids and Neuroinflammation" (2 hours); "Risk Management: Error Prevention" (I 
hour) 
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UCLA Nursing Practice Research Council, April 2009, "Pain and Inflammatory 
Mediators: A Research Review" 
UCLA Department of Anesthesiology, Weekly Morbidity and Mortality Conference, 
June 2009, "The Contribution ofNeuroimmune Activation to Chronic Pain" 
American Association of Nurse Anesthetists, Annual Meeting, San Diego, California, 
Research Forum, Oral Poster Presentation, "Preliminary Data: Pain and 
Neuroinflammatory Mediators" 
Nebraska Association of Nurse Anesthetists, October, 2009, "Chronic Pain and 
Neuroinflammation; Outpatient Anesthesia-Update on Issues; Anesthesia for Out of the 
OR Settings" 
California Association of Nurse Anesthetists, February 2010, Spring Meeting, "OPSU­
Issues and Update" (1 hour) 
American Association of Nurse Anesthetists, Assembly of School Faculty, February, 
2011, Research Report of the John F. Garde Researcher of the Year, "Pain, Cellular 
Adhesion Molecules, and Inflammatory Mediator Production" 
California Association of Nurse Anesthetists, March, 2012, Spring Meeting, "Policy 
Governance and CANA" 
American Association of Nurse Anesthetists, August 2012, Annual Meeting, "Anesthetic 
Management of the Patient with Implanted Cardiac Devices"; "Anesthesia for Out of OR 
Cases" 
Invited Lectures 
Medical Media Associated, Inc., Continuing Education Lecture Series for Professional 
Nurses, October 1984. "Airway Management in the Anesthetized Patient" 
UCLA Allied Health Program, Center for the Health Sciences. December 1984 ­
"Anesthesia, A Nursing and Medical Specialty"; June 1985 - "UCLA Nurse Anesthesia 
Program"; October 1985 - "Nurse Anesthesia at UCLA Medical Center" 
Post Anesthesia Recovery Nurses, UCLA, Continuing Education Lectures. July 1985 ­
"Anesthetic Agents"; January 1986 - "The Choice of General Vs. Regional Anesthesia; 
August 1986 - "Post Anesthesia Care of the Trauma Patient" 
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UCLA Operating Room Postgraduate Nursing Program: "The Role of the OR Nurse in 
Anesthesia Care" and "Anesthesia and Emergency Drugs" - 1985, 1986, 1987, 1988, 
1989, 1990 
Professional Symposiums, Inc. Continuing Education Lecture Series for Professional 
Nurses, February, 1986. "Anesthesia and Perioperative Nursing Care" 
CRNA Staff and Faculty, UCLA, May, 1986. "Motivation Theory and Nurse Anesthesia 
Education" 
UCLA Operating Room Nurses Continuing Education Conference, August 1986. 
"Anesthesia and Perioperative Nursing Care" 
CRNA Staff and Faculty, UCLA December, 1986. "Cognitive Psychological 
Approaches to Nurse Anesthesia Education" 
UCLA Operating Room Nurses Weekly Teaching Conference, UCLA, August, 1988. 
"Malignant Hyperthermia" 
UCLA Department of Anesthesiology, Educational Lecture Series for Stuart 
Pharmaceutical Sales Representatives. August - October 1988 "Monitoring in 
Anesthesia"; "Preoperative and Postoperative Assessment and the Ambulatory Surgery 
Unit" 
UCLA Post Anesthesia Care Unit, UCLA, August, 1988. "Malignant Hyperthermia" 
Jules Stein Operating Room Nurses, December, 1989. "The Pharmacology of Alfentanil 
and Its Applications to Ophthalmologic Anesthesia" 
UCLA Surgery Center Perioperative Nurses, June - September, 1990. Lecture Series 
entitled: "Continuing Education on Anesthesia Care for the OR Nurse", composed of 10 
two to four hour lecture-discussion classes. 
UCLA Surgery Center Operating Room Nurses, February, 1991. "Review of Commonly 
Used Anesthetic Techniques and Drugs" 
September, 1995; August 1996; February 1997 UCLA Perioperative Nurses, 
"Preoperative Anesthesia Evaluation for the Perioperative Nurse"(24 hours lecture) 
UCLA Surgery Center Operating Room Nurses, April 1996. "Monitoring and Sedating 
Patients in the OR" 
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UCLA Surgery Center Operating Room Nurses, Perioperative Evaluation Suite Nurses, 
and Pheresis Unit Nurses, Fall, 1996. "Chemoprophylaxis for Occupational HIV 
Exposure" 
Association of Operating Room Nurses, San Fernando Valley Chapter, March 1997. 
"HIV and AIDS - Implications for Perioperative Nursing Care" 
UCLA Surgery Center Operating Room Nurses, March, 1997; April, 1997, May, 1997 ­
"Anesthesia Equipment, Cart, Drugs, and Machine - A Hands-on Workshop" 
September, 1997 UCLA Perioperative Nurses, "Review of Preoperative Evaluation and 
Conscious Sedation" 
UCLA Surgery Center Operating Room Nurses, October, 1997 - "Review of Cardiac 
Arrest Procedures and Crash Cart in the OR" 
UCLA Surgery Center Operating Room Nurses, November, 1997 - "Malignant 
H yperthermia" 
November, 1997 West Los Angeles Veteran's Administration Medical Center 
Perioperative Nurses, "Update on HIV Epidemic and Chemoprophylaxis for 
Occupational Exposure"; Educational Workshop Organizer and Coordinator. 
UCLA Surgery Center Operating Room Nurses, March, 1998 - "Sedation and Airway 
Management for OR Nurses" 
March, 1998 UCLA Perioperative Nurses, "Conscious Sedation" 
March, 1998 UCLA Perioperative Nurses, "Perioperative Assessment for Anesthesia 
Care At UCLA Surgery Center" 
Jules Stein Eye Institute Perioperative Nurses, Fall, 1998 - "Discharge Criteria for 
General Anesthesia and Monitored Anesthetic Care Patients" 
October, 1998 UCLA Perioperative Evaluation Suite Nurses, "Perioperative 
Preanesthesia Evaluation for the Perioperative Nurse" (24hrs of lecture; proctored and 
tutored Angela Jackson, RN, BSN in assisting with class instruction) 
UCLA Surgery Center Operating Room Nurses, January, 1999 - "Local Anesthetics: 
Clinical Use and Pharmacology; Treatment of Adverse Reactions" 
UCLA Surgery Center Operating Room Nurses, March, 1999 - "Review and 
Demonstration of Defibrillator/Pacemaker and Crash Cart" 
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UCLA Surgery Center Operating Room Nurses, September, 1999 -"Review of 
Anesthesia and Sedation Equipment and Drugs" 
November, 1999 UCLA Ambulatory Surgery Center Anesthesia Technicians, "Part 1 
Introduction to Theory and Practice of Anesthesia - An Overview"; continuing through 
Nov 2000, 15 one-hour lectures 
Dept of Anesthesiology, Kaiser Harbor City Medical Center, March, 2000 - "Implications 
of HIV Disease to Peri operative Care" 
Medical Procedures Unit Nurses, UCLA Medical Plaza, May, 2000 - "Pre-Sedation 
Assessment" 
Procedure and Treatment Unit Nurses, UCLA Operating Room, May, 2000 - "Review of 
Pre- and Post-Anesthesia Assessment and Care" 
UCLA Ambulatory Surgery Center OR Nurses, May, 2000 - "Review of Crash Cart and 
Cardiac Arrest in OR" 
PACU Nurses, UCLA Operating Room, July 2000 - "Review of Anesthesia Techniques 
and Drugs" 
UCLA Ambulatory Surgery Center PACU Nurses, November 2000 - "Airway 
Management" 
PACU Nurses, UCLA Operating Room, November 2000 - "Preoperative Assessment ­
Implications for Postoperative Care" 
Procedure and Treatment Unit Nurses, UCLA Medical Center, November 2000 ­
"Implications of Pain Drugs and Antiemetic Drugs to Outpatient Treatment and 
Discharge" 
Jules Stein Eye Institute OR Nurses, May 2001, "HIV Chemoprophylaxis" 
August, 2001 UCLA Peri operative Nurses, "Pre-anesthesia Evaluation" 
Procedure and Treatment Unit Nurses, UCLA Medical Center, September 2001 ­
"Perioperative Geriatric Care" 
June, 2002 UCLA Perioperative Nurses, "Preanesthesia Assessment" 
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September 2005 UCLA Healthcare Enterprise Santa Monica Perianesthesia Nurses, 

"Coagulation Pathways and Implications for P ACU Care" 

October 2005 UCLA Healthcare Enterprise Santa Monica Perianesthesia Nurses, 

"Principles of Outpatient Surgery Nursing Care" 

November 2005 UCLA Healthcare Enterprise Santa Monica Perianesthesia Nurses, 

"Propofol: Pharmacology and Anesthesia Use" 

Jules Stein Perioperative Nurses, January 2006, "Intravenous Therapy" 

February 2006 UCLA Main OR Nurses, "Conscious Sedation Part l" 

Journal Club Leader, UCLA CRNA Group, March, 2006, "Complications of Ophthalmic 
Regional Anesthesia" 
April 2006 UCLA Procedure and Treatment Unit and Post-Anesthesia Care Unit Nurses, 
"Ophthalmic Surgery Postop Care" 
UCLA Healthcare Enterprise Westwood Perianesthesia Nurses, April 2006, "Phase 1 
Care, Post Anesthesia Care Unit" 
UCLA Healthcare Enterprise Santa Monica Perianesthesia Nurses, May, 2006, 

"Outpatient P ACU Care and Discharge Criteria" 

May 2006, UCLA Westwood MOR Nurses, "Conscious Sedation Part 2" 

June, 2006, UCLA Westwood MOR Nurses, "Conscious Sedation Part 3: 

UCLA Jules Stein Eye Institute Perianesthesia Nurses, July, 2006, "Jules Stein PACU 

Care" 
UCLA Santa Monica Perianesthesia Nurses, August, 2006, "Hemodynamic Monitoring 
Principles" 
UCLA Westwood MOR Nurses, August, 2006, "Conscious Sedation, Part 4" 





UCLA Medical Procedures Unit Nurses, October 4, 2006, "Combining Sedatives" 
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UCLA Radiology Services Nurses, October 20, 2006, "Pharmacology and Physiology of 
Sedation" 
UCLA Medical Procedures Unit Nurses, October 25, 2006, "Difficult Sedation" 





UCLA Medical Procedures Unit Nurses, November 1, 2006, "NPO Status, Propofol, 

Assessment and Emergency Sedation" 





UCLA Medical Procedures Unit Nurses, December 6, 2006, "Vasopressors, Reversal 

Drugs and Sedation" 





Santa Monica UCLA Medical Center, ICU Nurses, May 21, May 27, July 3, August 28, 

2007, "P ACU Care for the ICU RN" 

Jules Stein Operating Room Nurses, June 2007, July 2007, "Pre-Anesthesia Evaluation" 

UCLA Radiology Nurses, August, 2007, "Vasopressor Infusions" 





Jules Stein Perioperative Nurses, October, 2007, "Malignant Hyperthermia" 

UCLA Radiology Nurses, November, 2007, "Avoiding Oversedation" 

UCLA Radiology Nurses, February, 2008, "Treating Delirium During Sedation" 

Western University, Pomona California, Nurse Practitioner Program, March 2008, 





Santa Monica UCLA Medical Center, OR Unit Nurses, May, July 2008, "Basic 

Conscious Sedation-Introduction; Part 2, Part 3" 
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Jules Stein Perioperative Nurses, June, 2008, "Perioperative Cardiac Arrest and 
Resuscitation" 
Santa Monica UCLA Medical Center, OR Unit Nurses, August/September 2008, 
"Arrhytlunia Interpretation", Parts 1 - 4, one-hour lectures 
UCLA Ronald Reagan Medical Center, Emergency Department Nursing, October 2008, 
December 2008, "Sedation in the Emergency Room" 
Santa Monica UCLA Medical Center, OR Unit Nurses, Medical Procedures Unit Nurses, 
October 2008, "Arrhytlunia Interpretation" 
Santa Monica UCLA Medical Center, Medical Procedures Unit Nurses, December 2008, 
"ECG Interpretation" 
UCLA Ronald Reagan Medical Center, Ambulatory Nursing, March, 2009, "Pediatric 
Sedation" 
UCLA Ronald Reagan Medical Center, Ambulatory Nursing, March 2009, "Adult 
Sedation" 
Western University, Pomona California, Nurse Practitioner Program, March 2009, 
"Peri operative Stressors and Preoperative Preparation of the Patient by the Primary Care 
Nurse Practitioner" 
UCLA Ronald Reagan Medical Center, Emergency Department Nursing, May, 2009, 
"Pediatric Sedation" 
UCLA Ronald Reagan Medical Center, Radiology-Cardiac Catheterization Nurse Group, 
July, August, 2009, "Adult Sedation" 
Jules Stein Eye Institute, OR Nursing Group, September 2009, "Malignant 
Hyperthermia" 
Santa Monica/UCLA PACU Nurses, January, 2010 "PACU Phase 1and2" 
UCLA Ambulatory Surgery Center, OR Nurse Group, July, 2010, "Update on Anesthesia 
Drugs, Techniques, and SCIP Requirements" 
California Student Nurse Association, "Nurse Anesthesia as an Advanced Nursing Career 
Choice", October, 2010 
UCLA Medical Procedures Unit RNs, "Adult Sedation", January, 2011 
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Research Activities 
1. Thesis Research Project: "The Effects of Naloxone on the Exercise Hyperpnea". 
Human laboratory study. 
2. Independent Research: "The Use of Alfentanil in Outpatient Ophthalmologic 
Surgery": a clinical investigation of the use of the short-acting narcotic alfentanil in 26 
patients for monitored anesthetic care at the Jules Stein Eye Institute, UCLA Medical 
Center, May-August, 1989. 
3. Doctoral Dissertation Research Project: "The Effect of Pain on Leukocyte Cellular 
Adhesion Molecules" (human subjects). UCLA IRB Approval January 05, 2004. 
Dissertation Defense 12-02-05. 
Grant Support: 
UCLA School of Nursing, Intramural Grant Award, $10,000, January, 
2004 
UCLA General Clinical Research Center, NIH/NCRR Grant #M01RR00865, 
$10,000, January 2004-August 2005 
American Association of Nurse Anesthetists Research Foundation General 
Research Grant, $13,625, March 2004 - August 2005 
4. Post-doctoral Research Project, begins 08-04-06, UCLA General Clinical Research 
Center 
Grant Support: National Institute of Nursing Research, "The Effect of Pain on 
Leukocyte CAMs", Grant #1 R0-3 NR009106-01Al, August 2005 
UCLA General Clinical Research Center, NIH/NCRR Grant, #M01RR00865, 
April 2006 
American Association of Nurse Anesthetists Research Foundation, Post-doctoral 
Fellowship Grant, May, 2006 
5. Research Rotation for USC Program of Nurse Anesthesia students, practicum portion 
of ANST 512, Research Integration: Capstone Experience. Students attended 3 hours of 
theory lecture on research methodology and project theoretical framework; assisted with 
data collection and entry; chose a topic related to project and wrote a review paper, Sept 
2007-May 2008. 




$10,000. December 22, 2008 - June 30, 2009. Project Title: "Nuclear Factor Kappa-B 

Activation and Pain. 

7. American Association of Nurse Anesthetists "State of the Science" Poster and Oral 
Session August 2009, "The effect of pain on leukocyte cellular adhesion molecules and 
inflammatory mediators". 
8. National Institutes of Health, Grant # 1 R21 DA027558-0l, "Pain Opioids and Pro­
Inflammatory Immune Responses", September, 2010. Co-Investigator. 
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9. General Research Grant, American Association of Nurse Anesthetists Foundation, 
"Pain Opioids and Pro-Inflammatory Immune Responses", January, 2011. Co­
Investigator. 
10. American Association of Nurse Anesthetists "State of the Science" Poster and Oral 
Session August 2012, "Acute painful stress and inflammatory mediator production." 
Publications 
RESEARCH PAPERS 
1. Thesis - "The Effects ofNaloxone on the Exercise Hyperpnea" 

Program of Anesthesiology for Registered Nurses 

Department of Anesthesiology, School of Medicine 

University of California at Los Angeles 

Los Angeles, CA 

2. Griffis, C.A., S.A. Ward and R.D. Kaufman. "Naloxone and the ventilatory 
response to exercise in man." European Journal of Applied 
Physiology 55: 624-629, 1986. 
3. Griffis, C.A. "Monitored anesthetic care for outpatient cataract surgery with 
alfentanil" Nurse Anesthesia 1(2): 71-78, 1990. 
4. Dissertation. Griffis, C. "The effect of pain on proinflammatory cytokines and 
leukocyte cellular adhesion molecules" 
School of Nursing, Graduate Division 
University of California at Los Angeles 
Los Angeles, California 
December 05, 2005 
5. Griffis, C., Irwin, M.R., Martinez, 0., Doering, L., Nyamathi, A., Kaufman, 
R.D., Elashoff, D., Aziz, N., Compton, P. "Pain-related activation of leukocyte 
cellular adhesion molecules: preliminary findings". Neuroimmunomodulation 14: 
224-228, 2007. 




Elisha, S.M. (ed.), Case Studies in Anesthesia, "Ruptured Globe", author C.Griffis & E. 
McCall, Jones & Bartlett: Sudbury, MA, 2010, pp. 373-382. 
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Joyce, J. & Oullette, R. (ed. 's), Pharmacology for the Nurse Anesthetist, "Implications of 
the Immune System to Pain", author C. Griffis, Jones & Bartlett: Sudbury, MA, 2011, pp. 
437-444 
REVIEW ARTICLES 
Griffis, C.A. "Anesthetic implications ofvasovagal syncope", CANA Newsbulletin 40(1): 
5-10, October, 1985. 
Griffis, C.A. "Anesthetic implications of essential hypertension", CANA Newsbulletin 
41(1): 10 - 17, October, 1986. 
Griffis, C.A. "The future of nurse anesthesia education: curricular design, purpose and 
evaluation" CRNAForum 2(4): 11-12, 1986. 
Griffis, C.A. "End-tidal C02 Monitoring", AANA Journal 54( 4): 312 - 318, 1986. 
Griffis, C.A., Gerbasi, R., Samph, T., Stoll, D. "The impact of present day trends in 
testing on the certification process for nurse anesthetists" AANA Journal 55(3): 198-201, 
1987. 
Griffis, CA., Kelley, J. "The future of nurse anesthesia education", CANA Newsbulletin 
41(2): 20-21, 1987. 
Griffis, C.A. "Nurse Anesthesia: An Awakening Specialty" California Nursing Review 
10(2): 32 - 35, 1988. 
Griffis, C.A. "Implications of recent antiviral pharmacology to prevention of 
occupational HIV transmission in anesthesia clinical practice"AANA Journal 64(6): 525­
527, 1996. 
Griffis, C.A. "Anesthetic Implications of Human Immunodeficiency Virus" Nurse 
Anesthetist Forum 1(3): 3,11-12, 1998. 
Griffis, C.A. "Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome­
related drug therapy: anesthetic implications. CRNA The Clinical Forum for Nurse 
Anesthetists 10(3): 107-116, 1999. 
Griffis, C.A. "Prevention of occupational transmission of bloodborne diseases in nurse 
anesthesia practice" CRNA The Clinical Forum for Nurse Anesthetists 11(1): 2-7, 2000. 
Griffis, C., Compton, M., Doering, L. "The effect of pain on leukocyte cellular adhesion 
molecules". Biological Research for Nursing, 7(4): 297-312, 2006. 
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Griffis, C., Page, G., Kremer, M., Yermal, S. "Implications of immune function to 
anesthesia care". American Association ofNurse Anesthetists Journal, 76(6): 449-454, 
2008. 
Griffis, C. "Neuroimmune activation and chronic pain". American Association ofNurse 
Anesthetists Journal, 79 (1):31-37, 2011. 
CASE REPORTS 
Griffis, C.A. "Case Report--Management of examination under anesthesia and 
electroretinogram in a child with degenerative neurological disease", CANA Newsbulletin 
Flowmeter Column 43(3), 1989 
Griffis, C.A. "Case Report--Use of retrobulbar block during general anesthesia", CANA 
Newsbulletin Flowmeter Column 44(2), 1990. 
Rochin, M., Griffis, C., Kaufman, R. "The development of Mobitz 1 heart block under 
general anesthesia following chronic beta-adrenergic receptor antagonism", CANA 
Newsbulletin Flowmeter Column 44(3): 18-21, 1990. 
Griffis, C., Austin, J., Ritter, J. "The use of propofol and nitrous oxide for inguinal hernia 
repair" CANA Newsbulletin Flowmeter Column 45(1), 1990. 
Griffis, C.A. "The effect of intraoperative retrobulbar block on anesthetic management of 
enucleation under general anesthesia" Nurse Anesthesia 2(1): 28-32, 1991. 
Griffis, C. "Acute postoperative pain management and malfunctioning epidural catheter" 
Oncology Nursing Forum 30(2): 217-218, 2003. 
LETTERS TO THE EDITOR 
Griffis, C. "Expert witness testimony and CRNA practice". AANA Journal 72(5): 334, 
2004. 
EDITORIALS 
Griffis, C. "The Flowmeter", an educational column originated and written by C. Griffis 
in the California Association ofNurse Anesthetists Newsbulletin: 
"Review of research methods and statistical analysis for the mystified and/or totally 
disinterested" CANA New sbulleti n Flowmeter Column 41 ( 4), 1987 
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1988 
"Isoflurane: an emergmg controversy" CANA Newsbulletin Flowmeter Column 42(1), 
"Review of the Harvard Standards for Patient Monitoring: implications for practice" 

CANA Newsbulletin Flowmeter Column 42(3), 1988. 

"The uses of lidocaine in anesthesia" CANA Newsbulletin Flowmeter Column 42( 4), 1988 





"Cranial Nerve anatomy and physiology-clinical implications for the nurse anesthetist" 

CANA Newsbulletin Flowmeter Column 44(1), 1989. 

"Review of recent anesthesia-related incidents with medico-legal implications" CANA 

Newsbulletin Flowmeter Column 45(1), 1990. 

"HIV and AIDS--An update on the pandemic and some implications for anesthesia 

providers" CANA Newsbulletin Flowmeter Column 50(2): 24-29, February, 1996. 

"HIV and AIDS Part 2--New Drugs and Exposure Prophylaxis" CANA Newsbulletin 

Flowmeter Column 51(1): 25-25, October, 1996. 

"Pain and Leukocyte Cellular Adhesion Molecules: My Research Journey" AANA 

Newsbulletin, Foundation and Research News 63( 4): 36, April 2009. 

BOOK REVIEWS 
Griffis, C.A. Book review of Regional Anesthesia: An Illustrated Procedural Guide by 
Michael Mulroy, M.D. Boston: Little, Brown and Co., 1989, pp 1-289; appearing 
in Nurse Anesthesia, 1(4): 231-236, 1990. 
ABSTRACTS 
1. Griffis, C.A., S.A. Ward and R.D. Kaufman "The influence of the endogenous 
opiate system on the control of the exercise hyperpnea in man" Fed Proc 43(3): 
634, 1984. 
2. Griffis, C.A. "The exercise hyperpnea and the endorphin system: Abstracts of 
the 5Jrst Annual Meeting of the American Association of Nurse Anesthetists, 
August, 1984. 
3. Griffis, C.A. "End-tidal C02 monitoring" Abstracts of the 52nd Annual 
Meeting ofthe American Association ofNurse Anesthetists, 1985. 
4. Griffis, C.A. "Monitored anesthesia care for surgery with propofol and 
alfentanil" Poster Session Abstracts of the AANA Education and Research 
Foundation, 57th Annual Meeting of the American Association of Nurse 
Anesthetists, August, 1990. 
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5. Griffis, C.A. "Use of propofol/alfentanil bolus and infusion for anesthesia 
care" Summaries ofProfessional Sessions, 6dh Annual Meeting of the American 
Association ofNurse Anesthetists, August, 1993. 
6. Griffis, C.A. "Perioperative management: anesthesia for the ambulatory 
patient" Summaries of Professional Sessions, 64th Annual Meeting of the 
American Association ofNurse Anesthetists, August, 1997. 
7. Griffis, C.A. "Risk management in the ambulatory setting" Summaries of 
Professional Sessions, 64th Annual Meeting ofthe American Association ofNurse 
Anesthetists, August, 1997. 
8. Griffis, C.A. "HIV/AIDS drugs: anesthesia implications" Summaries of 
Professional Sessions. 65th Annual Meeting of the American Association of 
Nurse Anesthetists, August, 1998. 
9. Griffis, C. & Compton, P. "The effect of pain on cellular adhesion molecules" 
Communicating Nursing Research Conference Proceedings. Western Institute of 
Nursing Assembly, April, 2004. 
10. Griffis, C., Compton, M., Irwin, M.R., Kaufman, R. "The effect of pain on 





11. Griffis, C., Compton, M., Irwin, M. "The effect of pain on leukocyte cellular 





12. Griffis, C., Breen, E., Irwin, M., Compton, M. "Acute painful stress and 





C. Other Publications 

'I. Griffis, C.A. Book review of Regional Anesthesia: An Illustrated Procedural 

Guide by Michael Mulroy, M.D. Boston: Little, Brown and Co., 1989, pp 1-289; 

appearing in Nurse Anesthesia, 1(4): 231-236, 1990. 

Teaching 
A. Classroom Instruction 
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Fall, Spring, 1984, 85, 87 UCLA Program of Nurse Anesthesia, Lecture Series, Anes 

220A, B, C 

"Clinical Applications of Respiratory Physiology: (1 )Gas Transport (2) 





Fall, 1984 UCLA Program of Nurse Anesthesia, Anes 221 "Overview of Cardiovascular 

and Respiratory Physiology", Course Coordinator 

Fall, Spring, 1985 UCLA Program of Nurse Anesthesia, Anes 221 "Clinical Applications 

of Cardiovascular Physiology: Anesthesia for the Patient (1) With Hypertension (2) 









Fall 1986-87 UCLA Program of Nurse Anesthesia, "Review of Research Methods: (1) 

Experimental Design (2) Statistics Review 

Fall 1987-91 UCLA Program of Nurse Anesthesia, "Chemistry and Physics Review: (1) 

States of Matter (2) Gas Laws (3) Fluids and Flows ( 4) Vaporization" (Course 

coordinator for this lecture series) 

Winter, 1989 UCLA Program of Nurse Anesthesia, "Overview of Pharmacology" 









Fall 1989-91 UCLA Program of Nurse Anesthesia, "Clinical Applications of Chemistry 

to Nurse Anesthesia Practice: (1) General Chemistry (2) Pharmacology and Chemistry 

(3) Organic Chemistry (4) Biochemistry" (Course coordinator for this lecture series) 
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Winter, 1991-96 UCLA Program of Nurse Anesthesia, "Anesthesia for Outpatient 
Surgery" 
Fall, 1996 University of Southern California Program of Nurse Anesthesia, "Anesthesia 
for Ophthalmologic Surgery" 
July, 1997 Kaiser Permanente School of Nurse Anesthesia, Los Angeles, "Anesthesia for 
the Patient With HIV Disease and Chemoprophylaxis for Occupational Exposure to HIV" 
September, 1997 University of Southern California Program of Nurse Anesthesia, 
"Anesthesia, Universal Precautions, and Infectious Diseases" 
March 1998 Kaiser School of Nurse Anesthesia, Los Angeles, 
"Care of the Patient with HIV/AIDS" 
May, 1998 Kaiser School of Nurse Anesthesia, Los Angeles, 
"Anesthesia for Off-site Cases" 
September, 1998 USC Program of Nurse Anesthesia, Los Angeles, 
"Implications of Asepsis and Infectious Disease Control to Anesthesia Practice" 
November, 1999 USC Program of Nurse Anesthesia and Kaiser School of Nurse 
Anesthesia, Los Angeles. "Implications of Asepsis and Infectious Disease Control to 
Anesthesia Practice" 
November, 2000-2005 University of Southern California and Kaiser Permanente 
Programs of Nurse Anesthesia (combined), "Asepsis and Infectious Diseases ­
Implications for Anesthesia Care" 
January, 2003, 2004, 2005, 2006, 2007, 2008, 2009 UCLA School of Nursing, Nursing 
230, Pathophysiology-"Introduction to the Immune System" 
January 2004, UCLA School of Nursing, Nursing 264-Roles of the Advanced Practice 
Nurse, "Issues in Nurse Anesthesia Practice" 
April, 2004, Kaiser Permanente Program of Nurse Anesthesia, "Outpatient Anesthesia" 
January 2005, UCLA School of Nursing, Nursing 264-Roles of the Advanced Practice 
Nurse, "Issues in Nurse Anesthesia Practice" 
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UCLA School of Nursing, Nursing 239- Nurse Practitioner Professional Practice, 
Prescribing Schedule II Medications, January 2005, "Pain and Addiction 
Neurophysiology, Mechanism of Opioid Effects" 
April, 2005; April, 2006; June 2007; April 2008; April 2009 UCLA School of Nursing, 
N206 Theory Development, "Development of My Theory into My Research Project" 
January 2006, UCLA School of Nursing, Nursing 264-Roles of the Advanced Practice 
Nurse, "Issues in Nurse Anesthesia Practice" 
January 2006, 2007 UCLA School of Nursing, Nursing 239- Nurse Practitioner 
Professional Practice, Prescribing Schedule II Medications, "Pain and Addiction 
Neurophysiology, Mechanism of Opioid Effects" 
September 2006, 2007, 2008, 2009, 2010 Kaiser Permanente School of Nurse Anesthesia, 
"Principles of Asepsis and Prevention of Occupational Exposure to Infectious Diseases" 
UCLA School of Nursing, Nursing 242-Nurse Practitioner Professional Practice, 
Prescribing Schedule II Medications, January, 2007, "Pain and Addiction 
Neurophysiology, Mechanism of Opioid Effects" 
Kaiser Permanente School of Nurse Anesthesia, February 2007, February 2008, February 
2009, March 2010 "Anesthesia for Off-Site Cases" 
UCLA School of Nursing, Nursing 230, Pathophysiology, March, 2007, "Immune 
System, Stress, and Psychoneuroimmunology" 
USC Program of Nurse Anesthesia, Anst 503-Advanced Pharmacology, April 2007, 
April 2008, April 2009; April 2010 "Anesthesia, Stress and Immune System Responses" 
UCLA School of Nursing, Nursing 242-Nurse Practitioner Program, July 2007, 
"Introduction to Psychoneuroimmunology" 
UCLA School of Nursing, Nursing 262-MECN Program, August, 2007, "Overview of 
Perioperative Nursing Care of the Patient for Surgery" 
UCLA School of Nursing, Nursing 262-MECN Program, August, 2008, "Overview of 
Perioperative Nursing Care of the Patient for Surgery" 
Kaiser Permanente School of Nurse Anesthesia, Junior Class, November, 2008, 
"Principles of Asepsis and Occupational Disease Prevention in Nurse Anesthesia 
Practice" 
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Kaiser Permanente School of Nurse Anesthesia, Junior Class, January 2009, March, 2010 
"Anesthesia for Ophthalmology" 
Kaiser Permanente School of Nurse Anesthesia, Junior Class, January 2009, "Anesthesia 
for Bariatric Surgery" 
Kaiser Permanente School of Nurse Anesthesia, Junior Class, March 2009, March, 2010 
"Off-site Out of OR Anesthesia" 
UCLA School of Nursing, N206, Doctoral Students, March 2009, "Theory Development 
and the Dissertation Process" 
UCLA School of Nursing, Nl62, Bachelor of Science Students April 2009, "The 
Perioperative Nursing Process" 
USC Program of Nurse Anesthesia, Junior Class, June 2009 , "Nociceptive and Chronic 
Pain, Opioid Physiology, Tolerance and Neuroimmune Activation" 
Samuel Merritt Certified Registered Nurse Anesthetist Program, Junior Class, August 
2009, "Nociceptive and Chronic Pain, Opioid Physiology,Tolerance and Neuroimmune 
Activation" 
David Geffen School of Medicine at UCLA, Doctoring 3, Lecturing Faculty, September 
2009 - May 2010 
UCLA School of Nursing, N206, Doctoral Students, March 2010, "Theory Development 
and the Dissertation Process" 
UCLA School of Nursing, N270, MECN Students, January, 2011, "Ventilator 
Management" 
B. Clinical Instruction 
1. 1981-1989: supervision and teaching of nurse anesthetist students for the UCLA 
Program of Nurse Anesthesia at UCLA Medical Center Operating Rooms. 
2. 1992 - 97: supervision and teaching of nurse anesthetist students (UCLA Program of 
Nurse Anesthesia, now known as the University of Southern California Program of Nurse 
Anesthesia) and medical students (UCLA School of Medicine) rotating through 
Anesthesia Department, West Los Angeles Veterans Administration Medical Center, Los 
Angeles. 
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3. Simulation Laboratory: May 2004; May 2005; May 2006, May 2007; May 2008; May 
2009; May 2010. UCLA School of Nursing, N439A Clinical Laboratory Series Acute 
Care Nurse Practitioner students "Lumbar Puncture Workshop" 
4. February 2005-0ctober 2005: Clinical Coordinator of UCLA nurse anesthetist 
student rotation. Supervision of junior and senior nurse anesthetist students from Kaiser 
School of Nurse Anesthesia during clinical anesthesia administration. 
5. October 2005-Present: Senior consultant to clinical coordinators. Supervised and 
instructed medical students and nurse anesthetist students from the Kaiser and USC 
Programs of Nurse Anesthesia in the UCLA Operating Rooms. 
6. April, 2006: supervised and instructed Jules Stein perioperative nurses in insertion of 
intravenous catheters 
7. Fall, 2007-2008: arranged and supervised Master's Entry-Level Clinical Nurse UCLA 
School of Nursing students in OR visits for observational experiences (Dahianna Lopez 
[ dahianna@ucla.edu]; Evan Jacobson; Susan Chapdelain; Miriam 
Wesley[mirmir37@ucla.edu]; April Bautista [ aprill85@aol.com]) 
8. Simulation Laboratory: April & May 2009; March 2010. Supervision and instruction 
of nurse anesthetist students in the Kaiser Program of Nurse Anesthesia Simulation 
Training Facility 
C. Mentoring 
Certified Registered Nurse Anesthetists 
1. Sarah Rozycki, CRNA, MSN: mentored for first conference presentation, January, 
2008; mentored to supervise nursing student on observational rotation in the Department 
of Anesthesiology, April 2008; mentored participation in second conference presentation 
February 2009. 
2. Erica Zima, CRNA, MSN: mentored for curriculum vitae preparation (2008); co­
authorship of book chapter (2008); leadership guidance (2007-2009) 
Registered Nurses 
1. Bert B. Mekpongsatorn (bmekpongsatorn@mednet.ucla.edu), RN, BSN: 4/08 
arranged supervised OR visit, counseled about nurse anesthetist school 
Research Assistants 
1. Fall 2007: trained 4 research assistants (AJ Freeman [d.free.06@gmail.com], DM 
Verkade[dmverkade@mac.com], L Guerrero [lance.guerrero@gmail.com], and A Keyes 
[ annkeyesrn@yahoo.com]) to participate in post-doctoral project; also mentored these 
RNs in their consideration of and application to schools of nurse anesthesia. 
2. Summer, 2008: trained 2 research assistants (John Scott [jascott@mednet.ucla.edu]; 
Gregory Zweigle [gvbz@yahoo.com]) to participate in post-doctoral project; also 
mentored for preparation to apply and attend school of nurse anesthesia. 
Nursing Doctorate Students 
1. Samira Moughrabi (smoughrabi@gmailcom), UCLA School of Nursing: consulted 
and counseled on operationalization of doctoral study 4/22/08 
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2. Julia Lassegard (roadrunl@sbcglobal.net) UCLA School of Nursing: consulted and 
counseled on degree options, progress, and preparation for written qualifying 
examination 3/08-6/08. 
February 2009: Ms. Lassegard will participate in my research project "NFKappa­
B and Pain" as a research assistant, and as part of Nursing 299 in the UCLA School of 
Nursing Doctoral Program; I will supervise, train, and mentor her. 
Committee Service (UCLA) 
Department of Anesthesiology Committees 
1. Program of Nurse Anesthesia, Curriculum Committee (Member) 
1982-86. 
2. Program of Nurse Anesthesia, Student Evaluation Committee (Member) 
1981-1993. 
3. Program of Nurse Anesthesia Program Advisory Committee (Chair) 1985-87 
Program Evaluation Committee (Chair) 1985 - 87 
4. Quality Assurance Committee (Visiting Member) 1997, 1998, 1999; Full 
Member 2000-2001 
5. Task Force Perianesthesia Nursing Cross-training Project, UCLA Medical 
Enterprise, Chairman, March 2006-Present 
UCLA Medical Center 
UCLA Committee on Interdisciplinary Practice (Member) 1985-87 
Sedation Committee (Member) 2007-Present; (designated as Sedation Committee 
Educator) 
Research Thesis Committees, UCLA Graduate Division 
1. Passani, C. Topic: Characteristics of Best Clinical Instructors, Thesis 
approved, 1985. 
2. Brown, D. Topic: The Effect of Lidocaine on Reflex 

Bronchoconstriction, (Member August 1985-March 1987) 

3. Grogan, D. Topic: Cardiovascular Interactions of Lidocaine and 
Diltiazem Under Isoflurane Anesthesia, (Member) Thesis approved, 1986. 
Committee Service Professional Societies 
California Association of Nurse Anesthetists (CANA) 
Program Committee (Member) 1984-85 
Nominating Committee (Chairman) 1985-86 
Public Relations Committee (Member) 1985-86 
Government Relations Committee (Member) 1985-86; 90-92 
Co-chairman, CANA Annual Meeting, May, 1986 
CANA - CSA Liaison Committee (Member), 1986-87 
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Founder, editor, and contributor continuing education column, "The 
Flowmeter", CANA Newsbulletin 1987-97 
Member, Peer Review Committee, 1988-89-90 
Representative to California Board of Registered Nursing, 2008-2009 
Board of Directors, Trustee (elected), 2009-Present 
Bylaws Committee Chairman 2009-Present 




Examination Committee (Chairman) 1987 

Examination Committee (Member) 2007-2008-2009 

National Board of Certification and Recertification of Nurse Anesthetists 
Staff, Item Writer's Workshop, San Antonio, February, 2010 
Examination Committee (Chairman) March, 2010-Feb, 2012 
American Association of Nurse Anesthetists (AANA) 
AANA Journal, Editorial Advisory Board, 1992-94; 2009-2012 
Infection Control Taskforce, Chairman, 2009-present 
AANA Foundation 

Research Committee, 2009-present 

Kaiser Permanente School of Nurse Anesthesia 

Admissions Committee, February 2008 

Admissions Committee, February 2009 

Admissions Committee, February 2011 

University of Southern California, Program of Nurse Anesthesia 

Admissions Committee, March, 2009; March 2011 

Honors and Awards 
Phi Theta Kappa National Honor Fraternity (April 1970) 
"Who's Who Among Students in American Junior Colleges", 

Hillsborough Community College, Tampa, Florida (1973-74) 

Phi Kappa Phi Honor Society, University of South Florida (April 1973) 
Pi Lamba Theta National Honor and Professional Association in Education, UCLA 
Graduate School of Education, 1986 
"Who's Who in Professional Nursing" (1985-86) 
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Best Didactic Instructor Award, UCLA Program of Nurse Anesthesia, 1988 
Distinguished Faculty Award for academic and clinical excellence in nurse 
anesthesia education, UCLA/LAC/Oliveview Program of Nurse Anesthesia, 1994 
UCLA Department of Anesthesiology, UCLA School of Medicine, Incentive 
Award Program, Team Award "For his many contributions to the Department 
July 1, 1996, to June 30, 1997. 
UCLA Department of Anesthesiology, UCLA School of Medicine, 
Certificate of Achievement "For outstanding achievement in 
Department of Anesthesiology" for the year of 1998, 1999. 
UCLA Graduate Division Unrestricted Fellowship Award, 2001-2002 academic 
year 
Sigma Theta Tau International Honor Society of Nursing, Gamma Tau Chapter, 
2003 
Outstanding Research Presentation Award, "The Effect of Pain on Cellular 
Adhesion Molecules", Nursing Research Symposium, UCLA School of Nursing, 
March 2005 
American Association of Nurse Anesthetists Research Foundation, Post-doctoral 
Fellowship Award, August 2006 
UCLA Medical Enterprise Employee Incentive Award, June, 2008 
University of Southern California, Program of Nurse Anesthesia, Keynote 
Commencement Speech, August, 2009 
AAN A Foundation John F. Garde Researcher of the Year Award, 2010 
Community Service 
UCLA Health Fair Expo, volunteer in producing, 1985-86 
AIDS Project Los Angeles: Completing of 52-hour training course for telephone 
Hotline service in biology and pharmacology of HIV infection and treatment, and 
in therapeutic communication techniques. Served as Hotline phone volunteer 
from 1991-97 
Assistant volunteer instructor for AIDS Hotline training course, Fall, 1992. 
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California AIDS Ride (one week long bicycle non-profit event): volunteer 
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Associate Professor, University of San Diego DNP I PhD Program, 
Clinical Researcher I Clinician University of California, San Diego 
Clinical Coordinator I Department Head, NNCAP, San Diego 
Clinical Research Director Naval School of Health Sciences 
Vice-Chairman, Institutional Review Board 
Program Director, Advanced Cardiac Life Support 
Naval School of Health Sciences 
34101 Farrenholdt Drive. 
San Diego, CA 92134 
Didactic Instructor, 
Kaiser Permanente School of Nurse Anesthesia 
100 South Los Robles Street 
Pasadena, CA 91188 
Assistant Professor, School of Nursing, Georgetown University 
Medical Center: November 2005-2009 
Assistant Professor in Nursing, Nurse Anesthesia Program, 
Uniformed Services University of the Health Sciences: November 
2005-2010 
Nurse Anesthesia Scope I Responsibility I Function: Anesthetic management of patients to 
be rendered unconscious or insensitive to pain and emotional stress during surgical, 
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obstetrical, dental and certain medical procedures, including preoperative, intraoperative, 








August 2000-0ctober 2004 
August 2000- May 2003 
January 1999- August 2000 
January 1997- 1999 
October 1994 - January 1997 
Professional Experience 
Jonas Foundation Military Merit Fellow 
Visiting Health Policy Professor Samuel 
Merritt University, Oakland, CA 
Fellow AACN "Leadership for Academic 
Nursing Program" 
Member, Council on Accreditation, American 
Association of Nurse Anesthetists 
Member, Public Relations Committee, 
American Association of Nurse Anesthetists 
Vice-Chair, Institutional Review Board, 
Naval Medical Center, San Diego, CA 
Chairman, Advanced Life Support I 
Simulation Systems, Naval Medical Center, 
San Diego, CA 
President, Board ofDirectors California 
Association of Nurse Anesthetists 
Practice Chair, Public Relations Committee 
Clinical Instructor 
Navy Nurse Corp Anesthesia Program 
Naval School ofHealth Sciences 
San Diego, CA 92134 
StaffNurse Anesthetist 
Adjunct Clinical Instructor 
Naval Medical Center 
San Diego, CA 
StaffNurse Anesthetist 
Fleet Surgical Team Nine 
USS BOXER LHD-4 
Phibron Seven, USS BOXER 
FPO AP 96601-5806 
StaffNurse Anesthetist 
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August 1992 - September 1994 
January 1991 - July 1992 
August 1989 - December 1990 
August 1986 - May 1989 
January 1986 - July 1986 
October 1983 - December 1985 
February 1977 - October 1983 
August 2010-2011 
July 2001- December 2003 
U.S. Naval Hospital 
USS INDEPENDENCE CV-62 
Yokosuka, Japan 
U.S. Navy Nurse Anesthesia Program 
NSHS Bethesda, MD 
George Washington University 
NH San Diego, CA 
Staff Nurse, ICU 
NH Camp Pendleton, CA 
Clinical Instructor, ICU, PACU 
Staff Nurse, Med I Surg unit 
NH Camp Pendleton, CA 
BSNProgram 
Fairfax, Virginia 
George Mason University 
Supervisor I Head, Lab Department 
CVN-71 
USS THEODORE ROOSEVELT 
Norfolk, Virginia 
Medical Lab Tech, Research Assistant 
Point Loma, CA 
Naval Health Research Center 




Fellow AACN "Leadership for Academic 
Nursing Program" 
DNSc Program- Acute Care/ Critical Care 
Nursing, University of Tennessee 
Dissertation: Bispectral Analysis and Motor Activity Assessment Scores in 
Mechanically Ventilated Patients in the Intensive Care Unit. 
August 1992 - September 1994 	 MS in Health Sciences (Nurse Anesthesia) 
George Washington University 
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August 1986 - May 1989 BSN 
George Mason University 
Fairfax, Virginia 
January 1984 - January 1986 AA Medical Laboratory 
Technology 
George Washington University 
Certifications 
Basic Cardiac Life Support Provider (BCLS) 
Basic Cardiac Life Support Instructor (BCLS-I) 
Advanced Cardiac Life Support Provider (ACLS-P) 
Advanced Cardiac Life Support Instructor (ACLS-I) 
Director, Advanced Cardiac Life Support 
Advanced Cardiac Life Support Affiliate Faculty I Program Director 
Pediatric Advanced Life Support Provider (PALS-P) 
Pediatric Advanced Life Support Instructor (PALS-I) 
Neonatal Advanced Life Support Provider (NALS-I) 
Certified Registered Nurse Anesthetist (CRNA) 
Critical Care Registered Nurse (CCRN) Inactive 
Medical Laboratory Technician (MLT) Inactive 
Cooper Institute Health Promotion Director 
Professional Membership 
American Association of Nurse Anesthetists (AANA) 
California Association of Nurse Anesthetists (CANA) 
American Association of Critical Care Nurses (AACN) 
Member Sigma Theta Tau 1989-Present 
Professional Honors I Committees 
October 2011 Faculty Appointment Jonas Foundation Military Merit Fellow 
August 2011 Faculty Appointment Uniformed Services University of the Health Sciences 
2011-Present 
July 2011 Western Institute ofNursing Abstract Reviewer 
2011 JOPANMary Hana Memorial Journalism Award 
USD Senate 2009-Present 
USD School of Nursing IRB Representative 2010-Present 
Western Institute of Nursing Poster Committee 2011-Present 
Fellow, AACN 2010-2011 
2009 RADM Mary F. Hall Nursing Publication Award 
Council on Accreditation, AANA 2006-2008 
Public Relations Committee, AANA 2005-2008 
214 
President, California Association of Nurse Anesthetists, 2002-4 
Board of Directors, California Association of Nurse Anesthetists 2000-2004 
Golden Key National Honor Society 
Surface Warfare Medical Department Officer 
Class of2000 Instructor of the Year, Navy Anesthesia Program 
Class of2002 Instructor of the Year, Kaiser Permanente School of Nurse Anesthesia 
Professional Grants 
Burkard, J.F., Skerrett, K, Terry, M.J. (2012, June). Resi.liency Education Program/or 
Physi.cians, Advanced Practice Nurses and Therapists: Treating the Wounded 
Warrior and their Families. The Sence Foundation Grant submitted 1 June 2012 
for the amount of $62,044 
Bopp, E.J, Burkard, J.F., Spence, D., Hazen, A.L. (2012, May). Is Combat Exposure 
Predictive ofHigher Preoperative Stress in Military Members. TSNRP Graduate 
Level grant submitted 30 May 2012 for the amount of$14,004. 
Burkard, J.F., Nolan, S. (2012, March). NIH Pain Consortium Centers ofExcellence in Pain 
Education (CoEPS) Grant NIH Grant proposed 3 March 2012 for a 3-year plan 
for the amount of 275,000. 
Burkard, J.F., (2011, December). USD !Pad Classroom Project Proposal. Grant proposal 
presented to incorporate iPad technology into the classroom. Faculty Grant 
proposed 15 December 2011 for 45 iPads and faculty support for the amount of 
20,000. 
Burkard, J.F., (2010, February). Will the inclusion ofa PO NV-PD NV risk assessment tool 
improve PONV measureable outcomes? Grant proposal presented at the ASU 
Research Intensive Workshop. Arizona. 
Burkard, J.F., (2010, November). Perioperative Outcomes? Faculty grant funded 17 
November 2010 for the amount of 4,000. 
Burkard, J.F., (2010, April). Will the inclusion of a PONV-PDNV risk assessment tool 
improve PONV measureable outcomes? Grant proposal submitted to UCSD 
"Innovations in Patient Safety & Quality Improvement". San Diego, California. 
(Ongoing) 20,000. 
Burkard, J.F., (2009, December). Emergence Delirium in the Combat Veteran. Faculty 
grant funded 1 Decem her 2009 for the amount of 3,000. 
Professional Papers/Abstracts/Poster/Book Chapters 
Gobi, M., Heil, J., & Burkard, J.F. (2012, January). Ultrasound guided paravertebral 
analgesia and multimodal pathway for acute pain management after breast cancer 
surgery. Accepted for poster presentation, Western Institute of Nursing Meeting, 
18-21April2012. 
Jones, S., Burkard, J.F. (2012, January). Effects of cofactors on postoperative recovery 
times of patients with obstructive sleep apnea. Accepted for poster presentation, 
Western Institute of Nursing Meeting, 18-21April2012. 
Kim, Y., Howell, J., & Burkard, J.F. (2012, January). Effective geriatric pain education 
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program for nursing home staffs: Evidence based practice model. Accepted for 
poster presentation, Western Institute of Nursing Meeting, 18-21 April 2012. 
Liaguno, M., Burkard, J.F. (2012, January). Priming the pump: Early hand expression of 
breast milk in mother's with NICU babies. Accepted for poster presentation, 
Western Institute of Nursing Meeting, 18-21April2012. 
Maclang, F., Burkard, J.F. (2012, January). Implementation of patient educational 
intervention to decrease the occurrence of type II diabetes in the gestational diabetic 
mother. Accepted for poster presentation, Western Institute of Nursing Meeting, 
18-21April2012. 
Nenno, L., Burkard, J.F. (2012, January). Venous thromboembolism assessment and 
prophylaxis: A process improvement initiative. Accepted for poster presentation, 
Western Institute of Nursing Meeting, 18-21April2012. 
Savage, A.I., Burkard, J.F. (2012, January). Impact of the patient-centered medical home 
model (PCMH) on selected patient outcomes and staff satisfaction in a primary care 
clinic in a military treatment facility. Accepted for poster presentation, Western 
Institute of Nursing Meeting, 18-21 April 2012. 
Todorova, E., Clark, M.J., & Burkard, J.F. (2012, January). Effects of glycemic 
management in cardiac surgery: Evidence based project. Accepted for poster 
presentation, Western Institute ofNursing Meeting, 18-21 April 2012. 
Savage, A.I., Burkard, J.F. (2011, September). Impact of the patient-centered medical home 
model (PCMH) on selected patient outcomes and staff satisfaction in a primary care 
clinic in a military treatment facility. Poster presentation, Doctors of Nursing 
practice Conference, 28-31 September 2011, New Orleans, LA. 
Zamora, Z., Clark, M.J., & Burkard, J.F. (2011). Orthotopic neobladder irrigation: 
Competency Assessment through simulation. Urologic Nursing. April 2011. 
Burkard, J.F. (2011, April). Perioperative Outcomes Analysis Phase One Analysis 
Project. Poster presentation, Western Institute of Nursing Meeting, 13-16 April 
2011. 
Eckhardt, J., Burkard, J.F., & Sawrey, P. (2011, April). Observation unit efficacy in 
decompensated heart failure patients. Poster presentation, Western Institute of 
Nursing Meeting, 13-16 April 2011. 
Garner, C. & Burkard, J.F. (2011, April). Applying the evidence: Using research based 
guidelines in treating patients with diabetes. Poster presentation, Western Institute 
of NursingMeeting, 13-16 April 2011. 
Ginn, K., Williams, H., Sarter, B. & Burkard, J.F. (2011, April). The relationship of a 
diabetes flow sheet on the adherence to national standards in an internal medicine 
office. Poster presentation, Western Institute ofNursing Meeting, 13-16 April 2011. 
Hyacinth, 0., Sarter, B. & Burkard, J.F. (2011, April). Weight management during 
pregnancy utilizing the IOM guidelines. Poster presentation, Western Institute of 
Nursing Meeting, 13-16 April 2011. 
McPherson, J. & Burkard, J.F. (2011, April). Implementation of high fidelity simulation to 
enhance criical thinking skills. Poster presentation, Western Institute of Nursing 
Meeting, 13-16 April 2011. 
Wolfe, T., Burkard, J.F., & Skerrett, K. (2011, April). Long acting injectables to improve 
medication adherence in psychotic disorders. Poster presentation, Western Institute 
of Nursing Meeting, 13-16 April 2011. 
Nolan, S. & Burkard, J.F. (2010). Effect of morbidity and mortality peer review on nurse 
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accountability and ventilator-associated pneumonia. JONA. 40:9, 374-382. 
McGuire, J. & Burkard, J.F. (2010). Risk factors for emergence delirium in U.S. military 
members. Jour of PeriAnesthesia Nur. 25:6, 392-401. 
Burkard, J.F. (2010, October). Evidence Based Practice: Fostering Nursing Scholarship 
through Nursing Scholarship. Poster presentation, National DNP Conference 
Meeting, 29-30 October 2010. 
Burkard, J.F. (2010). Liver failure and nonalcoholic steatohepatitis. In S. Elisha, (Ed), 
Case Studies in Nurse Anesthesia. (1" ed., pp. 105-115). Boston: Jones and Bartlett. 
Burkard, J.F., & Vacchiano, C.A. (2010). Regional anesthesia: Upper and lower extremity 
blocks. In J.J. Nagelhout & K.L. Plaus (Eds.), Nurse Anesthesia. (4"' ed., pp. 1077­
1102). St. Louis: Saunders. 
Burkard, J.F. (2009). 2009 PONV evidence based consensus guideline update. Anesthesia 
Abstracts, 3:9, 1-44. 
McGuire, J., & Burkard, J.F. (2010). Risk factors for emergence delirium in U.S. Active 
Duty military members. Manuscript submitted for publication. 
Arruda, T., Burkard, J. (2010). Predictors of critical care determint factors: Safest patient 
flow for emergency department admissions. Poster presentation: Western Institute 
of Nursing Meeting, 13-16 April 2010. 
Arellano, C., Izuchukwu, I. & Burkard, J. (2010). The use of simulation in improving the 
readiness skills of airforce squadron medical technicians in the care of patients with 
chest tube drainage systems. Poster presentation: Western Institute ofNursing 
Meeting, 13-16 April 2010. 
Fernandez, A., Burkard, J. (2010). Screening strategies to improve early diagnosis of 
diabetes mellitus in the adult population. Poster presentation: Western Institute of 
Nursing Meeting, 13-16 April 2010. 
Macauley, K., Clark, M.J., & Burkard, J. (2010). Warfarin therapy management in 
primary care. Poster presentation: Western Institute of Nursing Meeting, 13-16 
April 2010. 
Nolan, S., Davidson, J., & Burkard, J. (2010). The effect of nursing morbidity and 
mortality peer review on nursing accountability and ventilator associated 
pneumonia rates in the intensive care unit. Poster presentation: Western Institute 
of Nursing Meeting, 13-16 April 2010. 
Zamora, Z., Clark, M.J., & Burkard, J. (2010). Orthotopic neobladder irrigation: 
Competency assessment through simulation. Poster presentation: Western 
Institute of Nursing Meeting, 13-16 April 2010. 
Burkard, J.F. & McGuire, J. (2009). Survey of Certified Registered Nurse Anessthetists 
regarding the concept of emergence delirium. Unpublished manuscript, School of 
Nursing, University of San Diego, San Diego, California. 
Burkard, J.F., & Vacchiano, C.A. (2010). Regional anesthesia: Upper and lower extremity 
blocks. In J.J. Nagelhout & K.L. Plaus (Eds.), Nurse Anesthesia. (4"' ed., pp. 1077­
1102). St. Louis: Saunders. 
Williamson, W., Burks, D., Pipkin, J., Burkard, J.F., Osborne, L.A., Pellegrini, J.E. (2009). 
Effect of timing of fluid bolus on reduction of spinal-induced hypotension in patients 
undergoing elective cesarean delivery. AANA Journal, 77:2, 130-136. 
Rivera, J.J., Villecco, D.J., Dehner, B.K., Burkard, J.F., Osborne, L.A., Pellegrini, J.E. 
(2008). The efficacy of ketorolac as an adjunct to the bier block for controlling post 
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operative pain following nontraumatic hand and wrist surgery. AANA Journal, 
76:5, 341-345. 
Burkard, J.F. (2008). Care of the pregnant patient. In C.B. Drain & J. Odom-Forren 
(Ed.), Perianesthesia in nursing: A critical care approach. (pp. 729-737). St. Louis: 
Sanders-Elsevier. 
The efficacy of ketorolac as an adjunct to the bier block for controlling post-operative pain 
following non-traumatic hand and wrist surgery. LT Jesse Rivera, CRNA, LT 
Dante Villecco, CRNA, LT Bryan Dehner, CRNA, CDR Joseph Burkard, DNSc, 
CRNA, CDR Lisa Osborne, PhD, CRNA, CAPT Joseph Pellegrini, PhD, CRNA 
Accepted for publication in the October AANAjournal. 
Effect of timing of fluid bolus on reduction of spinal induced hypotension in patients 
undergoing elective cesarean delivery. LCDR Walter Williamson, CRNA, LT David 
Burks, CRNA, LT Jessica Pipkin, CRNA, CDR Joseph Burkard, DNSc, CRNA, 
CDR Lisa Osborne, PhD, CRNA, CAPT Joseph Pellegrini, PhD, CRNA. Accepted 
for publication in the AANA Journal. 
Prevention and Management of Postoperative Nausea and Vomiting: A Look at 
Complementary Techniques. Myrna E. Mamaril. MS, RN, CPAN, CAPA, Pamela 
E. Windle, MS, RN, CAN, CPAN, CAPA, Joseph F. Burkard, DNSc, CRNA 
Vocal Cord Dysfunction: A Case Report Erik C. Cline, LCDR, NC, USN, MSN, CRNA 
Roger Davis, LCDR, NC, USN, MSN, CRNAJoseph F. Burkard, CDR, NC, USN, 
CRNA, DNSc, AANA 2006 October journal. 
Burkard, J.F. (2006, August). Can Anesthesia Providers Accurately Predict Their Patient's 
Preoperative Anxiety? Oral and Poster Presentation, AANA Annual Meeting 
Washington, D.C. 
Will The Addition ofa Sciatic Nerve Block to a Femoral Nerve Block Provide Better Pain 
Control Following Anterior Cruciate Ligament Repair (ACLR) Surgery? Oral and 
Poster Presentation, AANA Annual Meeting Washington, D.C. 
Burkard, J.F. (2005). Kearns Sayre Syndrome: A Case Report. Accepted for publication in 
the GTJNA 2005 Journal. 
Burkard, J.F. (2005). A Modification of the Traditional Bier Block: A Case Report. 
Accepted for publication in the GTJNA 2005 Journal. 
Burkard, J.F. (2005). Propofol-Ketamine Infusion in an Umbilical Hernia Repair: A Case 
Report. Accepted for publication in the GTJNA 2005 Journal. 
Burkard, J.F. (2005). Vocal Cord Dysfunction: A Case Report. Accepted for publication in 
the AANA 2005 Journal. 
A comparison of ondansetron and transdermal scopolamine patches for patients identified 
to be high risk for the development of post operative nausea and vomiting. 
Accepted for publication in the AANA 2005 Journal. 
Author chapter 42, Regional Anesthesia, Third edition ofNurse Anesthesia by Nagelhout 
and Zaglaniczny. 
The effects of fatigue on the performance of anesthesia providers in a simulator setting. 
Poster presented at the AANA annual meeting, Seattle, WA 4-11August2004 
Effects of fiberoptic versus laryngoscopic intubation as measured by the bispectral index 
(BIS). Poster presented at the AANA annual meeting, Seattle, WA 4-11 August 
2004 
Burkard, J.F. (2003, November). Effect of Air versus Saline in the Loss of Resistance 
Technique in Identifying the Epidural Space when placing a Continuous Epidural 
218 
Catheter among the Parturient. Poster presented at the 15th annual Karen Rieder 
Poster Session, AMSUS, San Antonio, TX 15-19 November 2003 
Burkard, J.F. (2003 November). A comparison ofondansetron and transdermal 
scopolamine patches for patients identified to be high risk for the development of 
post operative nausea and vomiting. Poster presented at the 15th annual Karen 
Rieder Poster Session, AMSUS, San Antonio, TX 15-19 November 2003 
Bispectral Analysis and Motor Activity Assessment Scores in Mechanically Ventilated 
Patients in the Intensive Care Unit. Poster presented at the 15th annual Karen 
Rieder Poster Session, AMSUS, San Antonio, TX 15-19 November 2003 
The effects of clonidine added to bupivacaine on analgesia and post-operative outcomes to 
femoral I sciatic nerve blocks. Accepted for publication in the AANA 2004 journal. 
Published July-August 2004 
A comparison of levobupivacaine and ropivacaine in patients undergoing extremity surgery 
with brachia! plexus block. Accepted for publication in the AANA 2004 journal. 
Comparison of axillary Brachia! Plexus Block success using a 26 Gauge 112 Inch Needle 
versus a Standard Gauge 11/2 Inch Needle. Published in the AANA Journal 
January 2004 
The effects of clonidine added to bupivacaine on analgesia and post-operative outcomes to 
femoral I sciatic nerve blocks. Poster presented at the AANA annual meeting, 
Orlando, FA 1-8 August 2002 
Comparison of axillary Brachia! Plexus Block success using a 26 Gauge 112 Inch Needle 
versus a Standard Gauge 11/2 Inch Needle. Poster presented at the AANA annual 
meeting, Orlando, FA 1-8 August 2002 
A comparison of levobupivacaine and ropivacaine in patients undergoing extremity surgery 
with brachia! plexus block. Accepted for publication in the AANA 2004 journal. 
Poster presented at the AANA annual meeting, Orlando, FA 1-8 August 2002 
Professional Presentations 
Burkard, J.F. (2012, May). Joining Forces through Creative Curriculum Approaches: A 
Panel Discussion. AACNLeadership Collaboration Webinar. 14 May 2012. 
Burkard, J.F. (2012, March). Evidence-Based Practice: I know what it is, but how do I do 
it. Scripps 9th Annual Advanced Practice Oncology Providers Symposium: Innovation 
Through Practice. San Diego, Ca. 
Burkard, J.F. (2012, February). Health Policy for the Advanced Practice Nurse 
Anesthetist. Visiting Professor Workshop presentation, Samuel Merritt University 
25-27 February 2012. 
Burkard, J.F., Skerrett, K., Stanley, L., Suarez, M.J., & Terry, M.J. (2011, December). 
Readjustment Strategies for the Wounded Warrior. Military Healthcare Convention 
& Conference. Workshop conducted at the Institute for Defense and Government 
Advancement, Paradise Point, San Diego, Ca. 
Burkard, J.F. (2011, September). APRN's Returning for Doctoral Degrees: Identifying 
Health Policy Needs. Podium presentation, Doctors ofNursing practice Conference, 
28-31 September 2011, New Orleans, LA. 
Burkard, J.F. (2011, September). Research Ethics: Issues Concerning Human Subjects. 
Research methods training symposium conducted at Naval Medical Center, San 
Diego California. 
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Burkard, J.F. (2011, August). CRNA's Returning for Doctoral Degrees: Identifying Health 
Policy Needs. Podium presentation, American Association of Nurse Anesthetists 
National Meeting 6 August 2011. 
Burkard, J.F. (2011, March). Inovation in Anesthesia Practice. Podium presentation, 
California Association of Nurse Anesthetists Spring State Meeting 25-27 March 
2011. 
Burkard, J.F. (2011, February). Health Policy for the Advanced Practice Nurse 
Anesthetist. Visiting Professor Workshop presentation, Samuel Merritt University 
25-27 February 2011. 
McGuire, J. & Burkard, J.F. (2011, March). Post Traumatic Stress in the Combat Surgical 
Patient. First Place Award, Academic Research Competition. San Diego California 
Burkard, J.F. (2011, January). Preventing and treating PONV: An evidence 
approach. Podium presentation, University of California, San Diego 15 January 
2011. 
Burkard, J.F. (2010, July). Pain and sedation management: state of the art 2010. Podium 
presentation, University of California, San Diego 22 July 2010. 
Burkard, J.F. (2011, January). Preventing and treating PONV: An evidence 
approach. Podium presentation, University of California, San Diego 15 January 
2011. 
Burkard, J.F. (2011, March). Inovation in Anesthesia Practice. Podium presentation, 
California Association of Nurse Anesthetists Spring State Meeting 25-27 March 
2011. 
McGuire, J. & Burkard, J.F. (2011, March). Post Traumatic Stress in the Combat Surgical 
Patient. First Place Award, Academic Research Competition. San Diego California 
Burkard, J.F. (2009, December). A Multidisciplinary Expert Forum on Perioperative 
Nausea and Vomiting. Panel presentation done at the Institution of Medical 
Education and Reseach 15 December, 2009. Miami Florida 
Burkard, J.F. (2010, February). Analysis of Health Policy for the Advanced Practice Nurse. 
Health Policy Visiting Professor Series. Visiting professor symposium conducted at 
Samuel Merritt School of Nurse Anesthesia, Oakland California. 
Burkard, J.F. (2010, January). Evaluating the evidence in evidence based practice. 
Symposium conducted at the 23"" annual University of California San Diego 
anesthesia update, San Diego California. 
Burkard, J.F. (2010, March). Fostering Nursing Scholarship Through Academic and 
Service Partnership. In S. Hardin panel presentation given during the Janet A. 
Rodgers Nursing Leadership workshop. San Diego California 
Burkard, J.F. (2010, March). Trauma and Healing Health Policy Issues.. In K. Skerrett 
and S. Hardin, Trauma and Healing Workshop. Symposium conducted during the 
Hahn School of Nursing Trauma and Healing Workshop March 5'", 2010. San Diego 
California 
Burkard, J.F. (2009, August). Responsible conduct of research. Research methods training 
symposium conducted at Naval Medical Center, San Diego California. 
Burkard, J.F. (2009, April). Trauma & ARDS an EBP clinical case study review. 
Symposium conducted at the 2009 Critical Care Code Trauma Seminar, San Diego 
California. 
Burkard, J.F. (2009, April). Responsi.ble conduct ofresearch. Research methods training 
symposium conducted at Naval Medical Center, San Diego California. 
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Burkard, J.F. (2009, January). Evidence based practice- a model to change practice. 
Workshop symposium conducted at the University of San Diego Hahn School of 
Nursing, San Diego California. 
Burkard, J.F. (2009, January). Post operative nausea & vomiting: Evidence based consensus 
guidelines. Symposium conducted at the 22"" annual University of California San 
Diego anesthesia update, San Diego California. 
Burkard, J.F. (2008, December). Reviewer Chair, Congressionally Directed Medical 
Research Programs program for deployment relatd medical research programs 
held Decem her 15'", 2008 at Fort Detrick, MD. 
Burkard, J.F. (2008, August). Responsible conduct ofresearch. Research methods training 
symposium conducted at Naval Medical Center, San Diego Californi 
Burkard, J.F. (2007, August). Regional Anesthesia for the Upper and Lower Extremity: 
New Trends in Local Anesthetics and Block Techniques. IDAHO Spring 2007 
Conference for Nurse Anesthetists 
Burkard, J.F. (2007, August). USC Regional Anesthesia for the Upper and Lower 
Extremity: New Trends in Local Anesthetics and Block Techniques. USC Spring 
2007 Workshop for Nurse Anesthesia Students 
Burkard, J.F. (2006, March). USC Regional Anesthesia for the Upper and Lower 
Extremity: New Trends in Local Anesthetics and Block Techniques. USC Spring 
2006 Workshop for Nurse Anesthesia Students 
Burkard, J.F. (2006, August). Funderberg Lecture Series, Samford University, 
Birmingham, Alabama, Brachia! Plexus and Upper extremity Blocks for the 
Anesthesia Provider, Anesthesia Awareness Monitoring: A controversial Issue in 
Anesthesia Practice. 
Burkard, J.F. (2005, October). Presentation on Anesthesia Awareness Monitoring: A 
Controversial Issue in Anesthesia Practice. My Patient Has a Bleeding Disorder: 
Transfusion Guidelines. CANA Anesthesia Update Fall 2005 Monterey, CA 
Burkard, J.F. (2005, May). Responsible Conduct I Ethics of Research Presentation. Naval 
Medical Center CID Research Series, May 2005 
Burkard, J.F. (2005, February). Presented: The incidence ofAwareness During 
Anesthesia: A Multicenter United States Study. Journal Club NMCSD, February 
2005 
Burkard, J.F. (2004, October). Presented: Effects on the progress of labor: Do labor 
epidurals affect labor outcome. Fall CANA state meeting. Berkeley, Ca, October 
2004 
Burkard, J.F. (2004, October). Presented: Non-Obstetric surgery during pregnancy: Does 
anesthesia increase the risk to the parturient. Fall CANA state meeting. Berkeley, 
Ca, October 2004 
Burkard, J.F. (2004, August). Presented Two Day Advanced Airway Workshop at the 
AANA Annual meeting Seattle, WA, August 2004 
Burkard, J.F. (2004, May). Responsible Conduct ofResearch Presentation. Naval Medical 
Center CID Research Series, May 2004 
Burkard, J.F. (2004, May). Presented AANA Public Relations Topics at National Rural 
Health Association Annual Conference, San Diego, Ca, May 2004 
Burkard, J.F. (2004, April). Presented Bispectral Analysis Dissertation Manuscript at 
NMCSD Academic Research Competition, April 2004 
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Burkard, J.F. (2003, October). Outcomes Research in Regional Anesthesia and Analgesia, 
CANA La Jolla, CA, October 10, 2003 
Burkard, J.F. (2003, August). AANA National Conference, Boston, Ma Aug 4-5 2003. 
Spinal I Epidural Workshop Instructor 
Burkard, J.F. (2003, June). Trauma Fluid Resuscitation: An Anesthesia Provider's 
Perspective. CANA Las Vegas State meeting 8 June 2003 
Burkard, J.F. (2002, May). National Speaker ASPAN Conference San Diego, CA Regional 
Anesthesia in the Post Anesthesia Care Unit, April-May 2002 
Burkard, J.F. (2002, April). Training for the Future: Technology and the Anesthesia Team, 
Kaiser Permanente Anesthesia Symposium, April 2002 
Burkard, J.F. (2002, March). Comparison of axillary Brachia! Plexus Block success using a 
26 Gauge 112 Inch Needle versus a Standard Gauge 1112 Inch Needle. Naval 
Medical Center San Diego Annual Research Competition, March 2002 
Burkard, J.F. (2001, October). CANA Speaker, Napa CA on trauma anesthesia, Napa 
California, CANA Fall meeting, October 2001 
Burkard, J.F. (2001, January). Ethical Decision Making in a Changing Environment. 
Surface Warfare Medical Institute Presentation. Point Loma, CA, January 2001 
Burkard, J.F. (2000, August). AANA National Conference, Chicago, IL Aug 5-10 2000. 
Spinal I Epidural Workshop Instructor 
Burkard, J.F. (2000, June). Video Teleconference Pain Management for the PACU Nurse, 
Kaiser Permanente, AANA Upper Extremity Workshop Presentation, Chicago, IL, 
June 2000 
Burkard, J.F. (2000, May). Regional Anesthesia for the Millennium. Regional Anesthesia 
of the Lower Extremity Presentation and Workshop. CANA Spring Conference, 
Palm Springs, CA, May 2000 
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September 20, 2012 
AANA Foundation 
222 S. Prospect Ave. 
Park Ridge, IL 60068 
Dear Dr. Lorraine Jordan and the AANA Foundation Grant Selection Committee, 
It is with sincere gratitude that I write you this letter extending my appreciation for 
awarding me the AANA Baxter Research Doctoral Fellowship Grant. I assure you that 
our current project, Psychoneuroimmunology and Chronic Pain, for which I received 
your award has developed into a stellar project that is progressing rapidly. The purpose 
of this letter is to present you with the plan for utilizing the AAN A Baxter Research 
Doctoral Fellowship funds, as well as the funds applied for in this AANA General 
Research Grant. I would also like to appraise you of the progress we have made since my 
proposal submission in April 2012 when I submitted my Fellowship application. 
Since April, we have added an additional psychometric component to the study to reflect 
another highly pertinent component of chronic pain symptomatology. After a thorough 
literature search and through our collaboration with Dr. Michael Irwin, UCLA Professor 
and Director of the Cousins Institute of Psychoneuroimmunology, it was decided that a 
measurement of sleep deprivation would be added to the study to provide a more robust 
and complete picture of the symptoms experienced by chronic pain patients. Through my 
readings of the literature I found that not only is sleep deprivation and pain highly 
interrelated, but I have found that inflammation has been evolving throughout this body 
ofliterature as well. This is a very pertinent measurement to add to this study, there is 
relatively little known about the central inflammation levels related to sleep deprivation 
in chronic pain patients and the research is developing now. This is yet another cutting­
edge component of this project that not only increases the overall elegance, but also 
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makes it one of the most progressive studies on chronic pain, inflammation and the 
psychological components associated pain. 
I am elated to report that the UCLA Institutional Review Board application is being 
submitted and we will have pending status shortly. 
I can report that our budget has been comprehensively created to be both cost­
conscientious and practical for the volume and scope of laboratory and psychometric 
testing we are proposing to accomplish. Through collaboration with our Co-Investigator 
Dr. Elizabeth Breen, PhD, Director of the Cousins Inflammatory Biology Laboratory, as 
well as our Co-Investigator Dr. Andrea Nicol, MD, MS, Director of Research at the 
UCLA Pain Management Clinic, we have formulated a budget that incorporates the 
AANA Fellowship Grant monies. The $10,000 AANA Fellowship Grant funds will 
cover the total laboratory expenses for approximately half of our desired study population 
with three of the five desired cytokines being analyzed. With the funds sought from this 
General Research Grant, we would be able to analyze five cytokines on our full study 
population of thirty chronic pain patients. This further funding would allow for a 
population size that could yield significant results and provide us with the complete five 
cytokine analysis necessary to illustrate a comprehensive picture of the inflammation set 
forth in the study design. While our budget reflects that the amount still unfunded to run 
these laboratory tests is roughly $17,000, we do hope the Grant Selection Committee will 
award us considerably more to cover the $7,000 in indirect costs associated with 
performing this study at UCLA through USD. If this funding is not currently available 
from the AANA Foundation, I humbly request you consider me next spring for another 
Fellowship Grant award upon my application. 
Of note, the data collected in this cross-sectional study, will serve as both my dissertation 
research, as well as a preliminary study for a much more comprehensive longitudinal 
study designed to investigate inflammation, chronic pain and the psychological 
components of pain. I look forward to presenting the cross-sectional study findings to the 
AANA and continuing with Dr. Charles Griffis, CRNA, PhD on expanding this study 
into a longitudinal study with compelling results. I cannot express how ecstatic I am to 
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be a part of this revolutionary research and sincerely thank you for you assistance in 





Sarah Giron, CRNA, MS 
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September 24, 2012 
Dear Dr. Jordan, 
It is with great pleasure and enthusiasm that I write you this letter to support the AANA 
Foundation General Research Grant application for Sarah E. Giron, CRNA, MS. I have known 
Sarah for many years as we were colleagues in lhe Department of Anesthesiology at UCLA. We 
both moved on, I to a Pain Management fellowship and Masters in Clinical Research at UCLA 
and Sarah to USC and now the University of San Diego for a PhD. 
I believe Sarah has what it takes to become a leader in the field of anesthesiology and pain 
research. I have worked with many people during my time at UCLA on research projects and 
there are many attributes about her that make her unique and special and separate her in a 
positive way, from the rest of the pack. She takes the initiative in organizing email discussions, 
in-person meetings, and phone conferences and has the ability to unite the entire study team so 
that forward progress on projects happens at a very fast pace. She has an affable personality and 
is extremely pleasant and engaging to work with. 
She is well-regarded by her peers, colleagues, and mentors as evidenced by her many awards and 
honors dating back to 2000. Her academic merit and presence is clearly substantiated as 
evidenced by the amount of invited lectures and presentations she has given throughout her 
career. Her dedication to the advancement of current clinical and basic science evidence based 
medicine in our field is without question, given her return to the classroom to complete 
coursework and a thesis towards a PhD in Nursing. I have no doubt that she will complete this 
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additional educational training with the highest accolades and will have a very bright future in 
both the clinical and academic/research realms. 
Besides highlighting Sarah's strengths, this letter serves to support her application for a research 
grant through the AANA for the project she plans to complete for her PhD dissertation. I was 
approached about one year ago by Sarah regarding this project and from the very begirming, I 
was extremely excited to take part. I will be serving as a co-investigator on this project, which is 
a cross-sectional study that will investigate the emerging relationships between chronic pain 
syndromes and the role of central inflammation, as measured by cerebrospinal fluid patterns of 
inflammatory mediator molecules. In addition to the CSF patterns, the study will be exploring 
the relationships between the psychological responses to pain and then correlated to 
cerebrospinal fluid levels of inflammatory markers. This study hopes to gain knowledge of the 
relationship between the psychoneuroimmune responses to prolonged pain states propagated by 
central inflammatory mechanisms, with the ultimate goal of acquiring the information pertinent 
to more effective analgesic and psychological treatment of these patients. 
This study is unique, exciting, and unlike any study that has been done before on this topic. 
There is a great deal of possible knowledge to be gained from the cross-sectional comparison of 
the CSF between chronic pain and non-chronic pain subjects. Sarah and the rest of our team are 
extremely hopeful that the data we get from this cross-sectional analysis will provide the 
justification to perform a longitudinal analysis on the CSF of chronic pain patients as they 
undergo treatment with intrathecal opiates. 
It is with great honor and no reservations that I write this letter in support of Sarah Giron' s 
application for a research grant from the AANA. Please do not hesitate to contact me if you have 
any questions or need further information. 
Sincerely, 
~,/i/.S 
Andrea L. Nicol, MD, MS 
Director of Research, UCLA Pain Management Center 
Assistant Clinical Professor, Department of Anesthesiology 
David Geffen School of Medicine at UCLA 
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INSTITUTE Cousins Center for Psychoneuroimmunology 
Jane &Terry Semel Institute for Neuroscience &Human BehaviorU C L A 
September 24, 2012 
Lorraine Jordan, CRNA, PhD 
Executive Director, AANA Foundation 
222 South Prospect Avenue 
Park Ridge, Illinois 60068-4001 
Re: Giron Proposal "Pyschoneuroimmunology and Chronic Pain" 
Dear Dr. Jordan, 
Uni.versity of California, Los Angeles 
300 UCLA Medical Plaza, Suite 3129 
Box 957076 
Los Angeles, California 90095-7076 
Michael Irwin, M.D. 
Director 
voice (310) 825-8281 
fax (310) 794-9247 
www.CousinsPNl.org 
I am pleased to write in support of the research proposal being submitted by Ms. 
Sarah E. Giron, CRNA, MS, for consideration by the AANA Foundation. Ms. Giron's 
proposed study examining psychological and immunological measures in chronic pain 
patients represents both a new area of research for our laboratory, and an extension of 
previous collaborations on psychoneuroimmunology studies supported by the AANA 
Foundation (Dr. Charles Griffis, CRNA, PhD, 2011). 
Our Inflammatory Biology Core (IBC) Laboratory of the UCLA Cousins Center for 
Psychoneuroimmunology serves as a research resource for investigators wishing to 
include assessments of the immune system in their studies. We are able to perform 
evaluations of cellular signaling, gene expression, and biomarkers of immune system 
activation and/or inflammation. As the Co-Director of the IBC and an immunology 
researcher who has investigated immune activation and cytokine biology for more than 
twenty-five years, I have extensive experience in the collection, processing, and testing 
of immunological samples in clinical and epidemiologic studies. I oversee the day-to­
day operations of the IBC Laboratory, review all results for quality control, and work 
closely with co-investigators in the interpretation of immunologic data. 
I have been providing technical· advice and mentoring to Ms. Giron as she has 
developed her study design and research plan, and I express my enthusiastic support 
for her application to the AANA Foundation. I hope that we will have the opportunity to 
pursue the innovative study of chronic pain and the interaction with the mind and the 




Ettzab~ Crabb Breen, MT(ASCP), PhD 
Associate Professor, Department of Psychiatry and Biobehavioral Sciences 
Co-Director, Inflammatory Biology Core 
UCLA Cousins Center for Psychoneuroimmunology 




UNIVERSITY OF CALIFORNIA, LOS ANGELES Srhool of,Yursi11g 
700 Tiverton :\vc 
Factor Building 
Box 951702 
I,OS Angeles, c:A 90095-1702 
September 26, 2012 
Lorraine Jordan, CRNA, PhD 
Research Director 
AANA Foundation 
Re: General Research Grant Application 
"Psychoneuroimmunology and Chronic Pain" 
Dear Dr. Jordan: 
I am writing this letter to recommend the study referenced above for General 
Research Grant funding. As I have indicated in my own writing for the AANA 
J ournal1, chronic pain is a problem of tremendous scope, causing terrible suffering 
for millions ofAmericans and costing our beleaguered health care system billions of 
dollars a year. Basic and translational research to advance treatment of chronic 
pain syndromes is desperately needed, and I have found a graduate student who 
proposes to do just that as a dissertation project. Funding this research is in perfect 
alignment with the goals and mission of the AANA Foundation. 
Sarah E. Giron, CRNA, MS, has proposed a research study examining the 
cerebrospinal fluid (CSF) of chronic pain patients who are having the implantation 
of catheters and pumps to allow intrathecal opioid infusion pain treatment. 
The study has two specific aims: 
Specific Aim #1: This study will examine and characterize the relationships 
between chronic pain and pro- and anti-inflammatory mediator molecules. 
The study will bring together several talented groups to accomplish this aim. Ms. 
Giron is currently a doctoral student at the Hahn School of Nursing, University of 
San Diego and has assembled a committee of capable experts to assist her. In the 
fields of pain physiology and clinical pain intervention, one of the faculty of the 
UCLA Department ofAnesthesiology, Santa Monica Pain Group, Andrea Nicol, M.D. 
will provide guidance and clinical access. In the area of psychoneuroimmunology, 
the UCLA Cousins Center of Psychoneuroimmunology is represented, including Dr. 
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Michael Irwin, an internationally known researcher in body-mind phenomena. Dr. 
Irwin will focus his efforts on investigating any correlations between the behavioral 
manifestations of pain and the levels and type of inflammatory mediator molecules 
found in the cerebrospinal fluid of these patients. Elizabeth Breen, PhD, the Director 
of the Inflammatory Biology Laboratory, will use her extensive background in 
immunological laboratory science to oversee and assist in specimen collection and 
analysis. 
The CSF samples from patients will be compared to control samples from a bank 
established by researchers from the University ofCalifornia, San Diego in previous 
investigations, and which are already stored in the Inflammatory Biology 
Laboratory where the analysis will be conducted. Samples will be examined using 
ELISA for the presence and levels of immune inflammatory mediator molecules such 
as cytokines. The data comparing patients and controls will be analyzed using 
parametric and non-parametric inferential statistics. 
Specific Aim #2: To investigate relationships between pain levels, anxiety, 
depression, sleep deprivation and the expression of inflammatory molecules in the 
cerebrospinal fluid of chronic pain patients. 
To accomplish this specific aim, Ms. Giron has established a relationship with the 
UCLA Cousins Center of Psychoneuroimmunology. Dr. Michael Irwin, mentioned 
above, has joined the dissertation team as a committee member. As a consultant on 
the grant, he is eager to explore the mind-body connections within the human 
response to pain. To that end, Dr. Irwin is prepared to lend his expertise to the 
selection and use of appropriate instruments to assess the behavioral impact of 
chronic pain, such as anxiety, fear, depression, and sleep deprivation. Dr. Irwin will 
then assist in analyzing and interpreting the data, which will be examined for 
correlations between the behavioral manifestations of pain, pain severity, and the 
expression of inflammatory molecules in the CSF of chronic pain patients. 
To date, and to this team's knowledge, there have been less than 10 studies of 
chronic pain and CSF inflammatory response in humans, though a large body of pre­
clinical data, obtained mostly from rodent models of spinal cord or sciatic nerve 
injury, exists to guide the concepts and interventions. The data so far have been 
promising. revealing a propensity for the increase of inflammatory molecule 
production in CSF of chronic pain patients, yet the data is also contradictory in 
places, and sample sizes have been small. Thus our team firmly believes there is 
room for further investigation of this phenomenon, especially in view of the 
prevalence of chronic pain and the high stakes involved in treatment advances. This 
study will add validity, and hopefully provide some more direction in the clinical 
search for novel approaches to chronic pain treatment. Hopefully, our results will 
further guide new approaches to targeting central inflammation in pain patients, 
which as yet have not seen Phase 1 trials. 
2 
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September 26, 2012 
Dr. Lorraine Jordan, CRNA, PhD 
Executive Director of the AANA Foundation and AANA Senior Director ofResearch 
222 South Prospect Avenue 
Park Ridge, Illinois 60068-4001 
phone: 847-655-1170, fax: 847-692-6968 
AANA General Research Grant: Letter of Supprt ICO Sarah Elizabeth Giron, CRNA, MS, PhD 
Student, USO I Charles A. Griffis, CRNA, PhD 
I am writing to express my support for the planned AANA General Research Grant in support of 
"Psychoneuroimmunology and Chronic Pain" at the University of San Diego and University of 
California Los Angeles. The University of San Diego and University of California Los Angeles 
believes the prompt, thorough assessment and treatment ofchronic pain is a subject of 
paramount importance. This study will investigate the emerging relationships between chronic 
pain syndromes and the role ofcentral inflammation, as measured by cerebrospinal fluid patterns 
of inflammatory mediator molecules. More specifically, this study will investigate ifthe same 
central pro- and anti-inflammatory cytokines found in chronic pain-induced animal models are 
found in human chronic pain patients. 
As a doctoral student at the University of San Diego Sarah has established herself as an 
outstanding student with a strong academic and research focus. Ms. Giron has received the 
AANA Palmer Carrier Baxter Scholarship, which has funded the development ofher research 
proposal , facility costs and study preparation costs. TI1e AANA General Research Grant will 
cover laboratory costs and sample analysis. 
I enthusiastically look forward to future collaboration and research in this area between the 
University of San Diego, UCLA and the AANA. University of San Diego embraces the 
interdisciplinary model and the collaboration that will proactively move to the prompt and 
comprehensive treatment ofchronic pain at not only this facility but also region wide. 
I wholeheartedly support this grant application and support Sarah's team in the review process. 
chair her dissertation committee and pain team as she prepares for her PhDc proposal defense 
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Abstract 
There is increasing evidence linking chronic pain to altered levels of central 
nervous system (CNS) inflammation and increased levels of perceived pain, anxiety, 
depression and sleep disturbance. However the inflammatory molecules responsible for 
physiologic and psychological components of chronic pain still warrant identification and 
exploration. Using central inflammation as a paramount factor in the creation and 
maintenance of chronic pain, this study aimed to investigate and describe the physical 
and psychological aspects of chronic pain associated with CNS inflammation. 
Using a cross-sectional correlational design, cerebrospinal fluid (CSF) 
inflammatory cytokine patterns present in 8 chronic pain participants were compared to 
inflammatory cytokine patterns present in 30 control CSF samples using multivariate 
analysis of variance (MANOVA), with analysis of variance (ANOVA) analysis as a 
follow-up. Levels of depression, anxiety, sleep disturbance and pain were measured in 
approximately 8 chronic pain patients and correlated to CSF levels of inflammatory 
cytokines using Pearson's r, or Spearman's Rho correlations. Demographic information 
was also explored for relationships to central inflammation and descriptive statistics were 
examined for responses. 
To our knowledge, this is the first study to describe increased CSF levels of 
Interleukin-8 (IL-8) in a population of majority Failed Back Surgery Syndrome chronic 
pain patients (F (1, 36) ~ 14.89, p < 0.001, partial 11 2 ~ 0.293). Gender (F (1,6) ~ 7.782, p 
~ 0.032, 11 2~ 0.565), socioeconomic status (r ~ -0.823, p ~ 0.012) and educational level (r 
~ 0.727, p ~ 0.041) were also correlated with central levels of inflammation, indicating 
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that central physiologic changes may be related to host sex and psychosocial factors. All 
participants reported poor sleep quality and took at least one opioid medication, 
indicating that sleep and opioids may scaffold a portion of the chronic pain paradigm. 
This study richly describes the dynamic experience of chronic pain through the 
lens of Psychoneuroimmunology. Incorporating both physiologic and psychological 
aspects of the disease, this study describes an association between chronic pain, central 
inflammation, gender, socioeconomic status, opioid medications and poor sleep quality. 
Thus, the future of pain treatment must consider these aspects when treating patients and 
look to future studies for possible new treatment options which target these factors. 
Keywords: inflammation, cytokines, chronic pain, sleep quality, gender, socioeconomic 
status 
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Chronic pain continues to grow in patient numbers and healthcare costs as a 
condition that has relatively few successful treatment options and dismal recovery. 
Tolerance to medications, invasive treatment options and debilitating symptoms create a 
milieu devastating to the physiologic and psychological wellbeing of the patient. 
Multiple processes have been identified as agencies responsible for the creation and 
maintenance of chronic pain, one of them being central inflammatory changes brought 
upon by glial-mediated activation (Alfonso Romero-Sandoval, & Sweitzer, 2015; Taves, 
Berta, Chen, & Ji, 2013; Wang, Couture, & Hong, 2014). 
Prior studies have shown through glial-mediated activation, inflammatory 
cytokines contribute to the maintenance of chronic pain, as well as tolerance to analgesic 
treatment (Dubovy, Jancalek, Klusakova, Svizenska, & Pejchalova, 2006; Raghavendra, 
Rutkowski, & DeLeo, 2002; Sacerdote et al., 2008; Sung et al., 2004; Tai et al., 2006; 
Zelenka, Schafers, & Sommer, 2005). Interestingly, studies in anxiety, depression and 
sleep disturbances have also demonstrated altered levels of central inflammatory 
cytokines (Baker et al., 2001; Bonne et al., 2011; Camara et al., 2015; Dauvilliers et al., 
2014; Levine et al., 1999; Lindqvist et al., 2009). However, many of the previous studies 
in inflammation have failed to monitor the patterns of central inflammatory cytokines in 
relation to the psychological aspects specific to chronic pain. A high perception of pain, 
anxiety, depression and sleep disturbances are common within the chronic pain 
population (Burke, Mathias, & Denson, 2015; Chuang, Weng, Hsu, Huang, & Wu, 2015; 
Irwin et al., 2012) but yet how these psychological effects manifest physiologically is 
relatively not well understood. Central inflammation offers one possible mechanism that 
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links the physiologic and psychological aspects of the chronic pain paradigm. Thus, the 
purpose of this study was to investigate and describe the physical and psychological 
aspects of chronic pain associated with central inflammation. 
Materials and Methods 
Design 
A cross-sectional, correlational study design was utilized with a convenience 
sample of approximately eight chronic pain patients recruited from the Pain Management 
Center at the University of California, Los Angeles (UCLA). One-time collections of 
cerebrospinal fluid (CSF) samples were analyzed for 10 inflammatory cytokines and 
compared to 30 control CSF samples to discern patterns of inflammation present in 
chronic pain. Psychological analysis of pain perception, anxiety, depression and sleep 
disturbances in study participants allowed for correlational testing between psychological 
and physiologic inflammatory patterns. Demographic data analysis allowed for further 
inspection. 
Subjects 
Study participants. Approximately eight patients with a chronic pain diagnosis and who 
were eligible for medical treatment with an intrathecal analgesic infusion pump were 
enrolled in this study after informed consent was obtained. All study procedures were 
approved by the University of California, Los Angeles (UCLA) Institutional Review 
Board (protocol ID: IRB #12-001588). Recruitment and participation in this study 
commenced between April 2013 and December 2014. Inclusion criteria for this study 
required that participants be 18 years or older and carry a chronic pain diagnosis of> 6 
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months. Diagnosis of chronic pain was made on standard clinical criteria, as suggested 
by the International Association for the Study of Pain (IASP). Exclusion criteria 
incorporated a combination of surgical and experimental criteria; surgical criteria that 
would exclude a patient from obtaining an implanted intrathecal analgesic infusion pain 
pump included meningitis, active upper respiratory infection/flu or febrile nature, acute 
medical or psychiatric disorders, acute psychological or physiologic danger/instability, 
altered mental status, pregnancy and the inability to communicate in English. 
Experimental exclusion criteria included a diagnosis of cancer, human immunodeficiency 
virus (HIV), recent epidural injections for treatment of chronic pain (within six months), 
drug abuse, meningitis or history of meningitis, history of blood transfusion(s) and 
palliative pain treatment. The inclusion and exclusion criteria were confirmed using 
standard clinical and laboratory methods of analysis, not above or beyond the standard of 
care, or at any additional burden to study participants. Only one patient who was 
approached to participate in the study declined, making the attrition rate for this study 
11%. All study participants were instructed to continue their medications and therapies 
without making any changes prior to, or during study involvement. 
Control samples. Control samples of CSF were obtained from the California 
NeuroAIDS Tissue Network. Thirty random, individual control samples of 1-2 milliliters 
(mL) of CSF, collected through the HIV Neurobehavioral Research Center between the 
years 2005-2012, were utilized from this tissue bank as a means to compare levels of 
central inflammatory cytokines. The control samples of CSF were selected randomly to 
include seronegative HIV and hepatitis C virus (HCV) donors, with no history of 
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recreational drug use, and an approximate equal distribution of men and women donors. 
No other identifying information of the control sample donors was provided to the 
research team except the date of collection. 
Procedures 
Data collection protocol. Approximately eight patients with the diagnosis of chronic 
pain were enrolled in this study. After informed consent was obtained using Institutional 
Review Board (IRB)-approved forms, participants completed the psychological 
instruments to measure their pain perception, depression and sleep deprivation. The 
anxiety tool was completed by the practitioner collecting demographic clinical data and 
consent for study involvement. Participants underwent a structured interview to compile 
their demographic information and all results were number coded to ensure participant 
anonymity. Upon completion of the psychological questionnaires, study participants 
were given a $25 Visa gift certificate and parking reimbursement for their participation in 
the study. 
Approximately one month after recruitment, the study participant underwent a 
surgical outpatient procedure called an intrathecal analgesic infusion pain pump trial. 
The surgical procedure and study procedure of collecting intraoperative CSF samples was 
performed in the operating suite at the UCLA Santa Monica Orthopedic Hospital 
Outpatient Surgery Center. Strict, standard sterile surgical protocol was followed per the 
regulations and policies of the hospital. Intrathecal access was performed with or without 
the use of fluoroscopy per surgeons' discretion. Three mL of CSF were collected from 
each participant intraoperatively in appropriate polypropylene specimen collection tubes 
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before 1300. All specimens were processed, stored and analyzed at the UCLA Cousins 
Center for Psychoneuroimmunology Inflammatory Biology Laboratory. 
Thirty samples of 1-2 mL ofCSF were utilized from the California NeuroAIDS 
Tissue Network as a means to compare levels of central inflammatory cytokines. All 
samples were processed, stored and analyzed at the UCLA Cousins Center for 
Psychoneuroimmunology Inflammatory Biology Laboratory. 
Psychological instruments. To measure the psychological variables associated with 
chronic pain, various tools were selected for this study. These questionnaires were 
selected for their internal consistency and reliability (reflected in Table 1 as the 
Cronbach's us), their ease of completion and their use in previous studies. They were 
used to measure the study participants' level of pain perception, anxiety, depression, and 
sleep quality. 
Assays. To quantify patterns of inflammatory markers in both chronic pain and control 
samples of CSF, the Luminex Performance Human High Sensitivity Cytokine Panel 
(R&D Systems, Minneapolis, MN) and the Bio-Plex 200 instrument (Luminex®) with 
Bio-Plex Manager software version 5.0 were utilized. All CSF samples were received 
and centrifuged at 2000G for 10 minutes at 4°C. Samples were then partitioned into 0.25 
mL aliquots, labeled for anonymous identification and stored at -80°C until batch 
analysis could be performed. Before Multiplex analyses, CSF samples were diluted 1:2, 
following the protocol recommended for serum and plasma. All analyses were run in 
duplicate per the manufacturer's recommendation. Samples with a coefficient of variation 
(CV%) > 20 % between duplicates were evaluated on a case-by-case basis for repeat 
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assays and/or modified data analysis. Table 2 indicates the range and mean detection 
limits for the cytokines studied. 
Data Organization/Statistical Analysis 
This study was designed to be a cross-sectional, correlational study. First, a sample size 
was calculated using Cohen's d analysis. Cohen's d was selected to estimate the sample 
size needed to yield statistically significant results in the testing of the difference between 
two means (the CSF cytokine levels between healthy and chronic pain participants). 
Using this analysis to estimate the sample size and reduce the risk of a Type II statistical 
error aided in estimating the sample size when the population effect size was not known. 
The calculated sample size to generate adequate power was far above the actual recruited 
participants, limiting the interpretation of our results. 
Descriptive statistics were then calculated for all variables in the study and examined for 
significant responses. Data were tested for normal distribution and the level of 
significance was set at p < 0.0 5 for all statistical testing. All data are reported as mean ± 
standard deviation unless otherwise noted. Cerebrospinal fluid levels of inflammatory 
cytokines in study participants were compared to controls using parametric statistics for 
normally distributed variables to include multivariate analysis of variance (MANOV A) 
for related dependent variables and one-way analysis of variance (ANOVA) for 
additional follow-up. Differences in gender, race, diagnosis and medications between 
CSF cytokines were also analyzed using MANOV A and ANOV A. Correlations were 
calculated to explore relationships between psychological instrument measures, 
demographics, and CSF levels of cytokines using Pearson's r or Spearman's Rho 
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Correlations. Calculations were accomplished with SPSS software version 22 (SPSS, 
IBM Inc., Armonk, NY). 
Results 
Demographics 
Of the eight chronic pain patients who participated in the study, five participants 
were female, three participants were male. The age range for the study participants was 
41-74 years of age, with a mean age of 53.50 ± 10.53 years. The mean body mass index 
(BMI) of study participants was 32.35 ± 4.21 kg/m2, indicating that the majority of 
participants in this study were obese. The mean metabolic equivalents (METS) reported 
by participants was 3.38 ± 1.51 indicating participants could complete moderate intensity 
activities. The majority of the patients suffered from Failed Back Surgery Syndrome 
(FBSS) with a mean length of diagnosis of 9.31 ± 7.75 years. The most frequently 
reported medications for treatment of chronic pain were gabapentin, oxycodone and a 
fentanyl patch, respectively, with the mean usage of medications 3.50 ± 4.59 years. 
Table 3 summarizes the demographics of the study participants. 
Psychological Results 
The eight study participants self-reported a mean pain rating index (PRI) of 22.88 
± 7.1 out of a total score of 45. The mean present pain intensity (PPI) was 3.57 ± 1.13 
out of 5, and visual analog scale (VAS) score was 7.38cm ± l.32cm out of 10 cm. The 
latter two of these variables had one missing data point that was omitted in analysis and 
not replaced secondary to the small population size. Participants self reported a mean 
depression score of 19.75 ± 10.51 indicating an overall group level of mild-moderate 
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depression. The Hamilton Anxiety Rating Scale was administered by a total of four 
researchers and yielded a mean score of 20. 75 ± 11.31 indicating mild-moderate anxiety 
levels. Table 4 summarizes the psychological data. Of note, the self-reported mean sleep 
quality was found to be 15.50 ± 3.16, indicating poor overall sleep quality in the chronic 
pain study population; every participant reported poor sleep quality. 
Cytokine Results 
A total of 10 cytokines were assessed using Multiplex assay analyses, including 
Inerleukin-IB (IL-IB), IL-2, IL-4, IL-6, IL-8, IL-10, Tumor Necrosis Factor-alpha (TNF­
u), Interferon Gamma (IFN-g), Vascular Endothelial Growth Factor (VEGF) and 
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). Three cytokines 
yielded measurable quantities; IL-6, IL-8 and GM-CSF. Interleukin-IB, IL-2, IL-4, IL­
10, TNF-u, IFN-g and VEGF were undetectable in the majority of samples. While CSF 
from control samples yielded some within-range values for IL-2 and IL-10, they were 
found at the lower level of detection and were therefore excluded from analysis. Missing 
values for GM-CSF were replaced with the mean of the data series. Table 5 summarizes 
CSF cytokine levels detected via Multiplex assay. Figures 1, 2 and 3 display box plots 
for those cytokines that were detected with Multiplex assay analysis. 
Analysis ofIL-6, IL-8 and GM-CSF in Chronic Pain 
Data was screened and monitored for normality, linearity and homoscedasticity, 
and descriptive data was inspected. Both IL-6 and IL-8 were found to be non-normally­
distributed and transformed using a log transformation. Granulocyte-Macrophage 
Colony-Stimulating Factor data were found to be normally distributed between 
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population samples and required no transformation. The dependent variables (IL-6, IL-8 
and GM-CSF) were then monitored for association through correlation. With a low 
correlation between dependent variables, MANOVA was nonetheless conducted to 
investigate significant differences between study and control samples of CSF cytokines to 
decrease the rate of a type I statistical error ofmultiple ANOVA tests. 
A one-way MANOVA was conducted to determine IL-6, IL-8 and GM-CSF 
differences in pain categories. Multivariate analysis of variance results revealed 
significant differences among the pain categories on the cytokines, Wilks' Jc~ 0.676, F 
(2,34)~ 5.436,p ~ 0.004, multivariate 112 ~ 0.324. Analysis of variance was then 
conducted on each cytokine as a follow-up test to MANOVA. Pain differences were 
found to be significant for IL-8, F (1, 36) ~ 14.89, p < 0.001, partial 11 2 ~ 0.293. The 
calculated effect size indicated a decent proportion of IL-8 variance was accounted for by 
the presence or absence of chronic pain. Differences in IL-6 and GM-CSF were not 
significant, p ~ 0. 759 and p ~ 0.581 respectively. 
Analysis of Psychological and Demographic Data 
Correlations were analyzed to determine significance between demographic data, 
psychological data and CSF levels of IL-6, IL-8 and GM-CSF. Pearson's r correlations 
were utilized to assess significance of interval/ratio-level independent variables. 
Spearman's Rho correlations were utilized to determine significance of ordinal-level 
independent variables. Tables 6 and 7 summarize correlation analysis and indicate 
significance. 
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No significance was found between psychological data and levels ofIL-6, IL-8 or 
GM-CSF, but all participants did report poor sleep quality. Factors that were found to 
have significant or near-significant positive correlations to cytokines included age (p ~ 
0.069), length of diagnosis (p ~0.082) and educational level (p ~ 0.041). Socioeconomic 
status (SES) was found to have a significant negative correlation (p ~ 0.012). 
Multivariate analysis of variance and ANOV A were used to assess significance of 
gender, race, diagnosis and medications to cytokines. Analysis of variance results 
displayed significant gender differences for IL-6, F (1,6) ~ 7. 782, p ~ 0.032, 11 2~ 0.565. 
The calculated effect size for gender indicated a moderate proportion of IL-6 variance 
was accounted for by sex. Figures 4, 5 and 6 are box plots that illustrate differences of 
cytokines and sex. No significant differences were found between race, diagnosis and 
medications with respect to inflammation, but all participants did report taking at least 
one opioid medication. 
Discussion 
The Relationship Between Chronic Pain and Inflammation 
Developing research demonstrates mounting evidence of alternative pain 
pathways that perpetuate the chronic pain state via physiologic self-propagating 
mechanisms. A barrage of aberrant pathways contributes to the maintenance of 
nociception in chronic pain states and one of the mechanisms responsible for, and 
described in the literature is through glial cell activity (Fleming et al., 2006; Loggia et al., 
2015). Investigative work on glial cells has identified a selection of various molecules 
involved in positive feedback loops responsible for chronic pain, and has established that 
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the underlying mechanisms involved render our current methods of fighting pain 
ineffective. Some of the proposed responsible molecules secreted by glial cells are 
inflammatory mediator molecules, specifically interleukins and tumor necrosis factor-
alpha (TNF-u ). All of these inflammatory cytokines have been shown to excite pain 
transmission and experience (Kreutzberg, 1996; Watkins, Milligan, & Maier, 2001 ); 
inflammatory cytokines can ramp up dorsal horn neurons in pain transmission (Reeve, 
Patel, Fox, Walker, & Urban, 2000; Samad, Wang, Broom, & Woolf, 2004), they 
increase the release of neurotransmitters from sensory afferent nerves responsible for 
pain response (Inoue et al., 1999; Morioka et al., 2002) and may enhance pain via 
upregulation of AMPA (2-amino-3-(5-methyl-3-oxo-l,2- oxazol-4-yl) propanoic acid) 
and NMDA (N-Methyl-D-aspartate) receptor expression and activity (Beattie et al., 2002; 
Samad et al., 2004, Viviani et al., 2003; Wang, et al., 2005). 
To adequately assess the level of inflammatory cytokines released from glial cell 
activation in response to established chronic pain syndromes, CSF was gathered from 
eight chronic pain patients and analyzed in this study. As a means for comparison, study 
participant CSF was compared to the CSF of 30 healthy controls. Interleukin-6, IL-8 and 
GM-CSF was detectable in CSF through Multiplex assay analyses. Only IL-8 was found 
to be significantly higher in chronic pain patients. Thus, this study details the 
significance between chronic pain and increased central IL-8 levels. 
While the majority of study participants for this study were FBSS patients, other 
studies have documented increased CSF levels ofIL-8 in osteoarthritis (Lundborg, Hahn­
Zoric, Biber, & Hansson, 2010), postherpetic neuralgia (Kikuchi et al., 1999; Kotani et 
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al., 2000; Rijsdijk et al., 2013), sciatica (Brisby, Olmarker, Larsson, Nutu, & Rydevik, 
2002) and fibromyalgia (Kadetoff, Lampa, Westman, Andersson, & Kosek, 2012). Other 
studies that utilized FBSS participants indicated increases in IL-6 (Zin, Nissen, 
O'Callaghan, Moore, & Smith, 2010) and increased levels of the neurotrophic factors 
Brain-Derived Neurotrophic Factor (BDNF) and VEGF (McCarthy, Connor, & McCrory, 
2013). A complete review of these studies was summarized by Bjurstrom et al. in 2014 
(Bjurstrom, Giron, & Griffis, 2014). The current study is the first to document increased 
CSF levels ofIL-8 in a majority ofFBSS patients. 
The Relationship Between Chronic Pain and Sleep 
The complex relationship between pain and poor sleep quality is one that has been 
extensively documented in the literature, but its causality not fully understood. Both 
processes of pain causing poor sleep, and poor sleep causing pain illustrate the 
bidirectional relationship between pain and sleep. From the protective sickness 
behavior/sickness response theory, sleep has been suggested as a critical component in 
the restorative process of healing (Dantzer, 2001; Hart, 1988; Watkins & Maier, 2000). 
Counterproductively, in the presence of chronic pain pathophysiology, the restorative 
process is impaired by a lack of sleep: In a complex, detrimental dynamic, pain itself 
causes sleep deprivation and sleep deprivation has been shown to increase pain 
perception (Chiu et al., 2005; Lautenbacher, Kundermann, & Krieg, 2006; Moldofsky, 
2001; Smith & Haythornthwaite, 2004). Up to 53% of chronic back pain patients and 
88% ofneuropathic pain patients report sleep disturbances (Meyer-Rosberg et al., 2001; 
Tang, Wright, & Salkovskis, 2007). Furthermore, patients with chronic lower back pain 
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are 18 times more likely than normal control subjects to experience clinical insomnia 
(Tang et al., 2007). Thus, literature supports that sleep and pain do interact with one 
another, the abnormalities of sleep are frequently reported by the chronic pain population, 
and the effects are not benign: The effects of sleep disturbances have been linked with 
poor physical and psychological outcomes, absence from work, decreased performance, 
difficulty with personal relationships, accidents and cognitive decline (Fulda & Schulz, 
2001 ). Even in healthy individuals, sleep deprivation has been noted to cause 
spontaneous pain (Smith, Edwards, McCann, & Haythornthwaite, 2007). 
The data linking central inflammation and sleep disturbances has been primarily 
found in preclinical reports. Repeated animal studies have shown that upon central 
administration of IL-1 to both rabbits and rats, the result is an increase in various aspects 
of sleep (Krueger, Walter, Dinarello, Wolff, & Chedid, 1984; Tobler, Borbely, Schwyzer, 
& Fontana, 1984) independent of, but similar to the somnogenic effects of TNF-a 
(Shoharn, Davenne, Cady, Dinarello, & Krueger, 1987; Kapas et al., 1992). The data on 
central inflammation, sleep and pain however is very lacking. In human pain populations 
there exists almost a complete deficiency of data comparing inflammatory markers, sleep 
and pain. A study by Heffner and colleagues, substantiates that patients with chronic 
lower back pain were found to have higher levels of plasma IL-6 than healthy control 
subjects. In the chronic pain population studied, poor sleep quality was found to be 
associated with greater pain on the following morning (Heffner, France, Trost, Ng, & 
Pigeon, 2011 ). The current study is one of the first to inspect central cytokine levels for 
associations with psychological factors known to contribute to the chronic pain 
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expenence. While data collected from the Pittsburgh Sleep Quality Index (PSQI) did not 
provide statistically significant correlations to levels of the central cytokines measured, it 
should be noted that all participants scored poor on the sleep measurement tool. Further 
inspection on the physiologic link between chronic pain and sleep must be explored. 
Socioeconomic Differences in Chronic Pain 
Socioeconomic status is well described in the literature as a prominent factor 
affecting health trajectories and outcomes, and studies in pain literature echo the same 
sentiment. Of those living in lower SES areas, worse pain severity and outcomes are 
frequently reported (Brekke, Hjortdahl, & K vien, 2002; Davies et al., 2009; Fuentes, 
Hart-Johnson, & Green, 2007; Green & Hart-Johnson, 2012). Studies on SES have 
indicated there is a difference in treatment patterns between the rich and the poor (Haider, 
Johnell, Weitoft, Thorslund, & Fastbom, 2009; Thorell, Skoog, Zielinski, Borgquist, & 
Halling, 2012; van Doorslaer, Koolman, & Jones, 2004; Vikum, Bj0rngaard, Westin, & 
Krokstad, 2013), there is an increased association between work disability related to 
chronic pain in the poor (Bergman et al.,2001; Kronborg, Handberg, & Axelsen, 2009; 
Patel et al., 2012), and ultimately chronic pain is associated with poorer SES (Jiiud et al., 
2014). Some of the causal factors associating pain to SES in the literature are income, 
employment status, social status and education (Bergman et al., 2001; Doran, Drever, & 
Whitehead, 2004; Saastamoinen, Leino-Arjas, Laaksonen, & Lahelma, 2005). In this 
study, socioeconomic status was found to have a strong negative correlation (r ~ -0. 823, 
p ~ 0.012) to inflammation indicating that as socioeconomic status goes down, 
inflammation goes up. This could be related to treatment modalities; higher SES 
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participants have been found to utilize specialized services, verses the poor who routinely 
utilize pharmaceuticals (Haider et al., 2009; van Doorslaer et al., 2004; Vikum et al., 
2013; Thorell et al., 2012). This could be secondary to the type of strenuous manual 
labor that is frequented by lower SES persons (Hagen, Holte, Tambs, & Bjerkedal, 2000; 
Hagen, Zwart, Svebak, Bovim, & Jacob Stovner, 2005). What is not clear is that contrary 
to previous studies that link a lower educational level to chronic pain, the current study 
describes educational level to be positively correlated with inflammation (r ~ 0.727, p ~ 
0.041). This could be due to an unanticipated bias in study recruitment; patients were 
recruited from a specialized pain service, and were undergoing a specialized and costly 
procedure in an affluent part of Los Angeles. This result could also reflect a lack in 
participant variability with respect to educational levels: The majority of participants in 
this study were highly educated. Further inspection of pain clinics from a large multi­
institutional health system, in multiple languages would aid assessing the relationship 
between pain, inflammation, SES and educational level. 
Gender Differences in Chronic Pain 
Gender differences with respect to pain are well documented, but a relatively new 
research topic. Owing to a 1990 National Institute of Heath policy suggesting 
participation of women in medical and behavioral research, the relationship of gender and 
pain are just now starting to be included. Women report pain more frequently (Fillingim, 
King, Ribeiro-Dasilva, Rahim-Williams, & Riley, 2009), the prevalence of several 
common chronic pain syndromes are found more often in women than men (Mogil, 
2012), and literature demonstrates that women consistently report higher pain ratings 
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compared to men across different diagnoses (Ruau, Liu, Clark, Angst, & Butte, 2012). 
Likewise their response to pain interventions are also different; women exhibit different 
responses to opioid analgesics than men (Niesters et al., 2010) and have been reported to 
take 3 months longer than men to show improvement of painful symptoms after pain 
management (Keogh, McCracken, & Eccleston, 2005). Postulated mechanisms that 
influence the difference in pain sensation and treatment include sex hormones (Craft, 
2007), differences in cerebral processing of pain (Berman et al., 2006; Derbyshire, 
Nichols, Firestone, Townsend, & Jones, 2002; Paulson, Minoshima, Morrow, & Casey, 
1998), differing endogenous opioid systems (Smith et al., 2006; Zubieta et al., 2002), 
endogenous dopaminergic differences (McEwen, 2001 ), and a multitude of psychosocial 
mechanisms including gender roles (Defrin, Shramm, & Eli, 2009; Robinson, Gagnon, 
Riley, & Price, 2003; Wise, Price, Myers, Heft, & Robinson, 2002). 
In the current study, females were shown to have significantly lower CSF IL-6 
levels, and nearly significant lower levels of CSF IL-8 (p ~ 0.111) when compared to 
men. Ifwomen are reporting more pain and experiencing more chronic pain diagnoses 
than men, this study's findings do not support that the inflammatory cytokines are 
responsible pain in females. However, it should be noted that inflammatory cytokines do 
offer one possible physiologic mechanism for the difference in pain experiences between 
the sexes. Perhaps the decreased levels of inflammation are responsible for the varied 
responses to treatment. Nevertheless, further research is needed to examine the gender 
differences with respect to central inflammation and chronic pain. 
Opioid Medication in Chronic Pain 
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It cannot be overlooked that all participants in this study took at least one opioid 
medication. This is consistent with the general chronic pain population and current 
national treatment averages (Ahlbeck, 2011; Ballantyne & Mao, 2003; Mehendale, 
Goldman, Mehendale, & Rana, 2013). Because data from this study describe an increase 
in at least one inflammatory cytokine, one must consider the relationship between opioids 
and inflammatory cytokines. Multiple studies have shown that upon administration of 
chronic opioids to pain-induced rodents, there was an increase in glial cell activity in the 
CNS (Raghavendra et al., 2002; Song & Zhao, 2001; Tai et al., 2006). Glia have also 
been shown to upregulate pro-inflammatory cytokine production and release in the CNS 
when the organism is treated with longstanding systemic or intrathecal opioids; this 
increase of cytokine production and release in the CNS has been shown to contribute to 
opioid tolerance and withdrawal induced pain enhancement (Johnston et al., 2004; 
Raghavendra, Tanga, & DeLeo 2004; Song & Zhao, 2001). Literature has repeatedly 
championed a relationship between central cytokines and opioid medications, and 
perhaps it is this relationship that could be exploited for new treatments. 
Hutchinson and colleagues' preclinical study demonstrated that by blocking IL-1, 
the length of time of opioid analgesia was significantly increased. The study also 
demonstrated that an approximate seven-and-a-half-fold increase in analgesic efficacy 
with morphine was possible by co-administrating the opioid with a receptor blocker of 
IL-1 (Hutchinson et al., 2008). In another preclinical study, Johnston and colleagues 
indicated that by blocking IL-1 in the CNS, the analgesia of an intrathecally administered 
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opioid was enhanced, opioid tolerance was blunted and both newly developed and 
established allodynia and hyperalgesia were reduced (Johnston et al., 2004). 
Study Limitations 
Because of the cross-sectional, correlational nature of this study's design, 
causality of chronic pain and the causal relationships between levels of pro- or anti­
inflammatory cytokines, chronic pain, anxiety, depression and sleep deprivation were not 
determined. The study design itself limited the findings to providing support for prior 
studies and serving as a basis for developing future studies. Given the specific criteria 
and study population of this cross-sectional study, this study design also limited the 
ability to generalize the results. 
The small sample size also limited study findings: While a power analysis was 
performed and a target of 30 study participants was determined, this study was only able 
to include eight study participants. This was due to changes in study and pain center 
personnel, and a trend towards clinically prescribing a different implantable pain device 
for treatment of chronic pain. While the small sample size does decrease the 
interpretation of the study results, it should be noted that due to the difficulty in obtaining 
CSF, this study describes rich results. Other studies with smaller samples sizes have been 
common in the pain literature that analyzes human CSF, highlighting the incredibly 
valuable data CSF contains (Alexander, Perreault, Reichenberger, & Schwartzman, 2007; 
Alexander, van Rijn, van Hilten, Perreault, & Schwartzman, 2005; Backonja, Coe, 
Muller, & Schell, 2008; Kadetoff et al., 2012; McCarthy et al., 2013; Nagashima, Morio, 
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Yamane, Nanjo, & Teshima, 2009; Rijsdijk et al., 2013; Yeager, Lunt, Arruda, Whalen, 
Rose, & DeLeo, 1999). 
Obtaining the control samples from an outside source was also a limitation of this 
study. While obtaining these samples confirmed that 30 healthy CSF samples could be 
obtained, it decreased the time to acquire the CSF samples, lessened the participant 
burden and cost of recruiting participants to obtain these samples, these control CSF 
samples only came with a limited description and external assurance. The control 
samples may not adequately represent the CSF of healthy participants in the general 
public. 
Three of the four psychological questionnaires utilized by this study were from 
direct participant report, while the Hamilton Anxiety Rating Scale was completed by a 
research practitioner that consented and obtained demographic information from study 
participants. While this study tried to limit the number of practitioners completing the 
scales on the participants, to limit inter-reporter variability, a total of four practitioners 
ultimately completed the Hamilton Anxiety Rating Scale for this study. This number of 
practitioners may have skewed the results for this psychological variable. 
Conclusion 
This is the first study to describe increased CSF levels ofIL-8 in a majority FBSS 
chronic pain population. The study provided supportive evidence that there may be a 
relationship between chronic pain and central inflammation in humans, but clearly the 
responsible cytokines need further inspection with a larger study population. This data 
also provides a rich description of the relationship between gender and central 
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inflammation in chronic pain. Psychosocial variables such as educational level and 
socioeconomic status were also described in relationship to central inflammation, which 
illustrates the complex paradigm chronic pain is. All of the study participants took at 
least one opioid medication for treatment of their pain and reported poor sleep quality, 
illustrating the need to investigate possible mechanisms of association. This study clearly 
demonstrates the need for further inspection of both physiologic and psychological 
attributes of chronic pain. Thus, with a greater understanding of the complete chronic 
pain picture, the entire patient may find relief in therapy that addresses all facets of the 
disease. 
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Table 1 
Summary ofPsychological Tools Utilized 
Behavioral Measurement Scale Cronbach's a 
Measures 
Pain The Short Form- Scores for the questionnaire can '0.73-0.89 
McGill Pain range from 0 to 45 on the Pain b0.96 
Questionnaire Rating Index, from 0 to 5 on the 
(SF-MPQ) Present Pain Intensity, and from 0 to 
10 centimeters on the Visual Analog 
Scale. No established scoring noted 
liy_authors 
Anxiety The Hamilton A total anxiety score of <17 '0.89 
Anxiety Rating indicates mild anxiety levels; 18 to 
Scale 24 mild-moderate anxiety levels; and 
(HAM-A) 25 to 30 indicates moderate-severe 
anxiety levels 
Depression The Beck 0-13: minimal depression; 14-19: d0.91 
Depression mild depression; 20-28: moderate 
Inventory-II (BDI­ depression; and 29-63: severe 
II) d~ession 
Sleep The Pittsburgh Nineteen components that yield a '0.83 
Quality Sleep Quality Index global score of 0-21, with a total of_:=::_ 
(PSQI) 5 associated with good sleep quality 
and> 5 associated with poor sleep 
_g_uali~ 
a .bNote. Taken from Burckhardt & Jones, 2003, Reported as an Intraclass Correlation 
Coefficient for total pain score by Grafton, Foster, & Wright, 2005;' Taken from 
Kummer, Cardoso, & Teixeira, 2010;dReported as a Coefficient Alpha by Beck, Steer, 
Ball, & Ranieri, 1996; 'Reported by Buysse, Reynolds, Monk, Berman, & Kupfer, 1989. 
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Table 2 
Summary ofthe Luminex!EJ Performance Human High Sensitivity Cytokine Panel for 
Laboratory Analysis 
Analytes Sensitivity (pg/mL) High Standard Value (pg/mL) 
IL-I beta 0.18 1,500 
IL-2 0.28 2,450 
IL-4 2.54 7,000 
IL-5 0.12 1,600 
IL-6 0.31 4,050 
IL-8 0.07 3,200 
IL-10 0.24 2,100 





IFN-g (Interferon Gamma) 0.08 1,350 
INF-alpha 0.54 3,350 
VEGF (Vascular Endothelial 
Growth Factor) 
1.35 2,000 
Note. Accessed from manufacturer's website on March 7, 2015 
http ://rndsystems.com/Products/FCS T09 
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Table 3 




















































































































> 6 months 
14 years 
Note. SES~ Socioeconomic Status, METF Metabolic Equivalent of Tasks, BMI~ Body Mass Index, AA~ African-America, 
W~White, N/R~not reported, FBSS~Failed Back Surgery Syndrome, DPN~Diabetic Polyneuropathy, S~Sacroiliitis, AS~Ankylosing 
Spondylitis, FP~Fentanyl Patch, G~Gabapentin, O~Oxycodone, M~Methadone, OA~Oxycodone/Acetaminophen, MoFMorphine, 
Pre~Pregabalin, HA~Hydrocodone/Acetaminophen, Mel~Meloxicam, Flex~Flexeril, Dil~Dilaudid, Rob~Robaxin, Ibu~Ibuprofen, 















































































Note. PPI~Present Pain Intensity; V AS~Visual Analog Scale; HAM-A~Hamilton 
Anxiety Rating Scale; BDI-II~Beck Depression Inventory-II; PSQI~Pittsburgb Sleep 
Quality Index; N/R~Not Reported. 
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Table 5 
Cerebrospinal Fluid Cytokine Levels 
Cytokine Healthy Controls Chronic Pain pvalue 
(pg/mL) (pg/mL) 
IL-I OOR OOR 
IL-2 OOR OOR 
IL-4 OOR OOR 
IL-6 1.33 ± 0.58 1.19 ± 0.26 _p_~ 0.50 
IL-8 49.49 ± 12.81 63.04 ± 12.16 _p_< 0.001 
IL-10 OOR OOR 
TNF-a OOR OOR 
IFN-g OOR OOR 
VEGF OOR OOR 
GM-CSF 0.24 ± 0.07 0.26 ± 0.07 p ~ 0.58 
Note. OOR denotes values were out of range of Multiplex Assay Analyses. 
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Table 6 
Pearson's r Correlations for Interval/Ratio Variables 
Psychological Tools IL-6 a IL-8 a GM-CSF 
Pain Ratit~ Index -0.458 -0.289 -0.517 
Present Pain Intensity 
b 
-0.515 -0.393 0.153 
Visual Anal~Scale c -0.411 -0.609 0.529 
Hamilton Anxiety 
Ratil_!g_ Scale 
-0.271 0.109 0.409 
Beck Depression 
Inventory-II 
-0.089 0.113 0.139 
Pittsburgh Sleep 
Quali.!Y_Index 
-0.179 -0.370 0.080 
Dem~~hics 
A__g_e 0.670(! 0.427 0.447 
Body Mass Index 0.095 -0.040 0.08 
Length of Diag_nosis 0.648 e 0.524 -0.007 
Length of Medication 0.288 0.046 0.183 
a b .. cNote. Values analyzed usmg log transformation, One value omitted from analysis, 
One value omitted from analysis; d p ~ 0.069; 'p ~ 0.082. 
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Table 7 
Spearman 's Rho Correlations for Ordinal Variables 
Demographics IL-6" IL-8 a GM-CSF 
Educational Level 0.341 0.727' -0.007 
Socioeconomic Status0 -0.013 0.650 -0.823° 
Metabolic E_g_uivalents 0.568 0.393 0.105 
a .o cNote. Values analyzed usmg log transformat10n, One value omitted from analysis, 
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Figure 2. Cerebrospinal fluid levels of IL-8 in chronic pain verses controls. 
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Figure 6. Cerebrospinal fluid levels ofGM-CSF by gender. 
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Appendix A 
University of California, Los Angeles Institutional Review Board-Approved Consent 
Fonu 
UNIVERSITY OF CALIFORNIA LOS ANGELES 

CONSENT TO PARTICIPATE IN RESEARCH 

Psychoneuroimmunology and Chronic Pain 
INTRODUCTION 
Dr. Irene Wu, and associates from the Department of Anesthesiology/Pain Management 
Clinic and Cousin's Center for Psychoneuroimmunology at the University of California, 
Los Angeles are conducting a research study. 
The researchers will explain this study to you. Research studies are voluntary and 
include only people who choose to take part. Please take your time about deciding 
whether to participate in this study. Before deciding: 
• 	 You can discuss this study with friends and family. 
• 	 You can also discuss it with your health care doctor or request a second opinion. 
• 	 If you have any questions, you can ask the researchers for more information before 
deciding to participate. 
The research team is asking you to be in this study because you have been diagnosed 
with a chronic pain syndrome and are scheduled to have a trial of opioid pain 
medication administered to you through a tube (catheter) that is placed in your 
cerebrospinal fluid (CSF). The CSF is located in an area of your body called the thecal 
sac. Since the catheter is placed inside the thecal sac, this procedure is called an 
intrathecal opioid catheter trial. Should you respond favorably to the trial, you will be 
considered to be a candidate for permanent implantation of a pain pump. This pain 
pump is called an intrathecal pain pump. An intrathecal pain pump is a surgically 
implanted device that continuously infuses and delivers opioid pain medications into 
your CSF for the treatment of chronic pain. 
WHY IS THIS STUDY BEING DONE? 
The purpose of this research study is to investigate the relationships between pain, 

inflammation, anxiety, depression and sleep patterns. 

Changes in inflammation particles found in the fluid surrounding the brain and spine 
(cerebrospinal fluid or CSF) and blood, and psychological responses related to chronic 
pain will be analyzed over the treatment period that encompasses 1) the intrathecal 
opioid catheter trial, 2) the permanent insertion of an intrathecal opioid infusion pain 
pump, and 3) at three to six months post insertion of an intrathecal opioid infusion pain 
pump. 
This study is being funded by the American Association of Nurse Anesthetists and a 

CTSI grant funded through the UCLA Cousins Center of Psychoneuroimmunology. 
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HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY? 

Approximately 30 people will take part in this study at UCLA 

WHAT WILL HAPPEN IF I TAKE PART IN THIS STUDY? 
Before you begin the study: 
Before you begin the study, you will need to be diagnosed with a chronic pain condition 
and as part of your standard clinical care be scheduled to have an intrathecal opioid 
catheter trial and possible insertion of intrathecal pain pump for the treatment of your 
pain. 
During the study: 
If you take part in this study, you allow the researchers to collect a small amount of the 
fluid that surrounds the brain and spine (cerebrospinal fluid or CSF) which VllOUld 
otherwise not be collected during the intrathecal opioid catheter trial and the permanent 
placement of the intrathecal pain pump. Specifically, less than a teaspoon of your CSF 
will be collected for inflammation analysis on three separate occasions, during your 1) 
intrathecal opioid catheter trial, 2) permanent pump insertion and, 3) at your pump refill 
visit. 
As part of this research, no additional needles sticks are necessary for the collection of 
this fluid except on the pump refill visit, which will take place 3-6 months after the 
permanent insertion. However, should it be determined that you are not a candidate for 
permanent insertion of the pain pump, you will not proceed with the study after the 
intrathecal catheter trial. 
During the pump refill visit, which is part of your clinical care, there will be an extra 
procedure for research purposes only. Researchers will use fluoroscopy (a live x-ray 
machine) to guide a very small needle to draw less than a teaspoon of CSF from your 
implanted pump. This should not take more than five minutes of additional time. 
During all three visits where your CSF is collected, approximately 2-3 teaspoons of 
blood will be collected from the IV started for the procedure or through venopuncture (a 
procedure where a small needle is used to withdraw the blood from your vein). 
Additionally, the researcher(s) will ask you to fill out three questionnaires at or during 
three doctor visits: 1) prior to the intrathecal catheter trial either on the day you are seen 
in clinic or the day of your intrathecal opioid catheter trial, 2) preoperatively the day of 
your permanent pump insertion and, 3) the day you return to have your pump refill. 
These questionnaires will evaluate your mood, anxiety, sleep patterns and level of pain. 
You will also be asked to complete forms or ansvver questions related to your 
demographic information and diagnosis of chronic pain. Your responses to these 
questions will be kept strictly confidential and will not become part of your UCLA 
medical record. Also, the way you answer the questions on the questionnaires will not 
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influence the medical care you receive. Answering all of the questionnaires should take 
approximately 20-30 minutes during each visit.. 
Should a participant be determined to not be a candidate for permanent implantation of 
intrathecal pump based on clinical information gathered at the time of trial (no 
improvement in pain response to the intrathecal pain medications or significant side 
effects to the pain medication), the participant will not proceed with the treatment course 
of a permanent intrathecal pump and any further study procedures. Should the 
participant not respond to the trial, and the permanent pump is not implanted, the 
patient's cerebrospinal fluid will be analyzed for the presence of the inflammation 
particles and only the initial three questionnaires on levels of anxiety, depression and 
sleep patterns will be used for research purposes. 
HOW LONG WILL I BE IN THIS STUDY? 
This study will last approximately one year. 
WHAT KINDS OF RISKS OR DISCOMFORTS COULD I EXPECT? 
Known risks and discomforts: 
The possible risks and/or discomforts associated with the procedures described in this 
consent form include: 
Cerebrosp1nal Fluid CCSF) Samol1na Your treatment involves undergoing a surgical 
procedure called an intrathecal opioid catheter trial with possible permanent intrathecal 
pain pump insertion. During these procedures, the sac containing CSF is punctured 
and a catheter is inserted in order for opioid pain medications to be infused. Prior to 
and during the placement of the catheter, a small amount of CSF is normally lost or 
drained through the needle. This drainage is a known and accepted component of 
performing this surgical technique. 
Your participation in the study involves allowing us to collect three milliliters (less than a 
teaspoon) of CSF from the needle that is placed. Collection of the CSF will not 
significantly increase the risks or reduce the benefits of your already scheduled surgical 
procedure to place the trial catheter or permanently implant the pump. Hovvever, you 
should be aware that there are risks during the collection of the last CSF sample once 
the pump is permanently in place. 
During the final CSF draw at the pump refill visit, a 25-guage needle will be inserted 
precisely (using an x-ray called fluoroscopy) through the study participant's surgically 
prepped and draped abdomen into the catheter access port on the Medtronic 
SynchroMed® II Pain Pump. Two milliliters (less than a teaspoon) of CSF will be drawn 
out and this specimen collection procedure is anticipated to take less than five minutes 
of surgical time. This CSF sample represents the only amount of CSF that is above and 
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beyond the surgically anticipated surgical CSF loss and represents a minimal amount of 
CSF present in the adult central nervous system (CNS). 
The 2 milliliters (less than a teaspoon) sample of CSF necessary for study analysis and 
the five minutes of surgical time to collect this sample represent a small but notevvorthy 
participant burden. The risk of developing a spinal headache from the 2 milliliters of 
CSF sampled is a small, but a serious risk to the study participant. A spinal headache 
is a severe headache that can increase in severity when one sits up or changes 
positions abruptly. Usually persons with spinal headaches report that the headache is 
less severe when lying down. Most of the time spinal headaches resolve on their own 
but occasionally a spinal headache requires treatment. Treatments for spinal 
headaches include a procedure called an epidural blood patch. This treatment involves 
taking a sample of blood and injecting it into the epidural space to stop the leakage of 
CSF and thus, the spinal headache. 
Infection: During the final CSF collection from the implanted pump, participants will 
receive an additional needle stick. The needle stick will be performed utilizing the same 
surgical sterile preparation and draping as the pump refill procedure but this collection 
of CSF does represent an additional risk of infection. An infection after a 25-gauge 
needle stick is rare, but does represent a potential additional risk to the participant. Should 
an infection occur, treatment including antibiotics or additional surgery may be necessary. 
Radiation: During the pump refill visit in which CSF will be withdrawn from the catheter 
access port of the Medtronic SynchroMed® II Pain Pump, fluoroscopy will be utilized to 
locate the catheter access port of the device. Fluoroscopy will be utilized to minimize 
the number of needle sticks necessary to access and precisely locate the catheter 
access port of the pain pump. This is both for your comfort and safety. 
You are exposed to radiation on a daily basis, both from natural (sun and earth) and 
manmade sources. The estimated radiation dose that you will receive as a volunteer for 
this type of research has been compared to the limits allowed for a radiation vvorker. 
This limit is low and is not expected to be harmful. The person obtaining your consent 
can ansvver any questions you have, and provide detailed written information about the 
amount of radiaiton resulting from this study. 
Pain Pump Reprogramming Malfunction: During the final visit for the pump refill of pain 
medication, CSF will be collected from a port on the Medtronic SynchroMed® II Pain 
Pump. Once the CSF has been collected, the pump will need to be refilled and 
electronically reset with the approved Medtronic N'Vision® 8840 Programmer to ensure 
the proper rate of pain medication infusion via the pain pump and intrathecal catheter. 
Although unlikely, malfunctioning of the repriming and reprogramming of the Medtronic 
SynchroMed® II Pain Pump can result in a wide spectrum of side effects expectant from 
an overdose of narcotic medications ranging from pruitis (itching) to ventilatory 
depression (difficulty breathing) to death if incorrectly programmed and left untreated. 
The UCLA Pain Management medical doctors that perform intrathecal opioid infusion 
pain pump maintenance, including pump refills, have done so in hundreds of past 
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patients in chronic pain treatment endeavors with no adverse events related to 

repriming and reprogramming of the intrathecal catheter or pain pump. 

Bleeding: It is possible, though unusual, to experience a bleeding episode through a 25 
gauge needle stick. Should bleeding occur, it may require emergency treatment to drain 
accumulated blood called a hematoma. 
Scarring: In rare cases, scarring from a 25-gauge needle stick may result. This 
represents a small but additional risk to study participants. There is no treatment for 
this risk. 
Blood Sampling: 
Infection. Before the surgical procedure where study samples of CSF will be collected, 
there is a risk of infection upon insertion of an intravenous catheter or upon 
venopuncture. An infection after an intravenous catheter insertion or venopuncture is 
rare, but does represent a potential risk. Should an infection occur, treatment including 
antibiotics or additional surgery may be necessary. 
Bleeding. It is possible, though unusual, to experience an excessive bleeding through 
an intravenous needle stick or venopuncture site. The smallest appropriate catheter or 
venopuncture needle will be used in every effort to minimize bleeding and discomfort for 
study participants. Should bleeding occur, it may require emergency treatment to drain 
accumulated blood called a hematoma. 
Scarring. In rare cases, scarring from an intravenous needle stick or venopuncture may 
result. This represents a small risk to study participants. 
Unknown risks and discomforts: 
The experimental procedure may have side effects that no one knows about yet. The 
researchers will let you know if they learn anything that might make you change your 
mind about participating in the study. 
ARE THERE ANY BENEFITS IF I PARTICIPATE? 
Possible benefits to me: 
You will not benefit directly from participating in this study. 
Possible benefits to others or society: 
This study will help the researchers learn more aOOut inflammation and chronic pain, 
depression, anxiety and sleep deprivation. Hopefully this information will help in the 
treatment of future patients with chronic pain like yours. 
WHAT OTHER CHOICES DO I HAVE IF I DON'T WANT TO PARTICIPATE? 
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If you decide not to take part in this study, or if you withdraw from this study before it is 
completed, the following alternative procedures or courses of treatment are available: 
Your alternative is not to participate in the research. You can proceed with the same 
procedures and treatments for your pain without participating in the research. 
CAN THE RESEARCHERS REMOVE ME FROM THIS STUDY? 
The researchers may end your participation in this study for a number of reasons, such 
as if your safety and welfare are at risk, if you do not follow instructions or if you miss 
scheduled visits. The researchers or the study sponsor might also decide to stop the 
study at any time. 
If you decide to stop being in the study, or are removed from the study, or the study is 
stopped the researcher will ask you to submit in writing your intent to discontinue your 
involvement in this study. 




The researchers will do their best to make sure that your private information is kept 
confidential. Information about you will be handled as confidentially as possible, but 
participating in research may involve a loss of privacy and the potential for a breach in 
confidentiality. Study data will be physically and electronically secured. As with any use 
of electronic means to store data, there is a risk of breach of data security. 
Use of personal information that can identify you: 
•The researchers will make every attempt to protect your confidentiality and to make 
sure that your personal identity does not become known. This signed consent form will 
be stored in a locked file that will be accessible only to a very small number of 
authorized people involved in this project. The research team will carefully follow the 
coding, storage, and data sharing plan explained below. 
How information about you will be stored: 
• No identifiable information about you will be kept with the research data. 
•All identifiable information about you will be replaced with a code. A list linking the 

identifiable information and associated code will be locked in tv-Jo secure locations. 

•Some research data and records will be maintained in a secure location at UCLA. 

Only authorized individuals will have access to it. 

•Some research data and records will be stored on a laptop computer that is passcode 
protected and your identifiable information will be kept separate from the research data. 
People and agencies that will have access to your information: 
The research team and authorized UCLA personnel may have access to study data and 
records to monitor the study. Research records provided to authorized, non-UCLA 
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personnel will not contain identifiable information about you. Publications and/or 

presentations that result from this study will not identify you by name. 

How long information from the study will be kept: 
•The researchers intend to keep the research data and records until the research is 
published and/or presented or until the analysis of the records are complete, whichever 
is longer. 
• In the future, data collected for this study may be shared with other researchers for 
other studies that are unknown at this time. Any data shared with other researchers, will 
not include your name or other personal identifying information. 
ARE THERE ANY COSTS FOR TAKING PART IN THIS STUDY? 
You or your insurer will be billed for the costs of any standard medical care you receive 
during your participation in the study and you will be responsible for any associated co­
payments and deductibles. Above the standard medical care costs, there are no 
additional cost burdens to you. You will not be charged for the laboratory tests that will 
be run on the CSF samples we collect from you. 
WILL I BE PAID FOR MY PARTICIPATION? 
You will be given a $25 VISA pre-paid gift card for your participation in this study at the 
time of enrollment. Should it be determined that you are not a candidate for f:ermanent 
pain pump insertion, you will not proceed with the remainder of the study and will not 
receive any further compensation. Should you proceed to the remaining steps of the 
study and complete the study, you will receive an additional $25 VISA pre-paid gift card 
at the time of your last CSF draw visit. 
You will be reimbursed for the following out of pocket expenses that you might have: 

Parking fees for each doctor visit that is research related. 

WHAT OTHER THINGS SHOULD I CONSIDER BEFORE PARTICIPATION? 
Use of My Specimens: 
Any specimens (e.g., CSF or blood) obtained for the purposes of this study will become 
the property of the University of California. Once you provide the specimens you will not 
have access to them. The University may share your specimens in the future with other 
researchers or outside institutions. Information that identifies you will not be shared with 
anyone outside of UCLA. The specimens will be used for research and such use may 
result in inventions or discoveries that could become the basis for new products or 
diagnostic or therapeutic agents. In some instances, these inventions and discoveries 
may be of potential commercial value and may be patented and licensed by the 
University. You will not receive any money or other benefits derived from any 
commercial or other products that may be developed from use of the specimens. 
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All of the specimens of cerebrospinal fluid will be labeled with a numeric code rather 
than any personal identifiers to maintain your anonymity. Only limited research 
personnel will have access to the list that links your personal information to your 
numeric code and this list will be destroyed once the research is published and/or 
presented or until the analysis of the records are complete, whichever is longer. 
WHO CAN I CONTACT IF I HAVE QUESTIONS ABOUT THIS STUDY? 
The Research Team: 
You may contact Dr Irene Wu and Dr Michael Ferrante at (310) 794-1841 with any 
questions or concerns about the research or your participation in this study. You can 
also call the UCLA Page Operator at (310) 825-6301 to reach Dr Irene Wu 24 hours a 
day, 7 days week. 
UCLA Office of the Human Research Protection Program (OHRPP): 
If you have questions about your rights while taking part in this study, or you have 
concerns or suggestions and you want to talk to someone other than the researchers 
about the study, you may contact the UCLA OHRPP by phone: (310) 825-5344; by 
email: mirb@research.ucla.edu or U.S. mail: UCLA OHRPP, 11000 Kinross Ave., Suite 
211, Box 951694, Los Angeles, CA 90095-1694. 




It is important that you promptly tell the researchers if you believe that you have been 
injured because of taking part in this study. You can tell the researcher in person or call 
him/her atthe number(s) listed above. 
If you are injured as a result of being in this study, UCLA will provide necessary medical 
treatment. The costs of the treatment may be covered by the University of California, or 
billed to you or your insurer just like other medical costs, depending on a number of 
factors. The University and the study sponsor do not normally provide any other form of 
compensation for injury. For more information about this, you may call the UCLA Office 
of the Human Research Protection Program at 310-825-5344 or send an email to 
mirb@research.ucla.edu. 
WHAT ARE MY RIGHTS IF I TAKE PART IN THIS STUDY? 
Taking part in this study is your choice. You can choose whether or not you want to 
participate. Whatever decision you make, there will be no penalty to you and you will not 
lose any of your regular benefits. 
• 	 You have a right to have all of your questions answered before deciding whether to 
take part 
• 	 Your decision will not affect the medical care you receive from UCLA. 
• 	 If you decide to take part, you can leave the study at anytime. 
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• 	 If you decide to stop being in this study you should notify the research team right 
away. The researchers may ask you to complete some procedures in order to 
protect your safety. 
• 	 If you decide not to take part, you can still get medical care from UCLA. 
HOW DO I INDICATE MY AGREEMENT TO PARTICIPATE? 
If you agree to participate in this study you should sign and date below. You have been 
given a copy of this consent form and the Research Participant's Bill of Rights to keep. 
You will be asked to sign a separate form authorizing access, use, creation, or 
disclosure of health information about you. 
SIGNATURE OF THE PARTICIPANT 
Name of Participant 
Signature of Participant Date 
SIGNATURE OF PERSON OBTAINING CONSENT 
Name of Person Obtaining Consent Contact Number 
Signature of Person Obtaining Consent Date 
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Appendix B 
Measurement ofPain Perception 
SHORT·FORM McGILL PAIN QUESTIONNAIRE 
RONALD MELZACK 
PATIENT'S NAME: DATE: 
~ MlL.12 MQQ!;BAili ~ 
THROBBING 0) 1) __ 2) __ 3) 
SHOOTING 0) 1) 2) __ 3) __ 
STABBING 0) __ 1) 2) 3) ___ 
SHARP O) __ 1) __ 2) 3) ___ 
CRAMPING O) __ 1) __ 2) 3) 
GNAWING 0) __ 1) __ 2) __ 3) 
HOT·BURNING OJ 1) 2) __ 3) __ 
ACHING OJ __ 1) __ 2) __ 3) __ 
HEAVY 0) __ 1) __•. 2) 3) __ 
TENDER OJ __ 1) __ 2) __ 3)_._ 
SPLITTING 0) __ 1) __ 2) __ 3) __ 
TIRING-EXHAUSTING 0) __ 1) 2) __ 3) __ 
SICKENING O) __ 1) __ 2) 3) __ 
FEARFUL 0) __ 1) __ 2) 3) __ 
















I Hamilton Anxiety Rating Scale (HAM-A) 
Below is a list of phrases that describe certain feeling that people have. Rate the patients by finding the answer which best describes the extent 
to which he/she has these conditions. Select one of the five responses for each of the fourteen questions. 
0 = Not present, I =Mild, 2 = Moderate, 3 = Severe, 4 =Very severe. 
Anxious mood 
Worries. anticipation of the worst, fearful anticipation, irritability. 
2 Tension 
Feelings of tension. fatigability. scrtle response. moved to tears 
easily, trembling, feelings of restlessness, inability to relax. 
3 Fears 
Of dark. of strangers. of being left alone. of animals. of traffic. of 
crowds. 
4 Insomnia 
Difficulty in falling asleep, broken sleep, unsatisfying sleep and fatigue 
on waking, dreams, nightmares, night terrors. 
s Intellectual 

Difficulty in concentration. poor memory. 

6 Depressed mood 
Loss of interest, lack of pleasure in hobbies, depression, early waking, 
diurnal swing. 
7 Somatic (muscular) 
Pains and aches, tv.ritching, stiffness, myoclonic jerks, grinding of 
teeth, unsteady voice, increased muscular tone. 
8 Somatic (sensory) 
Tinnitus, blurring of vision, hot and cold flushes, feelings of weakness, 
pricking sensation. 
9 Cardiovascular symptoms 
Tachycardia, palpiCltions, pain in chest, throbbing of vessels, fainting 
feelings, missing beat. 
I 0 Respkatory symptoms 

Pressure or constriction in chest. choking feelings. sighing. dyspnea. 

I I Gasfrointestinal symptoms []] DJ [}] [I] [1J 
Difficulty in swallov.ing. wind abdominal pain. burning sensations. 
abdominal fullness, nausea, vomiting, borborygmi, looseness of 
bowels. loss of weight. constipation. 
12 Genitourinary symptoms 
Frequency of micturition, urgency of micturition, amenorrhea, 
menorrhagia, development of frigidity, premature ejaculation, loss of 
libido, impotence. 
13 Autonomic symptoms 
Dry mouth. flushing. pallor. tendency to sweat, giddiness. tension 
headache, raising of hair. 
14 Behavior at interview 
Fidgeting. restlessness or pacing. tremor of hands. furrowed brow. 
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Appendix E 
Measnrement of Sleep Quality 
Page 1 of 4 
AM 
Subject's lnitials _______ID#________Date_______Time__PM 
PITTSBURGH SLEEP QUALITY INDEX 
INSTRUCTIONS: 
The following questions relate to your usual sleep habits during the past month only. Your answers 
should indicate the most accurate reply for the majority of days and nights in the past month. 
Please answer all questions. 
1. 	 During the past month, what time have you usually gone to bed at night? 

BED TIME ____ 

2. 	 During the past month, how long (in minutes) has it usually taken you to fall asleep each night? 
NUMBER OF MINUTES ____ 
3. 	 During the past month, what time have you usually gotten up in the morning? 

GETTING UP TIME ____ 

4. 	 During the past month, how many hours of actual sleep did you get at night? (This may be 
different than the number of hours you spent in bed.) 
HOURS OF SLEEP PER NIGHT ____ 
For each of the remaining questions, check the one best response. Please answer all questions. 
5. During the past month, how often have you had trouble sleeping because you . 

a) Cannot get to sleep within 30 minutes 

Not during the Less than Once or twice Three or more 

past month __ once a week__ a week __ times a week __ 

b) Wake up in the middle of the night or early morning 

Not during the Less than Once or twice Three or more 

past month __ once a week__ a week __ times a week __ 

c) Have to get up to use the bathroom 

Not during the Less than Once or twice Three or more 
past month __ once a week__ a week __ times a week __ 
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d) Cannot breathe comfortably 
Not during the Less than Once or twice Three or more 
past month __ once a week __ a week __ times a week__ 
e) Cough or snore loudly 
Not during the Less than Once or twice Three or more 
past month __ once a week __ a week __ times a week__ 
f) Feel too cold 
Not during the Less than Once or twice Three or more 
past month __ once a week __ a week __ times a week__ 
g) Feel too hot 
Not during the Less than Once or twice Three or more 
past month __ once a week __ a week __ times a week__ 
h) Had bad dreams 
Not during the Less than Once or twice Three or more 
past month __ once a week __ a week __ times a week__ 
i) Have pain 
Not during the Less than Once or twice Three or more 
past month __ once a week __ a week __ times a week__ 
j) Other reason(s), please describe 
How often during the past month have you had trouble sleeping because of this? 
Not during the Less than Once or twice Three or more 
past month __ once a week __ a week __ times a week__ 
6. During the past month, how would you rate your sleep quality overall? 
Very good 




Page 3 of 4 
7. 	 During the past month, how often have you taken medicine to help you sleep (prescribed or 
"over the counter")? 
Not during the Less than Once or twice Three or more 

past month ___ once a week__ a week ___ times a week ___ 

8. 	 During the past month, how often have you had trouble staying awake while driving, eating 
meals, or engaging in social activity? 
Not during the Less than Once or twice Three or more 

past month ___ once a week__ a week ___ times a week ___ 

9. 	 During the past month, how much of a problem has it been for you to keep up enough 
enthusiasm to get things done? 
No problem at all 
Only a very slight problem 
Somewhat of a problem 

A very big problem 

10. 	 Do you have a bed partner or room mate? 
No bed partner or room mate 
Partner/room mate in other room 
Partner in same room, but not same bed 
Partner in same bed 
If you have a room mate or bed partner, ask him/her how often in the past month you 
have had . 
a) 	 Loud snoring 
Not during the Less than Once or twice Three or more 
past month ___ once a week__ a week ___ times a week ___ 
b) 	 Long pauses between breaths while asleep 
Not during the Less than Once or twice Three or more 
past month ___ once a week__ a week ___ times a week ___ 
c) Legs twitching or jerking while you sleep 
Not during the Less than Once or twice Three or more 
past month ___ once a week__ a week ___ times a week ___ 
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d) Episodes of disorientation or confusion during sleep 
Not during the Less than Once or twice Three or more 
past month___ once a week___ a week___ times a week___ 
e) Other restlessness while you sleep; please describe_________________ 
Not during the Less than Once or twice Three or more 
past month___ once a week___ a week___ times a week___ 
©1989, University of Pittsburgh_ All rights reserved_ Developed by Buysse,D_J_, Reynolds,C_F_, Monk,T_H_, Berman,S_R., and 
Kupfer,D_J_ of the University of Pittsburgh using National Institute of Mental 1-iaalth Funding 
Buysse OJ, Reynolds CF, Monk TH, Berman SR, Kupfer OJ: Psvchiatry Research, 28:193-213, 1989. 
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Appendix F 
Demographic Clinical Data Questionnaire 
Code: 
To Be Filled Out by Research Practitioner: 
Cause/Diagnosis of Chronic Pain (i.e. Failed Back): 
Length of Chronic Pain Diagnosis: ______________ 
Types of Medications Taken by Patient for Treatment of Chronic Pain: 





Demographic Data Questionnaire 
Code: 
Please Do Not Flll in Above 
Age:____ 
Height: Weight:______ 
Gender: M F (Please Circle One) 
Race: White White, Non-Hispanic African-American Hispanic 
Asian-Pacific Islander Native American (Please Circle One) 
Education Level: (Please Circle One) 
Less than High School 
High School/GED 
Some College 
2-year College Degree (Associates) 
4-year CollegeDegree (BA, BS) 
Master's Degree 
Doctoral Degree 
Professional Degree (MD, JD) 
Total Household Income: (Please Circle One) 
















Eat, dress, use toilet, make bed 
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3 Walk around house, shower 
4 One flight stairs, walk up hill, walk flat - 2 block, 2mph 
Light house work, dust, wash dishes, golf, bowl 
5 Two flights stairs, walk on flat at 4mph, Sex 
6 Scrubbing floors, move furniture 
7 weight lifting 
8 Shovel Snow 
9 Doubles teruris, swing dancing 
10 Singles teruris, soccer, basketball, skiing, running 
12+ Competitive Sports 
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Appendix H 
University of California, Los Angeles Institutional Review Board Approval 
~/17/H 11:12AM 
Univers~y of California Los Angeles 
11000 Kinross Avenue. Suite 211 
Los Angeles. CA 90095-1694 
http://ohrpp. research. ucla .ed u 
GC-IRB (310) 825-7122 




TO: ANDREA NICOL 
ANESTHESIOLOGY 
FROM: JAMES MC GOUGH. MD 
Chair. MIRB3 
RE: IRB#l 2-001588 
Psychone1U0immunology and Chronic Pain 
Version: 1112312012 >&.O 
The UCLA Institutional Review Board (UCLA IRS) has approved the above-referenced study. The UCLA IRB's 
FederalwideAssurance (FVV~ w~h Department of Health and Human Services is FW)l()0004642 (IRED0004473). 
Submission and Review Information 
Type of Review Full Board Review 
Approval Date 12/2012012 
Expiration Date of the Study 1211212013 
Funding Source( s) 
1) AMERICAN ASSOCIATION OF NURSE 
jANESTHETISTS FOUNDATION 
Grant Title: Psychoneuroimmune Resp::mses 
land Chronic Pain 
Specific Conditions for Approval 
-- Research Participants Bill of Rights - By California law, a copy of the 
Research Participants Bill of Rights in a language in which the participant is fluent 
must be given to all research participants in this study as there is a real or 
lforeseeable risk of biomedical harm. Numerous translations are available for 
download on the HRPP website at http:l/www.ohrpp.research.ucla.edu/pageslbill­
of-rig_hts. 
https: I /We birb .resear<:h.uda. ed u/\\~blRt/Do<:/01 E.NS4P<I9C~2Kttl#C7S68C9D7&/fromString.html Page 1of2 
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3/17/ 131112AM 
Documents Reviewed included, but were not limited to: 
!Document Name l!Jocurnentj !version# 
12-001588 ....C..onse!Jlv3. O....C..SF ~df...12.df tJ:o1 
Important Note: Approval by the Institutional Review Board does not, in and of itself, constitute approval for the 

implementation of this research. Other UCLA clearances and approvals or other external agency or collaborating 

institutional approvals may be required before study activities are initiated. Research undertaken in conjunction with 

outside entities, such as drug or device companies, are typically contractual in nature and require an agreement between 

the University and the entity. 

General Conditions of Approval 
As indicated in the Pl Assurances as part of the IRB requirements for approval, the Pl has ultimate responsibility for the 

conduct of the study, the ethical performance of the project, the protection of the rights and welfare of human subjects, 

and strict adherence to any stipulations imposed by the IRB. 

The Pl and study team will comply with all UCLA policies and procedures, as well as with all applicable Federal, State, and 
local laws regarding the protection of human subjects in research, including, but not limited to, the following: 
• 	 Ensuring that the personnel performing the project are qualified, appropriately trained, and will adhere to the 
provisions of the approved protocol, 
• 	 Implementing no changes in the approved protocol or consent process or documents without prior IRB approval 
(except in an emergency, if necessary to safeguard the well-being of human subjects and then notifying the IRB as 
soon as possible afterwards), 
• 	 Obtaining the legally effective informed consent from human subjects of their legally responsible representative, 
and using only the currently approved consent process and stamped consent documents, as appropriate , with 
human subjects, 
• 	 Reporting serious or unexpected adverse events as well as protocol violations or other incidents related to the 
protocol to the IRB according to the OHRPP reporting requirements. 
• 	 Assuring that adequate resources to protect research participants (i.e., personnel, funding, time, equipment and 
space) are in place before implementing the research project, and that the research will stop if adequate resources 
become unavailable. 
• 	 Arranging for a co-investigator to assume direct responsibility of the study ifthe Pl will be unavailable to direct this 
research personally, for example, when on sabbatical leave or vacation or other absences. Either this person is 
named as co-investigator in this application, or advising IRB via weblRB in advance of such arrangements. 
https / /w@bi(b.f@S@an:h .w.:la.@d u/ W@blRB /Doc_/O/ENS4P49CMJ2 KBBNVG 7568G907B/ from5Uir1g .html 	 Pag@ 2 of 2 
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Appendix I 
University of California, Los Angeles Institutional Review Board Continuation 
Approval 2013 
2/18115, 11 :25 AM 
University of California Los Angeles 
11000 Kinross Avenue, Suite 211 
Los Angeles, CA90095-1694 
bll1lJLgbrp.p res•arch qc!a odq 
GC-IRB (310) 825-7122 
M-IRB (310) 825-5344 
APPROVAL NOTICE 
DATE: 12/ll/2D13 
TO: IRENE WU 
ANESTHESIOLOGY 
FROM: JAMES MC GOUGH, MD 
Chair, MIRID 
RE: IRB#12-DD1588-CR-DDDD1 
2D13 Review for IRB#12-DD1588 
Psychoneuroimmunologyand Chronic Pain 
Version ll/23/2D12 v2.D 
The UCLA lnsiitutional Review Board (UCLA IRB) bas approved the above-referenced siudy. The UCLA IRB's 
FederaM!ide Assurance (FWA) with Department of Health and Human Services is F\/\IA00004642 (IRB00004473). 
Submission and Review lnformalion 
ffype of Submission Continuing Review 
ffype of Review Full Boa rd Review 
jApproval Date 12/11/2D13 
Expiration Date of the Study 1D/9/2D14 
Funding Source(s) 
1) AMERICAN ASSOCIATION OF NURSE 
ANESTHETISTS FOUNDATION 
Grant Title: Psychoneuroimmune Responses 
and Chronic Pain 
2) Other: UCLA Cousins Center for 
Psychoneuroimmunology I UCLA CTSI 
Grant Title: Interdisciplinary Seed Grant 
Program of the Cousins Center for 
Psychoneuroimmunology 
Grant Number: UCLA CTSI Grant Number 
ULlTRDDD124 
Specific Conditions for Approval 
nnps :l/'lteOlrtl .reGesrcn.ucla.eQJ/WeO IR 8'0oc/O/OV4HOOS EM8P4H09GA3KNLN3N2E/fromSV'lng.mml Psge1of2 
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2118115, 11,25 AM 
- Research Participants Bill of Rights - By California law, a copy of the Research 
Participants Bill of Rights in a language in which the participant is fluent must be 
iven to all research participants in this study as there is a real or foreseeable risk 
fbiomedical harm. Numerous translations are available for download on the HRPP 
ebsite at htt ://www.ohr .research.ucla.edu/ a es/bill-of-ri hts. 
Documents Reviewed included, but were not limited to: 
!Document Name !Docurnentj !version # 
12-001588 Final Consentv5 Cleanllil[_llilf fl,02 
Important Note: Approval by the Institutional Review Board does not, in and of itself, constitute approval for the 

implementation of this research. Other UCLA clearances and approvals or other external agency or collaborating 

institutional approvals may be required before study activities are initiated. Research undertaken in conjunction with 

outside entities , such as drug or device companies, are typically contractual in nature and require an agreement between 

the University and the entity. 

General Conditions of Approval 
As indicated in the Pl Assurances as part of the IRB requirements for approval , the Pl has ultimate responsibility for the 
conduct of the study, the ethical performance of the project, the protection of the rights and welfare of human subjects , and 
strict adherence to any stipulations imposed by the IRB. 
The Pl and study team will comply with all UCLA policies and procedures, as well as with all applicable Federal , State, and 
local laws regarding the protection of human subjects in research, including, but not limited to, the following: 
• 	 Ensuring that the personnel performing the project are qualified, appropriately trained, and will adhere to the 
provisions of the approved protocol , 
• 	 Implementing no changes in the approved protocol or consent process or documents without prior IRB approval 
(except in an emergency, if necessary to safeguard the well-being of human subjects and then notifying the IRB as 
soon as possible afterwards), 
• 	 Obtaining the legally effective informed consent from human subjects of their legally responsible representative , 
and using only the currently approved consent process and stamped consent documents, as appropriate, with 
human subjects, 
• 	 Reporting serious or unexpected adverse events as well as protocol violations or other incidents related to the 
protocol to the IRB according to the OHRPP reporting requirements. 
• 	 Assuring that adequate resources to protect research participants (i.e., personnel, funding, time, equipment and 
space) are in place before implementing the research project, and that the research will stop if adequate resources 
become unavailable. 
• 	 Arranging for a co-investigator to assume direct responsibility of the study ifthe Pl will be unavailable to direct this 
research personally, for example, when on sabbatical leave or vacation or other absences. Either this person is 
named as co-investigator in this application , or advising IRB via weblRB in advance of such arrangements. 
https://webirb. research.u cl a. e d u!Web IR BID oc/O / OV 4H 0 C 8EM 8 P 4H 0 9 GA3KN L N 3N 2 E/ fromStri n g .ht m l 	 Pag e 2of 2 
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Appendix J 
University of California, Los Angeles Institutional Review Board Continuation 
Approval 2014 
2/181'1 S. 11 :24 AM 
University of California Los Angeles 
11000 Kinross Avenue, Suite 211 
Los Angeles. CA90095-1694 
bllllJLgbrpp res•arch qcla odq 
GC-IRB (310) 825-7122 
M-IRB (310) 825-5344 
APPROVAL NOTICE 
DATE: 8/7/2014 
TO: IRENE WU 
ANESTHESIOLOGY & PERIOPERATIVE MEDICINE 
FROM: JAMES MCGOUGH. MD 
Chair. MIRE3 
RE: I RB#l2-001588-CR-00002 
2014 Review for IRB#l2-001588 
Psychoneuroimmunology and Chronic Pain 
Version 11123/2012 v2.0 
The UCLA lns1itutional Review Board (UCLAI RB) has approved the above-referenced siudy. UCLA's F ederaMlide 
Assurance (FW~ with Department of Health and Human Services is FW)l()0004642 ( IRB00004473). 
Submission and Review Information 
[ype of Submission Continuing Review 
[YJl8 of Review Full Boa rd Review 
~proval Date 817/2014 
Expiration Date of the Study 7/23/2015 
Funding Source(s) 
1) AMERICAN ASSOCIATION OF NURSE 
ANESTHETISTS FOUNDATION 
Grant Pl SARAH GIRON 
Grant Title: F\iychoneuroimmune Responses 
and Chronic Pain 
2) Other: UCLA Cousins Center for 
Psychoneuroimmunology I UCLA CTSI 
Grant Pl IRENE WU 
Grant Title: Interdisciplinary Seed Grant 
Program of the Cousins Center for 
nnps :llvt«>lrtl .reisesrcn.uc1a.eOJ/weo 1R 8'0oc/OIKF8FPPSNKCOK7E67Q218 F0641 1/fromS11"1ng.rnm1 Psge1of3 
310 
2118115, 11,24 AM 
Psychoneuroirnmunology 
Grant Number: UCLA CTSI Grant Number 
ULlTROOOl 24 
Specific Conditions for Approval 
- UCLA Serving as Reviewing IRB - The UCLA IRB has agreed to serve as the 
eviewing IRB for University of California San Diego's involvement in this research 
jaccording to the provisions of the UC MOU. 
- Research Participants Bill of Rights - By California law, a copy of the Research 
Participants Bill of Rights in a language in which the participant is fluent must be 
~i_ven to all research participants in this study as there is a real or foreseeable risk 
~fbiomedical harm. Numerous translations are available for download on the HRPP 
tvve bsite at http://www.ohrpp.re search. ucl a .edu /page s/bil I-of-rights. 
- UCLA HIPAAAuthorization is required for this research. Copies in English and 
t-tarious translations are available at 
I:!_ttp :/lo ra. research .ucla. edu/OH R PP/Pages/PH I Permission Forms .aspx 
Documents Reviewed included, but were not limited to: 
Pocurnent Name pocurnentj ~rsion # 
12-001588 UCSD Studx Consentv2.lli!Ludf P.02 
12-001588 Final Consent v5 Cleanlli!Lllilf [l.03 
Important Note: Approval by the Institutional Review Board does not, in and of itself, constitute approval for the 

implementation of this research. Other UCLA clearances and approvals or other external agency or collaborating 

institutional approvals may be required before study activities are initiated. Research undertaken in conjunction with 

outside entities, such as drug or device companies, are typically contractual in nature and require an agreement be\\Neen 

the University and the entity. 

General Conditions of Approval 
As indicated in the Pl Assurances as part of the IRB requirements for approval, the Pl has ultimate responsibility for the 
conduct of the study, the ethical performance of the project, the protection of the rights and welfare of human subjects, and 
strict adherence to any stipulations imposed by the IRB. 
The Pl and study team will comply with all UCLA policies and procedures, as well as with all applicable Federal, State, and 
local laws regarding the protection of human subjects in research, including, but not limited to , the following: 
• 	 Ensuring that the personnel performing the project are qualified, appropriately trained, and will adhere to the 
provisions of the approved protocol, 
• 	 Implementing no changes in the approved protocol or consent process or documents without prior IRB approval 
(except in an emergency, if necessary to safeguard the well-being of human subjects and then notifying the IRB as 
soon as possible afterwards) , 
• 	 Obtaining the legally effective informed consent from human subjects of their legally responsible representative, 
and using only the currently approved consent process and stamped consent documents, as appropriate, with 
human subjects, 
htt ps:// web irb .res earch .u c! a .e du/Web IRB/ D oc/O / KF 6FPP5 NKCO K7 E67Q2!8F06411 / fromString . htm l 	 Pag e 2of 3 
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2/18/15, 11:24 AM 
• 	 Reporting serious or unexpected adverse events as well as protocol violations or other incidents related to the 
protocol to the IRB according to the OHRPP reporting requirements. 
• 	 Assuring that adequate resources to protect research participants (Le,, personnel, funding, time, equipment and 
space) are in place before implementing the research project, and that the research will stop if adequate resources 
become unavailable. 
• 	 Arranging for a co-investigator to assume direct responsibility of the study ifthe Pl will be unavailable to direct this 
research personally, for example, when on sabbatical leave or vacation or other absences. Either this person is 
named as co-investigator in this application, or advising IRB via weblRB in advance of such arrangements. 
https://web1rb.research.ucla.edu/WeblRB/Doc/O/KF6FPP5NKCOK7E670218FD6411/fromString.html 	 Page 3 of 3 
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Institutional Review Board 
Project Action Summary 
Action Date: April 8, 2013 Note: Approval expires one year after this date. 
Type: _New Full Review _New Expedited Review _Continuation Review _X_Exempt Review 
__Modification 
Action: _X_Approved _Approved Pending Modification _ Not Approved 
Project Number: 2013-04-154 
Researcher(s): Sarah Giron Doc SON 
Dr. Joseph Burkard Fae SON 
Project Title: Psychoneuroimmunology and Chronic Pain 
Note: 	 We send /RB correspondence regarding student research to the faculty advisor. who bears 

the ultimate responsibility for the conduct of the research. We request that the faculty 

advisor share this correspondence with the student researcher. 

Modifications Required or Reasons for Non-Approval 
None 
The next deadline for submitting project proposals to the Provost's Office for full review is N/A. You may submit 
a project proposal for exped~ed review at any time. 
b~~1L.:A 
Dr Thomas R. Herrinton 
Administrator, lnstitutonal Review Board 
University of San Diego 
herrinton@sandiego.edu 
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San Diego, California 92110-2492 
Office of the Executive Vice President and Provost 
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Phone (619) 260-4553 •Fax (619) 260-2210 • www.sandiego.edu 
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